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Abstract  
Because of the increased incidence of antibiotic resistance there is an increasing need 
to isolate new microorganisms producing new antibiotics. Because conventional 
sources such as soil have been exhausted, attention has been turned to unexplored 
sources. The aims of this research were to investigate terrestrial and aquatic 
invertebrates as a source of antibiotic producing microorganisms, to isolate the 
organisms and screen them for activity against Gram-positive and Gram-negative 
bacteria. Those with activity would be further characterised. Forty-seven antibiotic 
producers were isolated from 35 samples of different terrestrial and aquatic 
invertebrates using media designed to isolate streptomycetes. Identification by PCR 
and sequencing of 16S and 18S rRNA showed that the majority were in fact fungi, 
mainly Penicillium spp. and only 5 were Streptomyces spp. Three strains isolated 
from Helix aspersa (ES1), Lumbriculus variegata (La1a) and Baetis larvae (M1 11) 
that had strong activity against Gram-positive and Gram-negative bacteria including 
Methicillin-resistant Staphylococcus aureus (MRSA) were chosen for further study.  
PCR and sequencing of rRNA and Internal Transcribed Spacer (ITS) regions 
confirmed that the strains were closely related and were probably strains of P. 
chrysogenum. The organisms were grown in liquid media and on agar and the active 
components were extracted with ethyl acetate and fractionated by HPLC. As facilities 
for large scale liquid cultures were not available large scale preparation was 
performed from agar medium and the active fractions. HPLC showed that the extracts 
were complex and contained more than one active component.  The purified fractions 
were chemically characterised by NMR, FTIR and MS. The results showed that the 
active components were novel flavones and isoflavones. Such compounds have 
extracted from plants and only previously been shown to be produced by endophytic 
fungi. The minimal inhibitory concentrations (MIC) against test bacteria and 
inhibitory concentration IC50 (IC50
 
is the concentration of a compound at which 50 
% of human cancer cell tissue cultures are killed) showed potential for use in 
chemotherapy as all purified fractions except Es1 F3/3 and Es1 F6 were found to have 
IC50 values>100 µg/ml, High IC50 and low MIC (0.39 to 50 µg/ml) may indicate 
fractions suitable for testing for treatment of human infections. The results showed 
that the invertebrates were indeed a source of antibiotic producing organisms. 
 xviii 
Whether the organisms were acquired by the invertebrates from the environment or 
whether they were in a symbiotic association needs further study. 
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Chapter 1 
 
1. INTRODUCTION 
 
1.1 Definition of antibiotics and antimicrobial agents 
By definition, an antibiotic (from the Greek: Anti; "against", and   – bios, "life") is a 
substance or compound formed by one organism which at low concentrations can 
inhibit the growth of or kill other organisms and is usually used to describe substances 
that act on microorganisms (Agbor et al., 2011, Sharma et al., 2013). Antimicrobial 
chemotherapeutic agents also includes agents that can be can be chemically 
synthesized. Many antibiotics are now made chemically or are chemically modified 
(semi-synthetic) so that the difference between the two terms is often blurred. 
Antibiotics are therefore described as naturally occurring, semi-synthetic and synthetic 
compounds with antimicrobial activity that can be administered parentally, orally or 
topically (Lee et al., 2001). 
 
Microbes produce a very large number of different organic compounds, often with 
low molecular weights, which makes up a very diverse chemical and biological 
ecology. It has been suggested that, at low concentrations, most of these compounds 
play a crucial role in the alteration of metabolic function within natural microbial 
environments (Yim et al., 2006). In these environments, organisms that produce 
antimicrobial compounds have higher survival rates because the compounds produced 
can destroy or inhibit the growth of other existing competing bacteria (Kumar et al., 
2012b).  
Before the discovery of antibiotics there were few options for treating infections 
caused by microorganisms. The first chemotherapeutic agent was arsphenamine 
(Salvarsan), an organoarsenic compound that was introduced by Paul Ehrlich in 1910 
as a treatment for syphilis although it was extremely toxic (Williams, 2009). The 
sulphonamide drugs which were introduced in the late 1930’s were effective 
antibacterial agents and were important in the UK during World War II, However, 
they had serious side effects and they were rapidly superseded by the introduction of 
penicillins after their discovery by Fleming in 1928 and their purification by Florey 
and his co-workers in the early 1940’s (Davenport, 2011). The discovery of 
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antibiotics in the 20
th
 century was considered a great achievement, however, now 
there is a concern in the increase of antibiotic resistance within hospitals, 
communities and the environment related to their use (Davies and Davies, 2010). 
Indeed there are some infections that are resistant to most if not all antibiotics 
(Livermore, 2009, Fifer et al., 2016).  
The discovery of penicillin started the “golden age” of antimicrobial therapy. Newer 
antibiotics both from natural origins and synthetic were discovered mainly in the 
period between 1940 to 1990. During this period most of the antibiotics including β-
lactams, tetracyclines, chloramphenicol, aminoglycosides, macrolides, glycopeptides, 
streptogramins and quinolones with different mechanisms of action on and affecting 
different targets in bacteria were introduced into clinical practice. Since the “golden 
age” most “new” antibiotics/antibacterial agents have been produced by chemically 
modifying pre-existing antibiotics in order to make various generations with enhanced 
efficacy and spectra of activity (Bbosa et al., 2014). Since the discovery and 
development of penicillin in the 1940s, further research has been carried out, in 
particular the Streptomyces spp., to develop antimicrobials that can act against 
pathogenic bacteria. Currently, there are more than 350 agents that have been 
introduced to the world industry as antimicrobials (Silber et al., 2016). The research 
and study of antibiotics/antibacterial agents have greatly transformed the treatment of 
bacteria related infections that used to overwhelm millions prior to the “golden age”. 
(Bbosa et al., 2014). However there have been few new antibiotics and few new 
targets identified over the last 30 -40 years. 
 
1.2 The Basic characteristics of antibiotics 
 
An ideal antibiotic should fulfill certain criteria. Concerning toxic side effects it must 
be relatively toxic to microbes but nontoxic to host cells. It is preferred to be 
microbiocidal rather than micro-biostatic. Moreover, it is recommended to be 
reasonably soluble and functional even when highly diluted in body fluids. Some of 
the most valuable characteristics are that resistance to the antibiotic does not develop 
quickly, that it does not cause allergic reactions in host tissues or be prematurely 
excreted or broken-down. Finally it is preferable to be of reasonable price (Talaro, 
2007). 
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The antibiotic concept stated above indicates that small molecules are produced 
naturally by bacteria and/or fungi in adequate quantities to suppress or destroy other 
microorganisms thus reducing competition in natural environments. This was 
demonstrated in the laboratory when strains acquired from starved environments were 
exposed to rich, unnatural growth conditions, this triggered the production of 
compounds in large quantities (Yim et al., 2006).  
The production of appropriate amounts of compound for preliminary chemical and 
clinical studies requires efforts in microbiology (e.g. use different media, different 
incubation period, etc.), chemistry (e.g. use of different solvents for extraction, use of 
different chromatography technique to purify the active compounds etc.), and the 
isolation of strains of the microorganism that produce higher yields. Therefore, small 
molecules produced in low concentrations are not easily detected by these methods. 
One of the more interesting discoveries from genome sequencing efforts is the 
demonstration that, based on current knowledge of biosynthetic pathways and their 
organization, some organisms possess the genetic capability to produce variable 
numbers of different small bioactive molecules (Bentley et al., 2002, Ikeda et al., 
2003). The genome sequence of S. coelicolor revealed 18 clusters of genes for 
secondary metabolite synthesis include some that had not previously been identified. 
These include polyketide synthases type I and II, non-ribosomal peptide synthetases 
(NRPSs), chalcone synthases and others (Bentley et al., 2002).  
 
 
1.3 Mechanisms of antibiotic action  
 
The classification of antibiotics is based on either the cellular component or the 
system they affect, in addition to whether they trigger cell death (bactericidal drugs) 
or simply inhibit cell growth (bacteriostatic drugs). Currently bactericidal 
antimicrobials, inhibit DNA synthesis, RNA synthesis, cell wall synthesis, membrane 
permeability, intermediary metabolism or protein synthesis (Figure 1.1; Kohanski et 
al., 2010). 
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On the basis of their mechanism of action, antibiotics are classified as: 
Those affecting the biosynthesis of the bacterial cell wall, leading to loss of viability 
and often cell lysis (e.g. penicillins, cephalosporins, bacitracin, and  vancomycin) but 
often only on actively growing cells. 
Those that act directly on the cell membrane, disrupting its barrier function and 
causing leakage of intracellular components (e.g. polymyxins). 
Those that affect protein biosynthesis (e.g. chloramphenicol, tetracyclines, 
erythromycin, streptomycin, gentamycin) 
Those that interfere with nucleic acid biosynthesis (e.g. rifampicin, novobiocin, 
quinolones). 
Those that block specific steps in intermediary metabolism (e.g. sulfonamides, 
trimethoprim; Husain et al., 2010).  
 
 
Figure 1.1: Mode of action of antibiotics on cell components  
Modified from Bbosa et al. (2014)  
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1.4 Microbial resistance to antibiotics 
 
The ability of a microorganism to withstand antibiotic effects is referred to as 
antibiotic resistance. It evolves through natural processes such as natural selection via 
random mutation, or it could also be engineered by applying an evolutionary stress on 
a population. The antibiotic action is an environmental pressure such that resistant 
bacteria will survive and continue to reproduce. The specific trait is then transferred 
to the offspring, leading to a fully resistant generation. As antibiotic resistance 
protects antibiotic-producing organisms from their own products and other originally 
susceptible organisms from competitive attack, it is has coevolved with antibiotics 
(Sarmah et al., 2006, Kemper, 2008).  
The resulting genes can then be transferred by horizontal gene transfer between 
individuals via transduction, conjugation or transformation (Morell, 1997, Konaté et 
al., 2013). Antibiotic resistance can be introduced into a microorganism by artificially 
implanting genes into it (Gaude and Hattiholli, 2013). 
In both humans and veterinary medicine, antibiotics are used to cure and prevent 
disease. The development of resistant bacterial strains impacts on the use of 
antibiotics as treatment in both humans and animals and represents a major health 
concern. The extensive use of veterinary pharmaceuticals is supposed to be an 
important public health risk that results from the emergence and spread of resistant 
bacteria. Particularly, the application of veterinary antibiotics to food animals is likely 
to increase the selection for strains resistant to antibiotics used in human medicine 
(Marshall and Levy, 2011). These strains may be transmitted to humans through 
direct contact with animals or via the food chain to the consumers, in food animal 
adding antibiotics encompasses a wide variety of nontherapeutic purposes that include 
growth promotion. For example, growth promotion in animal husbandry using the 
streptothricin antibiotic nourseothricin led to plasmid-borne resistance to 
streptothricin in Escherichia coli from nourseothricin fed pigs, from workers in pig 
farms and from their family members. Furthermore, resistant E. coli were found in 
people without any contact to pig farms (as part of the gut mocrobiota and even 
causing urinary tract infections). However, these individuals lived in villages and 
towns of the region where nourseothricin was used on pigs (Hummel et al., 1986). 
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The risks that originate from excessive use of antibiotics lead to environmental 
contamination with antibiotic resistant bacteria and antibiotics. Furthermore, the 
impacts on the biotic environment are a major concern (Kemper, 2008). 
 
1.4.1 Mechanisms of resistance 
 
There are five main mechanisms of antibiotic resistance (Figure 1.2): 
Production of inactivating enzymes 
Changes in the target site 
Induction of alternate pathways (bypass pathways) 
Failure to activate the antibiotic to its active state 
Exclusion of the antibiotic from the target site or active efflux  
The latter may happen by restriction of access through porins (only in Gram-
negatives) or by active secretion (Scott, 2009). 
The major mechanisms of antibiotic resistance are classified as modifications of the 
Antibiotic Molecule (chemical alterations of the antibiotic and destruction of the 
antibiotic molecule), Target site change (target protection and modification of the 
target site (mutations of the target site, enzymatic alteration of the target site and 
complete replacement or bypass of the target site)) and exclusion and active efflux of 
the antibiotic (decreased permeability and efflux pumps  (Munita and Arias, 2016) 
 
Modifications of the Antibiotic Molecule 
Production of enzymes by resistant bacteria to inactivate the antimicrobial compounds 
is one of most successful strategies to survive in case of exposure to antibiotics by 
adding chemical moieties to the antimicrobial molecule or that destroy molecule 
itself.  
 
1. Chemical alterations of the antibiotic  
Gram-positive and Gram-negative bacteria are well known mechanism of acquired 
antibiotic resistance is synthesize enzymes that introducing chemical changes to the 
antimicrobial molecule. Aminoglycosides are inactivated by modifying enzymes that 
phosphorylate (aminoglycoside phosphoryltransferase, acetylate (aminoglycoside 
acetyltransferase, or adenylate (aminoglycoside adenytransferase; Poole, 2005a). 
One of the best example of the resistance due to chemical alteration of the antibiotic is 
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modifying enzymes that inactivate aminoglycosides by covalently modifying the 
hydroxyl or amino groups of the aminoglycoside molecule. These enzymes are 
usually carried on mobile genetic elements, but chromosomal genes coding for 
modifying enzymes have also been found in in some bacterial species, such as 
aminoglycoside acetyltransferases in Providencia stuartii, Enterococcus faecium and 
Serratia marcescens (Ramirez and Tolmasky, 2010) 
     
2. Destruction of the antibiotic molecule  
Degraded β-lactam ring by the action of β- lactamases is the main mechanism of β-
lactam resistance. In general, Gram-positive bacteria produce a large amount of β-
lactamase, which is secreted extracellularly, in Gram-negative bacteria, β-lactamases 
are found in relatively small amounts and are located in the periplasmic space, 
between the inner and outer cell membranes. In this group, beta-lactamases destroy 
the amide bond of the β-lactam ring resulting in inactivation of the antibiotic (Cesur 
and Demiroz, 2013, Soares et al., 2012). 
 
Target site change 
Bacteria avoid the action of the antimicrobial molecule by interfering with their target 
site, this strategy common in bacteria to develop antibiotic resistance; these include 
protection of the target and modifications of the target site    
 
1. Target protection  
In this mechanism the target site is protected by prevention of the antibiotic reaching 
its binding site. Clinically relevant genes coding for proteins that mediate target 
protection are usually carried by mobile genetic elements but some have been found 
on the bacterial chromosome. Tetracycline resistance determinants Tet(M) and Tet(O) 
are classic examples of the target protection mechanism. Tet(M) and Tet(O) are now 
widely distributed among different bacterial species, Tet(M) at first was described in 
Streptococcus spp. and Tet(O) in Campylobacter jejuni, possible because both have 
been found in several plasmids and in broad-range conjugative transposons (Connell 
et al., 2003). TetO and TetM interact with the ribosome and dislodge the tetracycline 
from its binding site.  
 
 
 8 
2. Modification of the target site   
There are different ways to modify of the target site, mutations in the genes encoding 
the target site, enzymatic alterations of the binding site (e.g. addition of methyl 
groups), and/or replacement or bypass of the original target. All this causes decrease 
in the affinity of the antibiotic for the target site (Munita and Arias, 2016).  
 
2.1 Mutations of the target site  
Crucial target site changes include topoisomerases II and IV (attacked by quinolones, 
(Fàbrega et al., 2008), β subunit of DNA-dependent RNA polymerase (usually a 
target of rifamycins, (Depardieu et al., 2007). The development of rifampin resistance 
is an example of mutations of the target site. The rifampin binding pocket is located in 
the β subunit of the RNA polymerase (encoded by rpoB), the antibiotic molecule 
interrupts transcription after binding to its target site by directly blocking the path of 
the nascent RNA (Campbell et al., 2001). Single-step point mutations resulting in 
amino acid substitutions in the rpoB gene causing high-level rifampin resistance have 
been reported, these mutations decrease the affinity of the antibiotic for its target 
(Floss and Yu, 2005). 
 
2.2 Enzymatic alteration of the target site  
In one of the macrolide resistance mechanisms, bacteria develop resistance through 
the modification and methylation of the ribosomal RNA binding site of the antibiotic 
by an enzyme encoded by the erythromycin ribosomal methylation genes (erm genes). 
These enzymes are capable of mono- or dimethylating an adenine residue in position 
A2058 of the domain V of the 23rRNA of the 50S ribosomal subunit, which this 
change will cause low affinity of the antimicrobial molecule to its target site 
(Weisblum, 1995, Leclercq, 2002).  
 
2.3 Complete replacement or bypass of the target site  
This is observed in β-lactam resistance in MRSA by the acquisition of a foreign gene 
(likely from Staphylococcus sciuri) designated mecA often located in a large DNA 
fragment designated staphylococcal chromosomal cassette mec (SCCmec), which 
encodes a novel penicillin-binding protein (PBP2a), which has low affinity for β-
lactam antibiotics and enables the bacteria to assemble the cell wall in the presence of 
the β-lactam antibiotics (Ba et al., 2013, Munita and Arias, 2016, Hawkey, 1998).  
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Another of resistance mechanism whereby the normally inhibited metabolic pathway 
is bypassed by overproducing the antibiotic target by increasing the amount of target 
site available and the antibiotic not overwhelming the bacteria. Trimethoprim-
sulfamethoxazole resistant bacteria are a good example of this mechanism. This 
antibiotics interact with the folic acid synthesis, two enzymes involves in folic acid 
synthesis, dihydropteroic acid synthase (DHPS) inhibited by sulfamethoxazole and 
dihydrofolate reductase (DHFR) inhibited by trimethoprim, due to mutations in the 
promoter region of the DNA encoding these enzymes result in the production of 
increased quantities of the DHPS and DHFR, this allows bacteria to survive and 
trimethoprim-sulfamethoxazole do not inhibit folic acid production (Flensburg and 
Skold 1987, Eliopoulos and Huovinen 2001) 
 
Exclusion and active efflux of the antibiotic    
Porins are protein structures located in the outer bilipid membrane of Gram-negative 
organisms. They control what passes into and out of the cell based on molecular size 
and charge. Mutations in the genetic elements encoding porins (permeability 
mutations) may prevent entry of one or multiple antibiotics (Poole, 2005b).  
Escherichia coli K-12 produce large amount of OmpF and OmpC, two major outer 
membrane proteins regulated by the ompB locus. Mutants lacking the OmpF proteins 
have increased antibiotic resistance (Jaffe et al., 1982). In P. aeruginosa loss of 
OprD proteins due to mutation in the oprD gene causes a significant decrease in the 
sensitivity of P. aeruginosa to carbapenems (Sanbongi et al., 2009, Azimi et al., 
2015).  
Alternatively, organisms may actively excrete antibiotics. McMurry et al. (1980) were 
the first to describe efflux pumps as a mechanism of resistance to tetracycline. Tet 
efflux pumps are able to actively expel tetracycline from E. coli by plasmid-encoded 
proteins. Later, many efflux pumps have been described (in both gram-negative and 
gram-positive pathogenic bacteria) and these pumps may be specific for certain 
antibiotic (substrate-specific) such as tet determinants for tetracycline and mef genes 
for macrolides in pneumococci or for multi antibiotics (broad substrate specificity), its 
usually found in multi drug resistance bacteria (Poole, 2005b).    
Efflux pump encoding genes can be located in mobile genetic elements such as Tet 
efflux pumps encoded by the tet gene (mention above) and MsrA is a plasmid-borne 
determinant that was originally described in S. epidermidis or in the chromosome 
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such as MsrC efflux pump, chromosomal-encoded described in E. faecalis that 
confers resistance to erythromycin and other macrolide and streptogramin B 
antibiotics and Lsa efflux pumps encoded by the chromosomal gene lsa that causes E. 
faecalis resistance to lincosamides and streptogramin A (Singh et al., 2002, Poole, 
2005b). The Mef pumps are mainly found in S. pyogenes and S. pneumonia encoded 
by the mef genes (mefA and mefE), mefA located in the chromosome and usually 
carried o a n a transposon (Tn1207), MefE has been fond located in different regions 
of the bacterial chromosome in fragment of DNA called macrolide efflux genetic 
assembly element, these pumps cause resistance to macrolide antibiotics Ross et al., 
1990.  
Efflux pumps have been divided into five major families on the basis of structural 
conformation, sequence similarity, energy source, range of substrates they are able to 
extrude (single or multiple) and in the type of bacterial organisms: the adenosine 
triphosphate (ATP)-binding cassette (ABC) superfamily, the resistance-nodulation-
division (RND) family, the small multidrug resistance (SMR) family, the major 
facilitator superfamily (MFS) and the multidrug and toxic compound extrusion 
(MATE) family (Blanco et al., 2016, Munita and Arias, 2016).  
The MFS, ABC, SMR, and MATE families are broadly spread in Gram-positive and 
Gram-negative bacteria, whereas the RND superfamily is specific to Gram-negative 
bacteria Blanco et al., 2016. Efflux pump group belong to MFS family is most 
relevant to Gram-positive bacteria, PmrA from S. pneumoniae and NorA from S. 
aureus the best described of MFS family (Lorca et al., 2007, Ubukata et al., 1998), 
also Tet efflux pumps belonging to the MFS family Poole, 2005b. Msr(A) efflux 
pumps resulting in macrolide resistance in gram-positives, belonging to the ABC 
superfamily Reyes et al., 2007. Examples of the RND family are AcrAB-TolC in 
Enterobacteriaceae and MexAB-OprM in P. aeruginosa (multidrug resistance efflux 
pumps) Visalli et al., 2003, Dean et al., 2003.     
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Figure 1.2: Four major biochemical mechanisms of antibiotic resistance 
Modified from Hawkey (1998)  
 
1.4.2 Acquisition of resistance 
Direct mutation of chromosomal genes causes resistance, and non-fatal mutations are 
passed to all offspring (which acquire a selective advantage in the presence of the 
antibiotic). Alternatively, bacteria may acquire external genetic material from other 
bacteria (even bacteria of different species) by three different mechanisms.  
Conjugation like the direct transfer by type IV, F- or P- (“sex”) pili. In the process of 
Conjugation is a process in which a mobile or conjugative genetic element (such as a 
plasmid or transposon) is transferreded from the contributor cell. In the appropriate 
environment, plasmids can reproduce each time an organism divides and can be lost 
as easily as they are acquired. Transposons are large genetic elements usually 
containing various genes essential to confer phenotypic resistance (Holmes, 1996). 
Transformation is one of the processes to transfer genetic elements material including 
antibiotic resistance gens into a bacterial cell, free DNA from dead bacteria and even 
mammalian cells can be taken up and merged into bacterial chromosomes by the 
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process of transformation (Scott, 2009). The third mechanism for horizontal genetic 
transfer is transduction involving transfer of DNA from one bacterium into another 
via bacteriophages. Table 1.1 shows some examples of acquired resistance (Abebe et 
al., 2016). 
Table 1.1: Examples of acquired antibiotic resistance  
Modified from Abebe et al. (2016), Lyon and Skurray (1987) 
Acquired resistance by Resistance observed  
 
Mechanism involved 
Mutations Mycobacterium 
tuberculosis resistance to 
rifamycins 
Point mutations in the rifampin-
binding region of rpoB 
Resistance of many clinical 
isolates to fluoroquinolones 
Predominantly mutation of the 
quinolone-resistance-
determining-region (QRDR) of 
GyrA and ParC/GrlA 
E.coli, Hemophilius 
influenzae resistance to 
trimethoprim 
Mutations in the chromosomal 
gene specifying dihydrofolate 
reductase 
Horizontal gene transfer S. aureus resistance to 
methicillin (MRSA) 
Via acquisition of mecA genes 
which is on a mobile genetic 
element called “staphylococcal 
cassette chromosome” 
(SCCmec) which codes for 
penicillin binding proteins 
(PBP2a)  
Resistance of many pathogenic 
bacteria against sulfonamides 
Mediated by the horizontal 
transfer of foreign genes or parts 
of it 
E. faecium and E. faecalis 
resistance to vancomycin 
Via acquisition of one of two 
related gene clusters VanA and 
Van B, which code for enzymes 
that modify peptidoglycan 
precursor, reducing affinity to 
vancomycin. 
S. aureus resistance to 
gentamycin 
Mediated by the conjugational 
transfer of self- transmissible  
(Tra+) plasmids transferred 
between apparently 
nonlysogenic strains of S.aureus  
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1.5 Importance of resistance in Healthcare acquired infections 
Patients undergoing treatment within the healthcare are exposed to infections that are 
recognized worldwide to contribute to morbidity and mortality. Some patients such as 
children, elderly and patients with weakened immune systems are more fragile and 
are at greater risk of acquiring these infections. The close cohorting of patients with 
reduced resistance to transmissible diseases provides an ideal environment for 
antibiotic resistant bacteria to spread from one patient to another. Health Care 
Associated Infections (HCAI) are infections resulting from medical care, these 
infections can be acquired by various means such as through long stays in hospitals; 
not using sterile equipment; failure of healthcare personnel to wash hands, overuse of 
antibiotics and failure to maintain aseptic techniques (Tabatabaei et al., 2015). 
HCAI effecting people with direct result of treatment in, or contact with health care 
setting, also people acquired infection outside a healthcare and brought into a 
healthcare by patient, staff, or visitors and transmitted to others. HCAI Pose a 
significant risk to patients, staff and visitors to health and social care premises. 
According to reports from Health Protection Agency, 2011; Public Health England 
(PHE), 2012 approximately 1 in 8 patients are affected by a HCAI which can incur 
costing to the NHS in excess of £1 billion per year and estimated that 5000 people 
die a year from such infections. HCAI covers a wide range of infections, the most 
well known include those caused by MRSA, Methicillin-sensitive S. 
aureus (MSSA), Clostridium difficile (C. diff) and E. coli (Carr, 2016). As a result, 
Public Health England (PHE) advise and support the NHS in efforts to prevent and 
control HCAI. 
PHE annual epidemiological commentary dated 2016/17 on HCAIs reports that across 
England the rate of MRSA bacteraemia remained steady at 1.5 cases per 100,000 
population in 2016/17 and over the last three financial years (2014/15 to 2016/17) 
dropped by 7.1% in 2014/15 compared to the previous financial year.  The rates of 
MSSA and E.coli bacteraemia both increased between 2015/16 and 2016/17, at 19.3 
cases per 100,000 population in 2015/16 to 20.9 in 2016/17 in MSSA, at 69.7 cases 
per 100,000 population in 2015/16 to 73.9 cases per 100,000 population in 2016/17 in 
E. coli. The rate of C. difficile infection has reduced from 25.8 cases per 100,000 
population in 2015/16 to 23.4 cases per 100,000 population in 2016/17. MRSA 
bacteraemia infection source from intravenous catheter or line have seen considerable 
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decreased in the percentage between 2007/08 and 2016/17,this is likely due to 
interventions aimed at improving care in the acute setting. Nevertheless, infection of 
MRSA bacteraemia from catheters and lines source have seen increase between 
2015/16 and 2016/17 and may require further effort to reduce it again.  
This is not unique problem to the UK, it is world wild problem for example according 
to report from Centers for Disease Control and Prevention (CDC) in United States, 
more than 2 million infections with 23 000 deaths annually causes by AMR 
(Holmstrup and Klausen, 2018) and in Europe, AMR causes approximately 25 000 
deaths per year and cost over €1.5 billion in healthcare expenses related to these 
infection (Ronnerstrand and Lapuente, 2017). In India the situation is even more 
alarming with estimated that more than 58 000 infants died in the year 2013 as a 
result of AMR infections (Rather et al., 2017). In Thailand, more than 38 000 death 
per year (Jepsen and Jepsen, 2016). 
Plans to overcome antibiotic resistance within the healthcare professions include 
multidisciplinary collaboration in operating local policies on use of antibiotics and 
infection control measures, early detection and reporting of the antibiotic resistant 
strains, enhanced surveillance, and make good strategies to control transmission of 
epidemic resistant bacteria (Struelens, 1998) 
 
1.6 The need for antibiotic research and discovery 
 
          One solution to the emergence of bacterial resistance is the development of new 
antibacterial agents for substitution for ineffective drugs, therefore the search for new 
antibiotics either of unique structure or improved activity from this apparently endless 
source (microorganisms) continues to be of extreme importance in research programs 
around the world, especially with the increased prevalence of resistant pathogens. In 
the 21st century, antimicrobial resistance (AMR) described as one of the major threats 
to individual and population, AMR have repeatedly underlined the urgent need for 
action by national and international organizations (Davies and Gibbens, 2013, 
O'Neill, 2014) 
Infectious diseases are the second highest causes of death worldwide despite the 
progress made in the process and production of antibiotics (Silber et al., 2016). 
The appearance of infectious caused by multi-drug resistant strains and important 
clinical indication of drug resistance has led to increased interest in the research of 
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antimicrobial resistance from various aspects. To solve this problem, further research 
is required to discover new more efficient antimicrobial agents. Fungi, particularly 
from the genera Aspergillus and Penicillium are eukaryotes that serve as a reservoir of 
bioactive metabolites which can be used for the purpose of medicinal study 
(Compaore et al., 2016a) 
In the coming years, advancing screening programs for the selection of different 
natural and modified chemical compounds will be a necessity to discover new 
antibiotics active against resistant bacteria (Sanchez et al., 2010).  There is also an 
increasing demand for antibiotics. For example, in a study carried out by 
“marketresearch.com”, China’s demand for penicillin had grown exponentially 
between 1990 and 2000 and this demand was forecast to continue to grow and expand 
over the subsequent years (Dayalan et al., 2011). 
 
1.7 Natural products 
Nature has been a source of therapeutic agents for thousands of years, and an 
impressive number of modern drugs have been derived from natural sources, many 
based on their use in traditional medicine (Murugan and Mohan, 2011). Products 
came from natural origins can be called “natural products”.  
Natural products come from four major sources  
(i) An entire organism (e.g., a plant, an animal, or a microorganism) that has not been 
subjected to any kind of processing or treatment other than a simple process of 
preservation,  
(ii) Part of an organism (e.g., leaves or flowers of a plant, or an isolated animal 
organ),  
(iii) An extract or an exudate of an organism, and  
(iv) Isolated pure compounds from plants, animals, or microorganisms, (e.g., 
alkaloids, flavonoids, glycosides, steroids, sugars, terpenoids, etc.)  
Nevertheless, in most cases the term natural products refers to secondary metabolites 
(small molecules produced by an organism that are not strictly necessary for the living 
of the organism). Natural products can be from any terrestrial or marine source: 
plants, animals, or microorganisms. The databases of natural products (Super Natural 
II database) comprises 325 508 natural compounds from almost all part of the world 
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(Xie et al., 2015) The natural product drug discovery process in general includes the 
testing of extracts of plant, marine or microbial origin in adequate in vitro assays 
target based, followed by bioassay- guided fractionation of the active extracts and 
isolation and purification of active constituents. Those constituents showing 
significant in-vivo activity in appropriate animal models are considered as lead 
molecules, which may be chosen as candidates for preclinical development.  
 
1.8 Secondary metabolites 
Due the fact that they are not produced during normal growth antibiotics are 
categorized as secondary metabolites. Characteristically they are not usually produced 
during the phase of rapid growth (trophophase), but are synthesized during a 
subsequent phase of secondary metabolism that starts when growth is limited by the 
exhaustion of one key nutrient source. Secondary metabolites are substances that are 
indirectly involved in normal growth, development, or reproduction of an organism; 
these compounds are not involved in a physiological role during exponential phase of 
growth. 
Secondary metabolites are organic compounds produced by strain of certain microbial 
species and by some plants, they are regarded as a crucial component in the discovery 
and development of drugs (Shaala and Youssef, 2015), these compounds are varied 
and sophisticated chemical structures, there are many metabolites with an enormous 
range of biological activities but the antibiotics are the best known secondary 
metabolites. Most secondary metabolites of commercial importance are produced by 
actinomycetes, especially genus Streptomyces, and by fungi (Gonzalez et al., 2003).  
Endophytic fungi which can be found in the tissue of living plants seem to contribute 
secondary metabolites as part of the plants normal functions (Devi et al., 2012). Spore 
pigments also have structures similar to those of other secondary metabolites and are 
synthesized by the same kinds of mechanisms (Nakano et al., 2000). The genes 
coding for the enzymes responsible for the synthesis of secondary metabolites are 
often clustered. These clusters include the genes for the actual biosynthesis, as well as 
determinants for regulation and self-resistance (Pissowotzki et al., 1991). Sometimes 
the genes are located on plasmids. It is apparent that horizontal transfer of genes 
coding for secondary metabolites can take place in soil (Egan et al., 1998, Ōmura et 
al., 2001). The gene clusters are frequently polyketide synthetases (PKS) or non-
ribosomal peptide synthetases (NRPS), Wang et al., 2014a have been reported the 
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widespread occurrence of NRPS and PKS genetic machinery across the three domains 
of life (bacteria, archaea, and eukarya) with the discovery of 3,339 gene clusters from 
991 organisms, by examining a total of 2,699 genomes.  
The production of secondary metabolites is affected by the availability of nutrients. In 
fermentation experiments, the production of antibiotics is increased by the presence of 
a non-preferred carbon source, or by phosphate starvation (McDowall et al., 1999). 
By optimizing both the nutrition medium formulation and operating conditions for 
organisms, antibiotic production from these genes can be improved.  The use of new 
carbon and nitrogen sources can lead to better microbial growth and antibiotics 
production (Ilić et al., 2010). The regulation mechanisms of the production of 
secondary metabolites are not yet fully understood, whereas secondary metabolites 
must confer an adaptive advantage, the roles of most are not fully understood. This is 
true even for antibiotics (Bibb, 2005). 
The antibiotics may be useful unaltered or they may act as “lead” compounds. These 
leads can be structurally altered via combinatorial chemistry approaches to generate 
agents with improved activity or reduced toxicity. The growth of secondary 
metabolite-extracted drugs bears important challenges in multiple areas. The prime 
challenge is the supply of the drug in sufficient quantities to permit preclinical, and 
hopefully clinical, development, and eventually, if given a successful, clinical 
consequence, commercial production. Formulation considered as the major concern. 
A prime requirement for administration of the drug to human patients especially drugs 
used through the intravenous route is solubility and the natural products generally are 
highly insoluble in aqueous media (Cragg and Newman, 2005). Figure 1.3 is a 
summary of the possible outcomes of a typical bioactivity guided fractionation of any 
crude extract from natural source and the schematic representation shows that at in 
any stage would lead to a wide array of possible outcomes. Furthermore, these 
outcomes might provide unexpected opportunities for modifying the discovery design 
during subsequent stages. 
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Figure 1.3: Stages of natural products discovery  
Modified from (Katiyar et al., 2012). 
 
 
1.9 Organisms that produce antibiotics  
 Brief history of antibiotics and producer organisms 
             In 1684 Antonie van Leeuwenhoek was the first person to discover the 
existence of bacteria by grounding small spherical lenses to observe unicellular 
bacteria. Microbiology did not advance until 200 years later by pioneers such as Louis 
Pasteur, Robert Koch and Ferdinand Cohn. The discovery of the first antibiotic 
penicillin from the mold Penicillium notatum by Sir Alexander Fleming opened up a 
completely new era of chemotherapy, thereby changing the quality of human life 
(Silber et al., 2016).  
The first to describe a strain of Streptomyces was Ferdinand Cohn, this name was 
eventually conferred by Selman Waksman in 1942. Waksman’s interest in 
Streptomyces lead to the discovery that Streptomyces spp. produced antibiotics; he 
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was awarded with the Nobel Prize for his work. Antibiotics derived from 
Streptomyces spp. began with streptothricin and, two years later, streptomycin. 
Streptomycin was used commercially and with success (Chater, 2006). The 
importance of these microorganisms can be seen in the list of antibiotics and their 
dates of discovery shown in Table 1.2.  Antibiotics sourced from the genus 
Streptomyces and other actinomycetes were of paramount importance in their 
development (de Lima Procópio et al., 2012). 
 
Table 1.2: Key findings and dates of antibiotics. 
Antibiotic 
 
Year of 
discovery 
Year of 
introduc
tion 
Year 
resistance 
detected 
Producing organism 
 
Penicillin 1928 
1928 
 
1938 1965 Penicillium notatum 
Streptomycin 1943 1944 1948 S. griseus 
Cephalosporin 
 
1945 1964 
Unclear 
S. clavuligerus 
Bacitracin 1945 Unclear Unclear 
B.  licheniformis 
 
Polymyxin 
 
1947 Unclear 
Unclear 
B. polymyxa 
Chloramphenicol 
 
1946 1948 1955 S. venezuelae 
Neomycin 
 
1949 Unclear 
Unclear 
S. fradiae 
Chlortetracycline 
  
1944 1952 1959 S. aureofaciens 
Nystatin 
 
1950 
Unclear Unclear 
S. noursei 
Erythromycin 1948 1951 1955 S. erythreus 
Fidaxomicin 
 
1948 2011 1977 
Dactylosporangium aurantiacum 
 
Viomycin 
 
1951 Unclear Unclear 
S. vinaceus,  S. capreolus 
Virginiamycin 
 
1952 
Unclear Unclear 
S. pristinaespiralis, S. virginiae 
Lincomycin 
 
1952 Unclear 
Unclear 
S. lincolnensis 
Cycloserine 
 
1955 2000 2000 S. garyphalus 
Vancomycin 
 
1956 1972 1988 S. orientalis 
Noviobiocin 
 
1956 Unclear Unclear S. niveus 
Rifamycin 
 
1957 1985 1962 Amycolatopsis mediterranei 
 
Kanamycin 
 
1957 Unclear Unclear S. kanamyceticus 
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Antibiotic 
 
Year of 
discovery 
Year of 
introduc
tion 
Year 
resistance 
detected 
Producing organism 
 
Fusidic acid 
 
1963 Unclear Unclear Fusidium coccineum 
Gentamicin 
 
1963 1967 1979 Micromonospora purpurea 
Fosfomycin 
 
1969 Unclear Unclear S. fradiae 
Ribostamycin 
 
1970 Unclear Unclear S. ribosidificus 
Mupirocin 1985 Unclear Unclear Pseudomonas fluorescens 
 
 
Daptomycin 
 
1986 2003 1987 S. roseosporus 
Platensimycin 
 
2006 Unclear Unclear S. platensis 
Modified from (de Lima Procópio et al., 2012, Lewis, 2013, Hede, 2014) 
Note: The year of discovery, introduction and resistance detected of the antibiotics in 
Table 1.2 obtained from de Lima Procópio et al., 2012, Lewis, 2013, Hede, 2014)  
“Unclear” different sources quote different years for discovery and observation of 
resistance. 
  
Microorganisms have been shown to produce abundant metabolites with different 
activities including antimicrobial, anticancer and antiviral (Tawiah et al., 2012) 
Research carried out on soil bacteria and fungi have revealed that microorganisms are 
a rich source of structurally distinctive bioactive substances (Fenical, 1993). After the 
discovery of penicillin, various drugs were discovered as a result of studying 
microorganisms. As mentioned earlier, several of the pathogens (e.g., Mycobacterium 
tuberculosis, Staphylococcus aureus) involved in infectious disease are rapidly 
increasing resistance to the currently available antibiotics, thus rendering the 
treatment of such infections very challenging (Bhavnani and Ballow, 2000), and has 
caused research progress around the world to put a priority on antibiotic development,  
hence the urgent need develop more effective antibiotics from bacteria and fungi. 
Until recently, most of antimicrobial compounds were isolated from terrestrial 
microorganisms (Tawiah et al., 2012). Microbial sources are responsible for the 
production of thousands of natural antibiotics with more than 50% produced by 
actinomycetes, 10% - 15% produced by non-filamentous bacteria and approximately 
20% by filamentous fungi. In the past decade, there has been increased interest in 
fungi for the progress of anti-infective lead compounds, increasing the awareness of 
their importance in biotechnology (Silber et al., 2016). 
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1.9.1 Actinomycetes 
Recent reports show that the actinomycete group of microorganisms still remains an 
important source of antibiotics (El-Naggar et al., 2013). Indeed, the growing 
economic importance of this group of actinomycetes is due to the fact that the 
majority of antibiotic producing streptomycetes are found among this group 
(Suneetha and Raj, 2011). Streptomyces, a common genus in the actinomycetes, has 
long been of interest due to its diversity of chemical constituents and biological 
activities.  
Actinomycetes are Gram-positive bacteria belonging to the order Actinomycetales, 
characterized by the formation of substrate and aerial mycelium on solid media, 
presence of spores and a high G+C content of the DNA 60-70 mol % (Shobha and 
Onkarappa, 2010). Actinomycetes are one of the most attractive sources of novel 
antibiotics (Lazzarini et al., 2000, Attimarad et al., 2012). Researchers have so far 
discovered biologically active compounds of microbial origin, around 23, 000 
bioactive secondary metabolites produced by microorganisms have been reported and 
of which over 10, 000 are produced by actinomycetes. Among actinomycetes, 
approx.7,600 compounds are produced by Streptomyces species (Prashith Kekuda et 
al., 2010, Subramani and Aalbersberg, 2012). Several well-known antibiotics have 
been isolated from this genus, for example, chloramphenicol, streptomycin, 
lincomycin, tetracycline (Intaraudom et al., 2011) , thienamycin, cephamycin C, 
penicillin N, as well as drugs with anticancer, antifungal, and
 
immunosuppressant 
activities (Sudha and Masilamani, 2012), which has made streptomycetes the primary 
antibiotic-producing organisms exploited by the pharmaceutical industry.  
The metabolic diversity of the Actinomycetes family is due to their large genome, 
which has hundreds of transcription factors that control gene expression allowing 
them to respond to their specific needs (Goshi et al., 2002, Saadoun et al., 2007a). 
Accordingly, screening of actinomycetes for potential drugs is still a matter of 
concern for medical community of many research centers (Jongrungruangchok et al., 
2006) and they are still one of the most investigated groups particularly members of 
the genus Streptomyces (Boudjella et al., 2006). The number of antimicrobial 
compounds reported from the species of this genus per year has increased almost 
exponentially for several decades. As a result of the increasing prevalence of 
antibiotic-resistant pathogens and the pharmacological limitations of antibiotics, there 
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is a requirement for new antimicrobial substances. With the seemingly exponential 
emergence of microorganisms becoming resistant to the clinically available 
antibiotics already marketed, the need for discovering novel drugs is urgent (Deepa et 
al., 2012). 
Among various genera, Streptomyces, Saccharopolyspora, Amycolatopsis, 
Micromonospora and Actinoplanes are the major producers of commercially 
important biomolecules. As the streptomycetes are very potent producers of 
secondary metabolites (Atta et al., 2012, Subramani and Aalbersberg, 2012, Kekuda 
and Shobha, 2010) these will be looked at in detail.   
 
The genus Streptomyces 
 
Streptomycetes are aerobic, Gram-positive, filamentous bacteria that undergo 
morphological differentiation during their life cycle. Spores usually occur but when 
nutrients and moisture are present, germination can occur and progress to vegetative 
mycelium with environmental changes such as depletion of nutrients and dehydration, 
differential processes are set into motion; desiccation and starvation resistant spores 
are formed again. Production of pigments, antibiotics and other secondary metabolites 
is initiated at the same time (Maheshwari et al., 2010). 
Streptomycetes produce extensive branching vegetative (substrate) mycelium and 
aerial mycelium bearing chains of arthrospores. The substrate mycelium and spores 
can be pigmented, but also diffusible pigments are produced (Bentley et al., 2002, 
Nayaka and Babu, 2014). On agar plates, they form lichenoid, leathery or butyrous 
colonies. The cell wall of streptomycetes contains LL-diaminopimelic acid and 
glycine (Kumar et al., 2012a).  
Carbon sources from a wide range of organic compounds are utilized by 
streptomycetes, such as cellulose and lignin. Inorganic nitrogen source can also be 
utilized (Arunachalam et al., 2010).  
 
Life Cycle 
           Streptomycetes resemble fungi in their elaborate life cycle, in addition to their 
cellular structure (Figure 1.4). The development stage of streptomycete during 
vegetative growth causes DNA replication without division of cells.  Filamentous 
structures are created during this cycle. Post vegetative growth, streptomycetes 
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reproduce and disperse through the formation of spores, called conidia.  Spores in 
aerial filaments called sporophores are produced which rise above the colony.  The 
resemblance to multicellular eukaryotes that streptomycetes have enables researchers 
to utilise a simpler system to study their development and life cycle (Panda and 
Rameshaiah, 2009). 
 
 
 
 
 
 
Figure 1.4: Life cycle of Streptomyces  
Modified from (Wu, 2016) 
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Figure 1.5: (a), Vertical sections through a Streptomyces colony. Photograph of 
colony growing on agar. (b) A diagram to shows dead cells (white vegetative 
mycelium) are autolytically degraded to provide the necessary nutrients, this allows 
the formation of aerial growth and sporulation. Living cells are shown as black 
(Chater, 2006). 
 
 
Classification 
            In general, the taxonomic classification of streptomycetes is based on 
morphological and biochemical characteristics (Gherbawy et al., 2012, Haritha et al., 
2012). Physiological tests such as preforming the growth at different temperature 
range from 4 to 65, PH range from 5.0 to 10.5 and the growth under anaerobic 
condition (Goodfellow et al., 1987, Kämpfer et al., 1991, Reddy et al., 2011, Haritha 
et al., 2012, Parthasarathi et al., 2012), serological methods (Cross and Spooner, 
1963), phage typing  (Korn-Wendisch and Schneider, 1992) and protein profiling  
(Ochi, 1995, Takeuchi et al., 1996) have also been used in their classification. More 
recently, the application of genetic methods, such as DNA-DNA reassociation 
(Labeda and Lyons, 1992) and 16S rRNA gene sequence analysis (Kataoka et al., 
1997, Chen et al., 2012, Parthasarathi et al., 2012) has been used.  Anderson and 
Wellington, (2001) review and summarize all of the approaches to clarify the 
taxonomy of streptomycetes. Multilocus sequence analysis (MLSA) has shown 
promising potential for refining Streptomyces systematics, MLSA using three or four 
of the genes also shows good resolution for distinguishing between most close strains 
 25 
and more suitable for discriminating strains that show >99 % 16S rRNA gene 
sequence similarity (Rong and Ying, 2010). 
Identification 
     Within the actinomycetes, the largest number of varieties and species found in 
natural environments are in the genus Streptomyces, their morphology, biology and 
biochemical activities have been observed to differ greatly. Isolation and description 
of numerous new species have resulted from this focused research, paving the way for 
the discovery of new divisions into subgenera or series.  Some authors have 
considered making certain important characters such as morphology, the structure of 
the substrate mycelium, the nature and formation of aerial mycelium, and branching 
of pseudohyphae containing spores, and the spore surface in an attempt to make such 
separations. Cultural criteria, such as growth on different media, colour of aerial and 
substrate mycelia, and formation of soluble pigments were also taken into account. 
For the classification of Streptomyces spp. certain biochemical criteria such as the 
utilisation of carbon sources, proteolytic properties, usage of nitrogenous compounds, 
presence of oxidases and reductases as well as sensitivity to antibiotics and phages, 
serological reactions, ecological properties and genetic relationships have been used. 
(Taddei et al., 2006a). Based on 41 characteristics, a probabilistic identification 
matrix for Streptomyces spp. identification, characters such as spore chain and spore 
morphology, pigmentation, physiological abilities, antibiosis and resistance to 
antibiotics, was developed by (Williams et al., 1983).  This scheme was applied to 
unknown isolates, 80 % of which could be assigned to a cluster. (Kämpfer et al., 
1991) supplemented the method with rapid enzyme tests using fluorogenic substrates. 
Phage sensitivity and serological tests as well as cellular fatty acid characterisation 
can be useful for assigning an unknown isolate to the genus Streptomyces, the 
difficulties imposed with species discrimination at the intragenus level were quickly 
observed (Anderson and Wellington, 2001).  
           DNA based molecular methods have been used for species differentiation and 
the identification of Streptomycetes. DNA-DNA reassociation is a method measuring 
the DNA relatedness of two organisms and has proved to be suitable for the 
investigation of relationships between closely related taxa, such as species. Strains 
belonging to the same species will generally have greater than 70 % DNA-DNA 
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relatedness ( Anderson and Wellington, 2001, Stackebrandt and Goebel, 1994, 
Bouchek-Mechiche et al., 2000). While DNA-DNA reassociation has shown to be 
useful in the identification of Streptomyces spp., it should not be used alone, but in 
connection with other tests, because there is considerable genetic instability of certain 
regions within the chromosome (Redenbach et al., 1993).  
 Determination of difference in the sequence of the 16S rRNA gene is now a well 
established standard method for the identification and phylogenetic classification of 
prokaryotic species, genera and families, but more recently it has also become 
important as a means to identify an unknown bacterium to the genus or species level 
(Arunachalam et al., 2010). 
The DNA sequences of the ribosomal genes are highly conserved, but the genes also 
contain variable regions, which sometimes can be useful for species discrimination 
and Kataoka et al., (1997) utilised the hypervariable region of the 16S rRNA gene to 
create an index for Streptomyces spp. identification. Also repetitive intergenic DNA 
sequences (rep-PCR) (Sadowsky et al., 1996) and PCR-RFLP of the 65-kDa heat 
shock protein gene (Steingrube et al., 1997) have been used for the classification and 
identification of pathogenic and other clinically important Streptomyces spp.        
 
1.9.2 Fungi 
 
It is estimated that there are 1.5 million fungal species on earth, of which only about 
70 000 have been described so far (Dayalan et al., 2011) 
Fungal natural products consist of a broad range of compounds. Some of these 
compounds are medically attractive as drugs and drug leads (Anyaogu and 
Mortensen, 2015) 
Although actinomycetes are second to fungi as sources of secondary metabolites, the 
fungi produce only about 20% of products with antimicrobial activity. Fungi have 
long been known to produce antimicrobial agents (Broadbent, 1966).  
Classically, Penicillium chrysogenum (previously known as Penicillium notatum) was 
the first antibiotic producing organism to be discovered and penicillins, together with 
cephalosporins produced by Acremonium chrysogenum have been one of the 
mainstays of antibacterial chemotherapy (Muniz et al., 2007). Continued research into 
chemical modifications has lead to several generations of compounds with improved 
spectra of activity and/or chemical properties.  More recently attention has been given 
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to fungi as sources of novel compounds. For example novel classes of antimicrobial 
agents (new aromatic polyketides and diketopiperazines) were produced by 
Penicillium spp. from terrestrial and marine sources from Australia (Capon et al., 
2007), antimicrobial agents (methyl 6-acetyl-4- methoxy-5, 7, 8-
trihydroxynaphthalene-2-carboxylate, methyl 6-acetyl-4-methoxy-7,8-
dihydroxynaphthalene-2-carboxylate and methyl 6-acetyl-4-methoxy-5, 8-
dihydroxynaphthalene-2-carboxylate) have been obtained from Brazilian soil (Petit et 
al., 2009), and from soil in Northern Iran (Gharaei-Fathabad et al., 2009), from 
endophytic fungi (Selim, 2012) and even from filamentous fungi from culture 
collections (Rančić et al., 2006) .  
 
The genus Penicillium 
 
Penicillium is one of the most common fungal genera of the micro-fungi group. It has 
been well over 200 years since the name Penicillium was introduced by Link (1809). 
The definition of Penicillium is ‘brush’ and it was given this name due to its brush-
like appearance under the microscope.  
Link defined the three common species P. candidum, P. glaucum and P. expansum. 
Thereafter over 1000 names were introduced in the genus, many of which are 
currently not identifiable due to lack of information as set by modern standards. Some 
of the other names are considered to have been published invalidly, or are currently 
recognized to be synonyms of other species (Visagie et al., 2014). Penicillium spp. 
are ubiquitous soil fungi that prefer cool and temperate climates and can be found 
wherever organic material is present. Penicillium spp. conidia can be found in the air 
and dust of indoor environments including houses and public spaces and in and 
around foods, leather and fabric materials. Some species have a distinctive blue 
colour due to pigmentation of the conidia causing the blue fuzzy texture on foods 
such as breads (Ozdemir, 2015). Penicillium rots refers to the green and blue mould 
found on foodstuffs which is caused by different species of Penicillium. These 
particular species are responsible for the post-harvest loss of foods including during 
transit, storage and post-sales (Agrios, 2005)
 
With regards to human diseases, Penicillium purpurogenum, is a soil and plant 
contaminant that can grow at 37
°
C has been involved in only three human cases of 
pulmonary infection in patients afflicted by haematological diseases but no infections 
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in animal have been reported. Approximately 15 various species of Penicillium are 
responsible for mycotic infection in immunocompromised patient. (Zanatta et al., 
2006) 
The genus Penicillium became well established after the discovery ‘penicillin’ from a 
culture of P. notatum by Alexander Fleming and his studies as it related to growth 
inhibition of the pathogenic bacterium Staphylococcus aureus (Raper and Thom, 
1949) .  
Vegetative growth of Penicillium spp is in the form of mycelium which grows and 
branches through the growth medium. In response to starvation, aerial hyphae 
(conidiophores) are formed on which the asexual spores (conidia) develop. This may 
branch but at the tip develops finger-like phialides from which the conidia develop 
(Figure 1.6, Visagie et al., 2014). 
 
 
 
Figure 1.6: Conidiophore branching patterns seen in Penicillium spp. A. 
Conidiophores with solitary phialides. B. Monoverticillate. C. Divaricate. D, E. 
Biverticillate. F. Terverticillate. G. Quaterverticillate from (Visagie et al., 2014) 
 
The genus Penicillium has been shown to produce a wide range of compounds with a 
broad variety of biological activities (Debbab et al., 2010, Nakashima et al., 2008), 
antibacterial such as negapillin, antimicrobial agent isolated from metabolites of 
Penicillium chrysogenum (Shimi et al., 1966), antifungal such as atpenin isolated 
from Penicillium sp. FO-125 by Omura et al., (1988), and immunosuppressive agent 
such as stevastelin A, B and B3 isolated from Penicillium sp. by Morino et al., 
(1996). 
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Kurobane et al., (1981)
 
showed that Penicillium brefeldianum produced fulvic acid 
which has antiviral, antifungal, antioxidant and antibiotic activities. (Maskey et al., 
2003) isolated two active substances 8-O-methylaverufin and 1,8-O- 
dimethylaverantin as novel antifungal agents from Penicillium chrysogenum. (Nam et 
al., 2000) established that compounds 8-O- methylsclererotiorinamine isolated from 
Penicillium multicolor expressed antimicrobial activity. Funiculosin isolated from 
Penicillium funiculosum also has antivirus activity against Newcastle disease virus 
(NDV), Miyadera strain (Ando et al., 1969).  
 
Classification and identification of Penicillium 
 
Penicillium spp belongs to an ascomycete of the family Eurotiaceae and kingdom of 
fungi, the genus, Penicillium, is ubiquitous and most of the species are saprophytes 
(Talbot, 1971). One of its key roles in nature is the disintegration of organic materials 
and the species cause overwhelming rots as pre- and postharvest pathogens on food 
harvests and also produces varied forms of mycotoxins. However some species when 
exploited have a positive impact on the production of certain foods including cheese 
such as Camembert or Roquefort and fermented sausages (Visagie et al., 2014). 
Selected strains of these fungi are currently used as starter cultures as a way to 
colonize homogeneously the cheese or meat piece, therefore inhibiting the ultimate 
colonization by unwanted fungi and bacteria. Some of the fungal species include 
Penicillium nalgiovense and Penicillium chrysogenum for meat products, Penicillium 
roqueforti for Roquefort cheese, and Penicillium camemberti for Camembert cheese 
(Laich et al., 2002).  
Traditionally the identification and classification of fungi was based upon analysis of 
macroscopic and microscopic structures (morphology) (Larone, 1993). Physiological 
and biochemical procedures, applied in combination with morphology, (Pitt, 1995) 
and their features; may vary significantly depending on the environment and the 
conditions they are exposed to. More recently, molecular techniques have been used 
to assist in distinguishing the microorganisms (Jimenez et al., 1999). Ribosomal DNA 
(rDNA) is a useful aid to fungal phylogeny studies as it encodes the highly 
polymorphic 600-800 bp ITS region (Internal Transcribed Spacers), which is used for 
the isolation of many fungal species (Anderson and Cairney, 2004).  This region has 
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recently been accepted as the official sequence for identification of fungi (Schoch et 
al., 2012) 
 
1.10 Sources of Antibiotic- producing organisms 
 
1.10.1 Soil 
 
The significance of terrestrial bacteria and fungi as foundations of valuable bioactive 
compounds has been well recognized for over half a century. As a result, over 120 of 
the most crucial medicines used (penicillins, cyclosporine A, adriamycin, etc.) are 
acquired from terrestrial (soil) microorganisms (Karna Radjasa, 2004). Soil is a 
widely explored ecological niche for microorganisms which yield significant 
biologically active natural products including antibiotics and used in industrial 
antibiotic production (Kaur et al., 2014, Kumar et al., 2010). Some of the antibiotic 
drugs have been derived from microorganisms that inhabit the soil; this includes fungi 
(20% of isolated antibiotics), actinomycetes (70%) and eubacteria (10%) (Makut and 
Owolewa, 2011). 
The most common habitat for streptomycetes is soil, this bacteria can be found in 
various types of soils (Katsifas et al., 2000, Wu et al., 2007). Surfaces such as plant 
residue and fungal hyphae have been observed as good habitats for streptomycetes 
colonization. This may be important in the degradation of litter in soil (Maheshwari et 
al., 2010).  
Streptomycetes may play a role in promoting plant growth, through control of root 
pathogens or in some indirect way, since some species are able to produce antifungal 
compounds (Yuan and Crawford, 1995). Streptomycetes can be used as biocontrol 
agents (Kanini et al., 2013). On the other hand, potato scab, a plant disease, is caused 
by several species of Streptomyces, which causes significant financial losses to the 
agricultural community (Takeuchi et al., 1996, Lorang et al., 1995). 
However, soil from many parts of the world has been very extensively studied and 
isolation of new organisms and new active compounds is therefore difficult. Because 
of this attention has been turned to neglected sources in the hope of finding new 
strains of organisms producing novel metabolites. For example, marine organisms 
have become vital sources of novel products exhibiting antimicrobial, antiviral, 
antitumor and cardio-active properties (Kokare et al., 2004, Saadoun et al., 2007b) 
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which may serve as model systems in the discovery of new drugs.  Although soils 
have been screened by the pharmaceutical industry for the past five decades, only a 
small fraction of actinomycetes have been discovered (Atta et al., 2012). 
Actinomycetes from unexplored habitats have gained considerable attention in recent 
years for the production of bioactive metabolites. The list of novel actinomycetes and 
products derived from poorly explored areas of the world stresses the importance of 
investigating new habitats (Usha Kiranmayi et al., 2011).  
 
1.10.2 Aquatic sources  
 
Streptomycetes can be found in nearly all aquatic environments, fresh water as well as 
marine environments (Gebreyohannes et al., 2013).  This does not however, mean 
they are actively growing in aquatic environments, Streptomyces may be washed into 
marine environments from terrestrial sources e.g. by exporting spores that are hardy 
into the water which may remain in situ for extended periods of time (Zaitlin and 
Watson, 2006). However steptomycetes may be normal components of the aquatic 
biota. For example, streptomycetes accounted for 2-5 % of the microbial community, 
and were found to be an indigenous population in coastal marsh sediment (Moran et 
al., 1995).  
Earthy odours have been associated with actinomycetes, but it is not known whether 
actinomycetes are a contributing factor to earthy odours in freshwater. The earthy 
smelling secondary metabolites geosmin and 2-methylisoborneol (MIB) were 
identified from actinomycete cultures in the late 1960s.  Since then actinomycete 
derived taste and odour in drinking water have meant that actinomycetes have gained 
considerable notoriety in the water supply industry (Zaitlin and Watson, 2006). It is 
noteworthy to mention here that Streptomyces spp. have also been isolated from 
severely cold environments like Antarctica (Kim et al., 2007). 
The aquatic environment is now being recognized as an abundant and untouched 
source of different natural products. The marine environment in and of itself contains 
organisms with diverse taxonomic that show distinctive physiological and structural 
characteristics that allow them to survive even that harshest of environmental 
conditions, with the potential production of new secondary metabolites that have not 
been found in terrestrial microorganisms (Tawiah et al., 2012). 
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Bacteria and fungi are being isolated from various marine sources, including 
invertebrates, sediment and algae. These microbes have been examined for the 
discovery of new bioactive compounds; sponges have been recognized by chemists as 
an interesting source of bioactive compounds, Holler et al., 2000 isolated 681 fungal 
strains from 16 species of sponges from six different locations, the isolated were 
belonged to 13 genera of Ascomycota, 2 of Zygomycota, and 37 of mitosporic fungi. 
For the biological activity just ninety-two of the 681 isolates were selected for 
screening, the result showed that 75 strains of 92 (81.5%) were active in at least one 
agar diffusion assay for antibacterial, antifungal or antialgal activity, on other hand 
they found only six strains (7%) were active against the Gram-negative bacterium E. 
coli, while 33 strains (36%) were active against the Gram-positive bacterium, B. 
megaterium. Fungi were isolated from sponges from varied climatic and geographical 
marine habitats Holler et al., 2000. Marine fungi are recognized as a rich source of 
bioactive compounds with potential biomedical and pharmaceutical applications 
(Shaala and Youssef, 2015).The microbial biodiversity of marine environments is 
vast, and it is yet to be explored and characterized in both taxonomically and 
chemically. Therefore, secondary metabolites that are entirely created by marine 
organisms are assumed to facilitate their adaptation and survival in the marine 
environments categorized by very special conditions. A new compound terretrione D 
2 and known compound terretrione C 6 were isolated from marine-derived 
fungus Penicillium sp. CYE-87 showed significant antimigratory activity against the 
highly metastatic triple-negative human breast cancer cells MDA-MB-231 with 
IC50 values of 16.5 and 17.6 μM, respectively. Also, these compounds showed 
reasonable activity against C. albicans with a MIC value of 32 µg/mL (Silber et al., 
2016).   
 
1.10.3 Insects 
The existence of actinomycetes has been reported in association with insect habitats.  
The two best described examples being those of the Attine ants (Atta sp.), known to 
cultivate fungal gardens as a food resource and which appear to have a symbiosis with 
a Pseudonocardia bacterial species (residing on the ants' integuments) that assists in 
defending the fungus from a parasite through the production of secondary metabolites 
(not characterized) (Mueller et al., 2008) and secondly the beewolf wasp (Philanthus 
triangulum) which has specialised antennae containing a Streptomyces sp. which is 
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thought to produce antibiotics (not yet characterized) that the wasp smears over brood 
cells prior to oviposition to protect eggs from a fungal parasite (Kaltenpoth et al., 
2005). 
Aruna et al., 2008 reported antagonistic activity (not characterized) of new strain 
Streptomyces tritolerans sp. isolated from earthworm gut. The results showed that 
earthworm gut is favorable to streptomycetes and can be a vital habitat for adopted 
bacteria possessing antimicrobial activity. They should receive concentrated attention 
in research for biological controls worldwide (Aruna et al., 2008). 
(Ebrahimipour et al., 2011) reported the antagonistic activity (again not characterized) 
of a bacterium isolated from the digestive system of Iranian endemic slug, Parmacella 
iberica, and gave details of its biochemical identification and phylogenetic 
relationships and extraction of antimicrobial substance.  
 
Until recently, the majority of antimicrobial compounds were isolated from terrestrial 
microorganisms. In the last two decades however, the rate of discovery of novel 
compounds from this source has declined significantly. Recently researchers have 
begun investigating unconventional sources due to lack of research within those 
particular areas. This includes, on terrestrial invertebrates (Madden et al., 2013). 
  
Fungi isolated from marine invertebrates are of substantial significance as novel 
promising sources of distinctive secondary metabolites with important biomedical 
potential (Yue et al., 2015) 
Modern researchers highlight on the need to study unique unexplored places like rain 
forests, marine sponges, mangroves and endophytes for pharmacologically active 
compounds. The ever growing list of fresh microorganisms and the products resulting 
from poorly explored areas of the world like Australia, Jordan and Antarctica shows 
that new habitats if explored carefully can bring great benefit. The biopharmaceutical 
industry has become increasingly interested in new antibiotics to tackle the challenge 
of resistance (Kumar et al., 2010). 
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1.11 AIMS OF THE STUDY 
Marine invertebrates have been shown to be sources of antibiotic producing 
microorganisms but, apart from social insects, terrestrial invertebrates and freshwater 
invertebrates in particular have been relatively little studied. The aim of this project 
was therefore to screen invertebrates primarily for novel actinomycetes, which may in 
turn possess novel biosynthetic capabilities but also including other antibiotic 
producing organisms e.g. fungi. 
The main objectives of the programme of study were: 
1.  To field collect aquatic and terrestrial invertebrates and investigate them for the 
presence of actinomycetes and other organism by culture on selective media.  
2.  To identify isolates that showed antibiotic activity by primary screening against 
Gram-positive and Gram-negative bacteria. 
3. To use PCR amplification of 16S/18S rDNA, to profile species associated with 
different sources. Sequencing of ITS (internal transcribed spacer) regions would also 
be required for the identification of any fungi isolated. 
4.  To determine antimicrobial activity of isolated strains by screening isolates for 
inhibitory activity against a range of test organisms.  
5.  To purify the active compounds from species showing good activity using HPLC, 
determine their chemical structures and test their activity against antibiotic resistant 
pathogens and tissue cultures of cancer cells. 
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Chapter 2 
 
2. MATERIALS AND METHODS 
2.1 Sample of the invertebrates 
Some of the invertebrate samples were obtained from Commercial companies and the 
rest were provided by the School of Environment and Life Sciences of the University 
of Salford. The origins and numbers collected are shown in Table 2.1 and 2.2.    
 
Table 2.1: The aquatic invertebrates and the origins they were collected from. 
Aquatic invertebrates Origin 
Latin name  Common name  Number  
Gammarus pulex  Freshwater 
shrimp 
60-70 Collected from River 
Tame 
Daphnia sp. Water flea 100-150 Blades Biological Ltd 
(Collected from Kent) 
Chironomus sp. larva Bloodworm 15-20 Sciento (Collected 
from Manchester area) 
Eropobdella octoculata  A leech 10-15 Sciento (Collected 
from Manchester area) 
Lumbriculus variegatus  Black worm 30-40 Sciento (Collected 
from Manchester area) 
Nereis diversicolor Bristle worm 4-5 Sciento (Collected 
from Formby area) 
Actinia equine Sea anemone 5-10 Collected from Seaton 
Carew, Hartlepool 
Baetidae sp. nymph Swimming 
mayfly nymph 
15-20 Collected from River 
Tame 
Baetidae sp. nymph Flattened 
mayfly nymph 
15-20 Collected from River 
Tame 
Gyrinus sp. larva  Whirligig beetle 
Larva 
15-20 Collected from River 
Tame 
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Aquatic invertebrates Origin 
Latin name  Common name  Number  
Tubifex tubifex larva Sludge worm 
 
20-25 Collected from River 
Tame 
Culicoides sp. larva Biting midge 
larva 
15-20 Collected from River 
Tame 
Dendrocoelum lacteum  Flatworm 15-20 Sciento (Collected 
from Whitefield area 
of Manchester) 
Polycelis nigra  Flatworm 15-20 Sciento (Collected 
from Whitefield area 
of Manchester) 
Crangonyx pseudogracilis  Northern river 
crangonyctid 
40-50 Sciento (Collected 
from Whitefield area 
of Manchester) 
Asellus aquaticus  Waterlouse 
 
15-20 Sciento (Collected 
from Whitefield area 
of Manchester) 
Asellus aquaticus  Waterlouse 
 
15-20 Collected from River 
Tame 
Planorbis planorbis  Ram's horn snail 
 
5-10 Collected from 
Manchester area 
Lymnaea stagnalis  Great pond Snail 
 
5-10 Collected from 
Manchester area 
Planorbis corneus  Great Ram's-
horn snail 
 
5-10 Collected from 
Manchester area 
Calopteryx sp. Damselfly 
nymphs 
15-20 Blades Biological Ltd 
(Collected from Kent) 
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Table 2.2: The terrestrial invertebrates and the origins they were collected from. 
Terrestrial invertebrates Origin 
Latin name  Common name  Number  
Helix pomatia  Roman snail 
 
30-40 Collected from 
Manchester area 
Tenebrio molitor (larva, pupa 
and adult) 
Yellow 
mealworm 
 
20-30 Sciento and 
Livefood.co.uk 
(Commercially  bred 
cultures) 
Arion ater Black slug  
 
10-15 Collected from a North 
Cheshire field 
Myrmica rubra  Red ant 70-80 Blades Biological Ltd 
(Collected from Kent) 
Lasius Flavus Yellow meadow 
ant 
70-80 Blades Biological Ltd 
(Collected from Kent) 
Psyllobora 22-punctata 
  
22-spot 
Ladybird 
5-10 Collected from 
Manchester area 
Oniscus asellus  Common shiny 
woodlouse 
5-10 Collected from 
Westhoughton area 
Helix aspersa Garden snail 5-10 Sciento (Collected 
from Whitefield area 
of Manchester)  
Vespula vulgaris  Common wasp 15-20 Collected from a 
House in Rainhill, 
Merseyside 
Eisenia fetida Tiger worm 5-10 Blades Biological Ltd 
(Collected from Kent) 
Tribolium castaneum  Red flour beetle  15-20 Blades Biological Ltd 
(Breeding) 
Lasius niger  Black ants 30-40 Blades Biological Ltd 
(Collected from Kent) 
Lumbricus terrestris Common 
Earthworm 
5-10 Blades Biological Ltd 
(Breeding) 
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Terrestrial invertebrates Origin 
Latin name  Common name  Number  
Eisenia andrei Red tiger worm 5-10 Blades Biological Ltd 
(Collected from Kent) 
 
2.2 Test organisms 
The test organisms were obtained from the culture collection of the Microbiology 
Laboratory at the School of Environment and Life Sciences, University of Salford. 
All test organisms were incubated at 37ºC for 24 h except for P. fluorescens and S. 
cerevisiae which were incubated at 28±2 ºC for 24 h. The organisms and original 
sources are given below.  
 
2.2.1. Gram-positive Bacteria 
Bacillus cereus ATCC 10876 (Fakruddin et al., 2012), Staphylococcus aureus ATCC 
25923 (Taleb-Contini et al., 2003), Staphylococcus aureus AOH1 (University stock 
and unknown source), Methicillin-resistant Staphylococcus aureus (MRSA252 
obtained from Public Health England) (Holden et al., 2004), Enterococcus faecium 
NCTC 7171 (Cushnie et al., 2003) and Enterococcus faecalis NCIMB 13280 
(Thomson et al., 2011). 
 
2.2.2. Gram-negative bacteria 
Escherichia coli ATCC10536 (Šaric et al., 2009), Extended Spectrum Beta-
Lactamase (ESBL) producing E. coli (obtained from Public Health England), 
Pseudomonas aeruginosa NCTC 15692 (De soyza et al., 2013), Pseudomonas 
fluorescens ATCC 13525 (Arora et al., 2012) and Klebsiella pneumoniae ATCC 
10031 (Omoregie, et al., 2013). 
  
2.2.3. YEAST 
Saccharomyces cerevisiae ATCC 9896 (Christman et al., 1956) 
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2.3 Culture Media Preparation 
Muller Hinton Agar (MHA) was used for disk and well diffusion sensitivity tests and 
Muller Hinton Broth (MHA) (both from Oxoid Ltd, Basingstoke, UK) was used for 
preparing suspensions of the test organisms and determination of broth dilution 
minimal inhibitory concentrations (MIC). Nutrient Broth (NB; Oxoid) was used for 
preparing suspensions of the test organisms, Nutrient Agar (NA; Oxoid) was used for 
agar overlay technique experiment in the primary screening for antibiotic activity. 
Tryptone Soya Broth (TSB), Yeast Extract Broth (YEB) (both Oxoid, UK) and Malt 
Extract Broth (MEB; Fluka obtained from Sigma, UK) were used for comparative 
antibiotic production in the secondary screening and Actinomycete Isolation Agar 
(AIA; Fluka obtained from Sigma, UK) was used to isolate antibiotic producing 
organisms. Media were made up according to the manufacturer’s instructions. 
Actinomycete Isolation Broth (AIB), Starch Broth (SB) with two different nitrogen 
sources, Glucose Nitrate Broth (GNB) and Starch Broth (SB2) mixed in the ratio 2:1 
with Nutrient Broth (NB) before sterilization with two different nitrogen sources were 
all used for comparative antibiotic production in secondary screening.  
All media were autoclaved at 121° for 15 min. Agar containing media were cooled to 
50°C before pouring into Petri dishes. After setting, the plates were dried inverted at 
50°C for 15-25 min.  
AIB was prepared by suspending 68.4 mM glycerol (Sigma, UK) in 1 L of distilled 
water, 2.48 mM sodium caseinate (Fisher, UK), 0.76 mM L-asparagine (Sigma, UK), 
41.64 mM sodium propionate (CH3CH2COONa) (Sigma, UK), 2.87026 mM 
dipotassium phosphate (K2HPO4) (Sigma, UK), 0.083 mM magnesium sulphate 
(MgSO4) (Sigma, UK), 0.0036 mM ferrous sulphate (FeSO4.7H2O) (Sigma, UK) were 
added. The mixture was stirred for 15 min. The pH was adjusted to 7±0.2 at 25°C 
before autoclaving.   
SB was prepared by hydrolyzing 58.42 mM of soluble starch (Sigma, UK) in 300 ml 
of distilled water, with 27.42 mM hydrochloric acid (HCl) (Fisher, UK) in an 
autoclave at 120ºC for 6 min, cooling, then neutralizing with concentrated sodium 
hydroxide (NaOH) (Fisher, UK). 23.53 mM sodium nitrate (NaNO3) (Sigma, UK) or 
15.13552 mM ammonium sulfate (NH4) 2SO4 (Sigma, UK), 5.74053 mM K2HPO4, 
0.20286 mM magnesium sulfate heptahydrate (Mg SO4.7H2O) (Sigma, UK), 6.70679 
mM Potassium chloride (KCl) (Sigma, UK), 9.99132 mM Calcium carbonate 
(CaCO3) (Sigma, UK) and 0.0036 mM FeSO4.7H2O were added and the volume was 
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then made up to 1 L with water. The mixture was stirred for 15 min. The pH was 
adjusted to 7±0.2 @25°C before autoclaving.  
GNB was prepared by suspending 111.015 mM glucose (Fisher, UK) in 1 L of 
distilled water. NaNO3 23.53 mM, K2HPO4 5.74 mM, 0.203 mM 
Mg SO4.7H2O, 6.71 mM KCl, 9.99 mM CaCO3 and 0.0036 mM FeSO4.7H2O were 
added. The mixture was stirred for 15 min. The pH was adjusted to 7±0.2 at 25°C 
before autoclaving.  
 
2.4 Isolation of microorganisms 
Each group of invertebrates was externally sterilized with ethanol 70% for 30 seconds 
then washed with sterile distilled water. According to the invertebrates size, 5-10 
small sized invertebrates (less than 2 cm) or 1-4 invertebrates (between 3 to 5 cm) 
were put into 50 ml sterile conical end tubes, covered with 1 ml of sterile water then 
homogenized by grinding with a glass rod. One mililitre of sterile distilled water was 
then added to reduce the viscosity and serial 10-fold dilutions up to 10
-5 
made in 
distilled water. 
One hundred microliters of each dilution was transferred to a AIA medium and spread 
evenly on the surface of the medium using a sterile glass spreader and then incubated 
for 7 days at 28±2ºC. Filamentous colonies of actinomycetes or fungi characterized 
by their sharp round edges and powdery aspect sinking in the agar plate were picked 
and streaked on to AIA medium and then incubated at 28 ±2 ºC for 7 d to obtain pure 
colonies of organisms. 
Larger invertebrates (e.g. slugs/snails) used were surface sterilized with 70% ethanol 
for 30 sec and then washed with sterile distilled water. The digestive tract which was 
likely to contain the majority of bacteria was removed from each invertebrate and 
three digestive tracts were put in a 50 ml sterile conical end tube, covered with 1 ml 
of sterile water, then homogenized by grinding with a glass rod, then plated out and 
incubated as before and filamentous colonies picked and transferred colonies on to 
AIA medium. 
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2.5 Primary screening  
       2.5.1 Agar overlay technique 
Isolated organisms were subjected to primary screening procedures for assessment of 
their ability to produce antimicrobial activity using an agar overlay assay (Tyc et al., 
2014). A portion (50 µl) of 24 h culture (NB) of E. coli ATCC10536 and S. aureus 
ATCC 25923 was aseptically inoculated into a melted and cooled NA (25 ml at 40-
45°C)  and the agar was poured onto the AIA plates containing single isolated 
colonies of isolates which had been incubated for 7 d at 28±2ºC. Then the plates were 
incubated at 37°C for 24 h. At the end of incubation period the diameter of any clear 
zone around the isolated colony was measured and recorded in mm. 
 
2.5.2 Streak or single colony pattern on agar plates to detect antimicrobial 
activity 
A single isolate colony was removed and streaked onto AIA, a single streak was made 
on one side of the agar plate or a single colony inoculate in the middle of the plate and 
incubated for seven days at 28±2ºC. After 7 d the plates were removed and five test 
organisms that had been grown overnight on NB (S. aureus ATCC 25923, S aureus 
AOH1, B. cereus ATCC 10876, E. coli ATCC 10536 and P. fluorescens ATCC 
13525) were streaked on the same agar plate (Figure 2.1).  The plates were incubated 
for 24 h at 28±2 ºC to allow P. fluorescens ATCC 13525 growth then incubated for 
24 h at 37 °C. The diameters of any clear zones were measured as in 2.5.1  
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                                  Test Organisms                      Isolate   
Figure 2.1: Streak patterns on agar plates to detect antimicrobial activity 
 
2.6 Maintenance of cultures 
After antimicrobial activity screening, the isolates showing activity were maintained 
as suspensions of cells and mycelial fragments in aqueous 10% glycerol (v/v) at -
18°C. 
 
2.7 Secondary screening (submerged culture) 
Comparative antibiotic production using different media 
The primary isolates possessing antibacterial activity were subjected to a secondary 
screening procedure. Nine different media, SNB (NaNO3 as source of nitrogen), 
SNHB ((NH4)2SO4 as source of nitrogen), SNB (NaNO3 as source of nitrogen) mixed 
with NB 2:1, SNHB ((NH4)2SO4 as source of nitrogen) mixed with NB 2:1, GNB, 
YMB, YEB, TSB and AIB were aliquotted in 50 ml portions in 250 conical flasks, 
plugged with cotton wool, sterilized and cooled. Flasks were inoculated with two 
loopfuls of isolate Es1 isolated from Helix aspersa (which showed highest 
antibacterial activity against Gram positive and Gram negative bacteria in the primary 
screen) and incubated at 28±2 ºC on a rotary shaker at 120 rpm for 7 d. Cultures with 
good growth were then removed and filtered through cotton wool (cotton wool was 
used for filtration due to the presence of the mycelium, which causes blockage of the 
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membranes filters). Antimicrobial activity was detected by the agar well diffusion 
method (Irshad et al., 2012). Single colonies of both E. coli ATCC 10536 and S. 
aureus ATCC 25923 were placed into Falcon tubes into 5 ml of normal saline and 
vortexed until the colonies were completely dispersed and adjusted to 0.5 McFarland 
turbidity standard with saline.  Then the suspensions were spread on MHA plates with 
a cotton swab. Wells (10 mm diam.) were cut into the agar using a sterile cork borer 
and 1 ml of each filtrate was placed in the wells. The plates were incubated for at 
37°C for 24 h and the diameters of clear zones around the wells measured. 
 
2.8 Optimizing DNA Extraction from isolates  
Both liquid and solid cultures were prepared before DNA extraction.  
Liquid culture 
A single colony of each antibiotic producing organism was inoculated aseptically into 
30 ml of TSB and then incubated in a rotary shaker at 28 
o
C for 48 h at 180 rpm to 
allow the cultures to grow.   
Solid culture 
AIA plates were inoculated with single colony of each organism and the plates were 
incubated at 28
o
C for 2 d for DNA extraction. Different DNA isolation kits were 
evaluated for extraction of the DNA from the isolates. 
 
2.8.1 Master Pure (Gram Positive DNA Purification Kit) (Illumina, USA) 
All the reagents, enzyme and tubes provided with the kit.  
2.8.1.1 Sample Lysis 
After a 48 h of incubation, approximately 1.0 ml of each culture was pelleted by 
centrifugation for 5 min at 10,000 x g (Fisher, Accuspin micro 17) and the 
supernatant discarded.  Then 150 µl of TE Buffer was added to each pellet, vortexed 
to resuspend the pellets and 1 µl of Ready-Lyse Lysozyme (20-40 KU/µl) was added 
and incubated at 37 
o
 C for 24 h.  Proteinase K (1 µl of 50 µg/µl) was added to an 
Eppendorf tube containing 150 µl of Gram Positive Lysis Solution.  This master mix 
(150 µl) was added to each samples and vortexed thoroughly.  The samples were then 
incubated for 15 min at 65-70
o
C and vortexed briefly every 5 min.  The samples were 
then cooled to room temperature and placed on ice for 3-5 min.  
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2.8.1.2 DNA Precipitation  
When the samples had cooled, 175 µl of MPC Protein Precipitation Reagent was 
added and vortexed vigorously for 10 sec and the tubes were centrifuged at 4
o
C for 10 
min at 10,000 x g (Labnet international, PrismR, USA). The pellet (unwanted 
proteins) was discarded and the supernatant was transferred into a new micro 
centrifuge tube.  Then 1 µl of RNase A (5 µg/µl) was added to each sample, mixed 
thoroughly and incubated for 30 min at 37
o
C.  Then 500 µl of isopropanol (BDH 
Laboratory supplies, England) was added, mixed by inverting the tubes 30-40 times.  
The desired DNA was pelleted by centrifugation using the same conditions as before 
(4
o
C for 10 min) and the isopropanol was removed carefully without dislodging the 
DNA.  The pellets were then rinsed using 70% ethanol (100 µl) and left to completely 
dry out the ethanol at room temperature.  Finally, the DNA was dissolved in 35 µl of 
SD pure water for further analysis.   
 
2.8.2 FastDNA spin kit (MP Biomedical, France) 
All the reagents, enzyme and tubs provided with the kit.  
Cultures were incubated for 48 h in TSB medium and approx. 1.0 ml of each culture 
was pelleted by centrifugation and the supernatant discarded. From solid media a 
loopful of culture was taken. Pellets or the loopfuls of the culture were suspended in 
normal saline 0.9% (Fisher, UK) to give a maximum suspension volume of 200 μl, 
and the sample was added to Lysing Matrix A tube. Then 1 ml Cell Lysis Solution 
(CLS) was added to Lysing Matrix A tube, and a TissueLyser (TisseLyser II, Qiagen) 
was used to homogenize the samples (5 min at 27 Hz). Samples were then centrifuged 
at 14,000 x g for 5-10 min to pellet debris. 
 
2.8.2.1 Binding DNA to matrix 
The supernatant (700 – 800 μl) was transferred to a 2.0 ml microcentrifuge tube and 
an equal volume of Binding Matrix added. The tube was inverted to mix the contents 
then incubated for 5 min at room temperature on a rotator. Eight hundred microlitres 
of the suspension was transferred to a spin filter and centrifuged at 14,000 x g for 1 
min, the catch tube was emptied and the remaining suspension added to the spin filter 
and centrifuged as before. The catch tube was emptied again and 500 μl prepared 
SEWS-M (wash solution) added. The pellet was gently resuspended using the force of 
the liquid from the pipette tip and the tube was centrifuged at 14,000 x g for 1 min. 
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The contents of the catch tube were discarded and the tube was replaced and 
centrifuged a second time at 14,000 x g for 2 min and the catch tube was replaced 
with a new, clean tube. 
 
2.8.2.2 Elution and Collection of Final DNA 
DNA was eluted by gently resuspending the Binding Matrix above the spin filter in 
100 μl of DES incubated for 5 min at 55 ̊C in a heat block, which was then 
centrifuged at 14,000 x g for 1 min to force the eluted DNA into the clean catch tube. 
Finally the spin filter was discarded. 
Six different DNA isolation kits including the Bioline Kit (Isolate II Genomic DNA 
Kit), the Gene All Cell (Tamar Laboratory Supplies Ltd.), the Isolate Fecal DNA Kit 
(MO BIO Laboratories) and the Powersoil DNA Isolation Kit (MO BIO Laboratories) 
were investigated for extraction of DNA from the isolates but the isolated DNA’s 
were of low concentration and purity.  
 
2.9 PCR amplification of the 16S rDNA and 18S rDNA gene 
Extracted genomic DNA from each sample was then used as template for PCR 
targeting the 16S ribosomal DNA (rDNA) gene and 18S rDNA using primer sets 
shown in Table 2.3. 
 
Table 2.3: Primers used to amplify the full 16S rDNA gene for identification of 
bacteria and 18S rDNA gene for identification of fungi  
Name Sequence Ref 
16S bacterial universal 
primers 
F- 5’ AGA GTT TGA TCC TGG 
CTC AG- 3’ (Weisburg et al., 
1991) R- 5’ ACG GCT ACC TTG TTA 
CGA CTT-3’ 
18S fungal universal 
primers 
F-5’ GTA CAC ACC GCC CGTC- 
3’ 
(Amaral-Zettler et 
al., 2009) 
 R-5’TGA TCC TTC TGC AGG 
TTC ACC TAC-3’ 
 
The primers were obtained from Eurofins UK Ltd. 
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To amplify the 16S rDNA genes and 18S rDNA a standard Taq based PCR procedure 
was used. PCR reactions were set up using the reagents and volumes set out in Table 
2.4 and the PCR conditions and cycles as in Table 2.5. 
 
Table 2.4: The PCR reaction mixture for 16S rDNA gene and 18S rDNA 
amplification of cultured isolates 
Component Amount Concentration 
Taq DNA polymerase 
(Bioline, UK) 
12 µL    (0.625 units/25 µl 
PCR) 
Weisberg Forward Primer  1 µL 0.2 µM (0.05-1 µM) 
Weisberg Reverse Primer 1 µL 0.2 µM (0.05-1 µM) 
Template DNA  1 µL        Variable <100ng 
Nuclease-free water 
(Sigma, UK) 
10 µL  
Total volume 25 µL  
 
Table 2.5: 16S rDNA and 18S rDNA PCR cycling stages, temperatures and times 
Stage Temperature Time (MyTaq®) Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 30 sec 
25 Annealing 53°C 30 sec 
Elongation 72°C 1 min 
Final 72°C 1 min 1 
 
 
2.10 Gel Electrophoresis  
 
After thermocycling, PCR products were immediately stored on ice. A 1% (w/v) 
agarose gel was prepared using 1 g of agarose in 100 ml 0.5% v/v TBE (Bioline, UK).  
The solution was then microwaved and boiled for 1 min until it was completely 
homogenised and placed on an orbital shaker to cool down for 20 min at room 
temperature.  When the bottle was at approx. 50°C, 100 µl of Gel Red fluorescent 
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DNA stain (Biotium, USA) was added and the liquid swirled gently. The 100 mL 
mixture was then poured into a gel tray, the well forming comb was placed into the 
gel and the gel was left to set for 30-40 min. Samples were run at 100 v, 100 ma until 
the coloured markers (Red for the PCR product (5 µl) and blue for the 1 kb 
HyperLadder (Bioline, UK) 3 µl) were 3 cm from the end of the gel (~75 min). The 
gel was then viewed in a G:Box Chemi transilluminator (Syngene) to check for 
successful amplification and correct sizes of amplified genes. 
 
2.11 Sequencing analysis  
PCR products were sent to Source Bioscience Sequencing (Nottingham, UK) for 
purification and sequencing. The sequencing was performed using either of the 
primers used for PCR, forward and reverse reads were generated for all amplicons 
and analysed using FinchTV viewer (Version 1.4.0, Geospiza). Each chromatogram 
file of nucleotide sequences was individually checked for final use by using FinchTV 
viewer. Forward primer and reverse complement sequence were aligned by Omega 
Clustal (http://www.ebi.ac.uk/Tools/msa/clustalo). Consensus sequences were 
identified using BLAST function of GenBank database 
https://blast.ncbi.nlm.nih.gov/Blast.cgi. 
A phylogenetic tree was generated by Omega Clustal after all sequences were aligned.   
 
2.12 Production, Extraction of antibiotics from broth medium 
 
2.12.1 Production of the antibiotics 
              Two loopfuls from 7 d cultures on AIA of the Es1 isolate were inoculated 
into sterile 50 ml portions of AIB in 250ml conical flasks and incubated at 28±2 ºC on 
a rotary shaker at 120 rpm for 3 d to obtain heavily inoculated suspensions. Fresh 
sterile AIB medium was aliquotted in 250 ml portions in conical flask of 1 L capacity, 
then plugged, sterilized, cooled and heavily inoculated with the suspension. The 
flasks were fixed to a rotary shaker at 28±2 ºC 120 rpm and shaken for 7 d. Cultures 
were then removed and filtered through cotton wool. Antibiotic activity was detected 
by the agar well diffusion method; 1 ml of each filtered medium was added to the 
wells made in seeded HMA plates inoculated with a lawn of test organisms as before. 
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2.12.2 Extraction of antibiotics 
              The clear filtrate of the medium was extracted with ethyl acetate by vigorous 
shaking for 1 h. The organic layer was then separated in a separating funnel (Fisher, 
UK), and evaporated to dryness by rotary evaporation at 45°C. The aqueous phase 
was tested by the agar well diffusion method but had no antibiotic activity and was 
discarded. The crude orange residue obtained was redissolved in ethyl acetate and 
antibacterial activity tested against E.coli ATCC10536 and S. aureus ATCC 25923 
using the paper disc method (Bauer et al., 1966). Bacterial suspensions of two 
organisms were prepared to be tested against the extracted antibiotic from Es1. Two 6 
mm filter paper diffusion discs (Whatman, UK) were each loaded with 20 µl of the 
extracted antibiotic and allowed to dry (the control was two paper discs loaded with 
ethyl acetate solvent).  Lastly, using a sterilised dissection needle each disc was 
placed on a MHA plates that had been seeded with bacteria (E.coli ATCC 10536 and 
S. aureus ATCC 25923) as before, cooled in the fridge for 30 min to allow the discs 
to settle and incubated at 37
o
C for 24 h and clear zone sizes recorded. 
The mycelium was harvested after 7 d incubation by filtering the broth through cotton 
wool, extracted with 100 ml acetone by vigorous shaking for 1 h, then filtered through 
the cotton wool and assayed against the selected test organisms as above (the control 
was a paper disc loaded with acetone solvent as before).  
 
2.12.3 Time optimization for enhancement of yield of antibiotics  
Isolate Es1 was grown in 300 ml portions of AIB in conical flask of 1 L capacity at 
pH 7.0. The flasks were fixed to a rotary shaker at 28±2 ºC 120 rpm. Broth samples 
were taken 3, 5 and 12 d of incubation, filtered through cotton wool and tested for 
their antibacterial activities.  
 
2.12.4 Production, Extraction of antibiotics from solid medium 
2.12.4.1 Extraction of antibiotic 
One isolate (Es1) that had been tested and had showed good antimicrobial activities 
was grown on two plates of AIA for 7 d 28±2 °C. Two different methods were used to 
extract the antibiotic, the first method used was homogenizing the agar with the ethyl 
acetate using a magnetic stirrer for 2 h, the second method involved use of a sonicator 
(Ultrasonic Bath Fischer FS140H, frequency of 40kHz), which was used 
for 1 h. 
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A spatula was briefly flamed on a Bunsen flame. After this the spatula was used to cut 
into the agar of the sub cultured Es1 isolate into small pieces. The cut agar was then 
taken from the plate and placed into a clean flask or a beaker in a fume cupboard. 
Forty mililitres of ethyl acetate was added to the flask and then a small piece of tin 
foil was used to cover the flask. After being in the sonication machine or on the 
stirrer, the agar and ethyl acetate mixture was filtered through a sintered glass filter 
(Whatman, UK) and the filtered extracts were tested for antibacterial activity by the 
disc diffusion method. Two 6 mm filter paper diffusion discs were loaded with the 
solvent, 100 µl of the extracted antibiotic was loaded on each disc and allowed to dry 
for 20-30 min and the same process was repeated until the antibiotic concentration on 
each disc reached 300 µl, then tested as before.  
 
2.12.4.2 Inoculation methods  
Three different inoculation methods were tested to see which method would produce 
the highest antibiotic concentration. The inoculation methods were the zigzag, a 
straight streak and individual colonies, plated as shown in Figure 2.2. 
Isolate Es1 was grown on AIA for 7 d 28±2 °C, using the three different inoculated 
methods (6 plates for each inoculation method), then the agar was cut into small 
pieces, put in flask, 120 ml ethyl acetate was added, sonicated for one hour then 
filtered. As before samples were loaded onto filter paper disks 6 mm (300 µl) then 
tested.  
 
  
 
Figure 2.2: Es1isolate inoculated with different patterns. Individual colonies (left), 
Zigzag (middle) and Streak (right)  
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2.12.4.3 Scale up number of plates extracted 
Subcultured Es1 isolate was inoculated on 20 AIA plates incubated at 28±2ºC for 7 d. 
The antibiotic activity was extracted with the sonicator method on two portions first 
one as above 6 plates in one beaker, second portion scaled up, 14 plates in one beaker 
with 280 ml of ethyl acetate, then the extracts were filtered, two 6 mm filter paper 
discs were loaded with each extract (300 µl) then tested as before.  
 
2.12.4.4 Time of incubation   
Es1 was subcultured on 12 AIA plates, incubated at 28±ºC, on day 7 of incubation 6 
plates were removed from the incubator, the antibiotic was extracted by the sonicator 
method, the extracts were filtered, the filtered extract was labeled and stored at 4ºC.  
After 21 d the remaining 6 plates were extracted as before. Two 6 mm filter paper 
discs were loaded with each extract (300 µl) then tested as before.  
Differences in culture timescales were used for production of antibiotics from broth 
and solid medium as preliminary studies showed this to be the best incubation periods 
to obtain the maximum yields of the antibiotics (Table 2.6) 
 
Table 2.6: Summary of incubation times for enhancement of antibiotics yield from 
isolate Es1 
Broth medium  Solid medium 
3 d 5 d 12 d 7 d 21 d 
 
2.12.4.5 Different solvent for antibiotic extraction  
Isolate Es1 was grown on AIA at 28 ºC for 21 d each. Four batches of 6 plates were 
cut up into small pieces, put in flask in a fume cupboard and 120 ml of ethyl acetate, 
120 ml chloroform, 120 ml acetone and 120 ml combination of ethyl acetate + 
chloroform 1:1 were separately added to the 4 flasks to determine which solvent 
would give the highest extraction of the antibiotic from the solid medium. These were 
then sonicated for 1 h, filtered, loaded 300 µl of the filtrate on paper disk then tested 
as before.  
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2.13 Extraction of antibiotics from different isolates 
Single colonies of each isolate were streaked over AIA plates, one colony per plate, 
using the zigzag method, and then incubated at 28±2ºC for 21 d. Six plates of each 
isolate were cut to small pieces, put in flask in a fume cupboard, 120 ml of ethyl 
acetate was added, sonicated for 1 h then filtered and 300 µl loaded onto paper disks 
then tested as before.  
  
2.14 Large scale: Isolation of antibiotic produced by isolatesEs1, M1 11, and 
La1a  
Three isolates that gave good antibiotic activity (Es1, M1 11 and La1a) were selected 
and 300 AIA plates were inoculated by the zigzag method for each isolate and 
incubated at 28±2ºC for 21 d. The antibiotics were then extracted by cutting up 6 
plates put them in flask, 120 ml ethyl acetate was added to each flask, sonicated for 1 
h, the solvent was, filtered then evaporated by rotary evaporator, the crude extract was 
dissolved in HPLC grade methanol. 
All solution extracts were filtered again by 0.22 µm filters (Millex-GS Syringe Filter 
Unit, 0.22 µm, mixed cellulose esters, Sigma, UK) to prevent damage to the HPLC 
columns.  
 
2.15 Quantitative determination of the antibacterial activity of the extracts 
Dry weights of the extracts from isolates Es1, La1a and M1 11were determined by 
placing 2 ml crude extracts into weighed vials which were reweighed after 
evaporation of the solvent. Extracts were dissolved in ethyl acetate and adjusted to 1 
mg ml
-1
. Then 10 µl of each extract was loaded on paper disks, which were allowed to 
dry and placed the on plates seeded with E.coli ATCC 10536 and S.aureus ATCC 
25923 which were then incubated at 37ºC for 24 h. 
 
2.16 Calibration Graph  
Different volumes (5 µl, 10 µl, 15 µl, 20 µl, and 25 µl) of the three extracts were 
loaded onto 6x6 mm filter paper disks and allowed to dry and antibiotic activity 
determined as before.  
Two bacteria were used to create the calibration curve (S. aureus ATCC 25923 strain 
and E. coli ATCC 10536). 
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2.17: Purification and determination of the structure of the antibiotics 
 
2.17.1 High Performance Liquid Chromatography: Purification of the antibiotics 
for Es1 extract 
In this study, reverse phase, analytical and semi-preparative, high performance liquid 
chromatography (HPLC Agilent Technologies 1220 Infinity LC) was used for 
fractionation and purification of the extracts. Reverse-phase (RP) was chosen as this 
method works best for low molecular mass molecules as well as neutral compounds 
(Cseke et al., 2016). The success of HPLC separations in this study depends on the 
selection of mobile phases (solvent) and column type. Isocratic elution was used in 
this study to choose the best column and solvent system to use for fractionation and 
purification of the extracts, according to the study conducted by (Friesen et al., 2015), 
this method is easy to perform, reliable, and sufficient for separations, gradient elution 
was then used with semi-preparative column (Hichrom Ltd, UK) for collecting 
fractions with antimicrobial activity.  
 
Solvent systems 
HPLC (Agilent Technologies 1220 Infinity LC), analytical column, (HP Hewlett 
Packard Spherisorb ODS-2 5µm 250 mm x 4.6 mm I.D) was used. The separations 
were conducted by injecting 20 µl of the extract (from isolates Es1 and M1 11) onto 
the analytical column. Six solvent systems were used in this study for optimising the 
analytical RP-HPLC parameters. All systems used isocratic elution with different 
mobile phases (water: methanol 70:30 (v/v), water: methanol 50:50 (v/v), water: 
methanol 40:60 (v/v), water: methanol 30:70 (v/v), 30:70 (v/v) of water: methanol 
containing 0.1 % trifluoroacetic acid   (TFA) and a ratio 10:90 (v/v) of water: 
methanol). 
 
Chromatograms were obtained using a UV-VIS HPLC detector (Agilent 1200 series, 
G1311B), the solvent system that gave best separation was used and the peaks of the 
chromatogram collected separately (called fractions). One mililitre of each fraction 
was placed on to two 6 mm filter paper disks in a petri dish in a fume cupboard for 24 
h to evaporate the solvent. The filter paper disks were placed on MHA plates seeded 
with E.coli ATCC 10536 and S.aureus ATCC 25923 and incubated at 37
°
C to identify 
the fractions containing compounds with antimicrobial properties.  
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Columns  
Three other analytical columns, ACE Excel 5 C-18 amide, ACE Excel 5 SuperC18 
and ACE Excel 5 CN-ES (Hichrom Ltd, UK) were tried, the system was an isocratic 
elution using a mobile phase of water: methanol 30:70 (v/v), the separations were 
conducted by injecting an equal amount of sample (20µl) onto the analytical columns. 
The peaks of the chromatogram of the column that gave the best separation were 
collected separately and again 1 ml of each fractions was assayed for antimicrobial 
activity as before.   
 
Comparison of fractionation from Es1 extracts from solid medium (AIA), broth 
medium (AIB) and mycelium extraction obtained from dense cultures of Es1 in 
AIB. 
HPLC Agilent Technologies 1220 Infinity LC, analytical ACE Excel 5 C-18 amide 
column was used. The chromatogram was conducted by injecting an equal amount of 
the samples and the peaks of the chromatogram were collected separately and the 
fractions tested for antibacterial activity. 
 
Table 2.7: Summary of amounts of extract loaded on 6mm filter paper disc for 
different samples 
Extract Amount 
After extraction of antibiotics from filtered broth medium 2.12.2 20µl 
After two different methods were used to extract the antibiotic 2.12.4.1 300µl 
After three different inoculation methods used 2.12.4.2 300µl 
After scale up number of plates extracted 2.12.4.3 300µl 
After 7 and 21d of incubation 2.11.4.4 300µl 
After different solvents were used for antibiotic extraction 2.12.4.5 300µl 
After extraction of antibiotics from different isolates 2.13 300µl 
After collecting HPLC fractions 2.17.1 1000µl 
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2.17.2 Collection of the fractions with antimicrobial properties 
Based on the analytical HPLC separation results obtained from the first stage, a semi-
preparative ACE Excel 5 C-18 amide column, Gradient HPLC system with a mobile 
phase of water: methanol 30:70 (v/v) and a flow rate of 5 ml/min was used. The 
separations were conducted by automated injecting 500 µl of the sample (Es1extract) 
each time onto the semi-preparative column, automated collector collected each 
fraction with antibacterial activity. All fractions were evaporated by rotary 
evaporator, after that the crud of each fraction eluted on Methanol-d4, than analyzed 
by NMR spectroscopy to check purity of the antibiotics.  
The system used was an isocratic elution using a mobile phase of water: acetonitrile 
(Fisher, UK) 33:67 (v/v) for each fraction to remove impurities from the antibiotics. 
Two hundred and fifty microlitres of the semi pure antibiotic was injected into a semi-
preparative ACE Excel 5 C-18 amide column; the peaks of the chromatogram were 
collected separately, and antibiotic activity determined as before. Fractions from each 
run were pooled and the solvent evaporated by rotary evaporator, the dried extracts 
were dissolved in methanol-d4.  
 
2.17.3 High Performance Liquid Chromatography: Purification of the antibiotics 
from isolate M1 11 extracts 
The same procedure as above was used for purification the antibiotics produced by 
M1 11 isolate, except that the solvent system was different and to get pure antibiotic 
three different solvent system were used, Gradient HPLC system, mobile phase of 
water: acetonitrile 33:67(v/v) with a flow rate of 5 ml/min for collecting the fractions 
with antimicrobial properties, than an isocratic system was used with a mobile phase 
of water: methanol: acetonitrile 30:35:35 (v/v) to remove impurities from the 
antibiotics. When analyzed with NMR the proton spectrum showed that the 
antibiotics were not yet pure and a further purification step using an isocratic system 
with a mobile phase of water: methanol 30:70 (v/v) was used to further purify the 
antibiotics.  
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2.17.4 Identification of Chemical Structures    
 
NMR spectroscopy 
After purified fractions were obtained by HPLC all the samples were analyzed by 
NMR spectroscopy, all NMR measurements were performed on a Bruker Ultra-shield 
Avance AMX 400 MHz spectrometer, using 5-mm NMR tubes (Wilmad NMR tubes, 
5 mm diam., precision 500 MHz Sigma-Aldrich, UK). Samples (5 mg of the 
compound for some fractions and the available amount of the compounds for rest of 
the fractions) were dissolved in a 600 μl deuterated methanol-D4 (CD3OD) or 
deuterated Dimethyl sulfoxide-D6 (DMSO-D6). 
 
FTIR 
FTIR analysis of the each compound was carried out with a Thermo Nicolet iS10 IR 
spectrometer following the manufacturer’s instructions. For each sample, 16 scans 
were collected.  
Mass Spectroscopy (MS) of the active compounds  
MS for pure compounds (Es1 fractions) were obtained first by LC-MS (Agilent 
Technologies 6120 Quadrupole LC/MS) at the University of Salford by injecting 10µl 
of each compound into instrument in positive and negative ion mode. Then, accurate 
MS were obtained by sending samples to the Cambridge University Chemical 
Laboratory to confirm the final structures of the compounds.   
 
2.18 Antimicrobial and anticancer activities 
 
2.18.1 Minimum Inhibitory Concentration (MIC) 
In this study, the minimal inhibitory concentration (MIC) of Es1, M1 11 and La1a 
whole extracts and Es1 and M1 11 purified fractions were determined by broth micro-
dilution method (Andrews, 2001). Two test organisms E.coli ATCC 10536 and S. 
aureus ATCC 25923 were used; the compounds were dissolved in Dimethyl sulfoxide 
(DMSO) as solvent.  
The UV spectrophotometer was balanced and MHB was used as blank to zero the 
absorbance to achieve desired suspension (0.1). Overnight cultures of E. coli and S. 
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aureus were measured at 600 nm; E. coli ATCC 10536 was 1.422 and S. aureus 
ATCC 25923 was 0.932. 
The following calculation was done to find out the concentrations of the bacteria and 
the broth needed to accomplish the MIC procedure: 
C1 x V1 = C2 x V2 
E. coli ATCC 10536: 1.422 x X = 0.01 x 20 ml  
  X = 0.2 / 1.422  
  X = 0.14 ml x 1000 
  X = 140 µl of E. coli ATCC 10536 and 20 – 0.14 = 19.85 ml of broth 
 S. aureus ATCC 25923: 0.932 x X = 0.01 x 20 ml 
        X = 0.2 / 0.932  
        X = 0.21 ml x 1000 
        X = 210 µl of S. aureus ATCC 25923 and 20 – 0.21 = 19.78 ml of broth 
 
The broth was then added into 2 Falcon tubes and the bacteria concentrations added 
separately to these tubes.   
Compound plate 
Fifty microliters of DMSO was added into each well in a sterilize 96-well microtitre 
plate except the first well of each row. One hundred microliters of each 
compound/whole extract were add to the first well in each row of the plate, then serial 
dilutions prepared by transferring 50 µl to the next well and mixing for each 
compound (the last well of each row was just DSMO as solvent control). 
Dosing plate 
One hundred microliters of MH Broth was add into each well in a sterilize 96-well 
plate then 10 µl of each compound from compound plat added and mixed. 
Bacteria plate 
At the final in a sterilize 96-well plate, 100 µl from dosing plate was loaded with 100 
µl bacterial diluted suspension (the final volume of each well was 200µl). 
Gentamycin and MHB medium were added in two separate rows as positive control 
and negative control respectively.    
The bacteria well plates were then incubated at 37
o
C for 24 h, then the MIC results 
obtained using a Multiskan FC plate reader (Thermo Scientific) at a wavelength of 
570 nm. 
Each determination was determined in triplicate and the mean value recorded. 
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2.18.2 Anticancer activity 
The compounds were screened by the anticancer research section and the method 
used to test the compounds is described below.   
2.17.2.1 Cell lines 
Two different cancer cell lines MDA-MB 468 (mammary gland/breast; derived from 
metastatic site: pleural effusion) Wang et al., (1997), MCF 7 (breast adenocarcinoma) 
Lee et al., (2015) were used to test for potential anticancer activity and HACAT cells 
lines (Human immortalized keratinocytes) Boukamp et al., (1988) were used as 
normal cells.  
 
2.17.2.2 Maintenance of cells 
Cell lines were growing by adhering to a plastic wall of T75 cell culture flasks 
(Thermo Fisher Scientific, UK).  
Dulbecco's modified Eagle's medium (DMEM; Sigma, UK) was used as a growth 
medium and the temperature was maintained at 37°C and 5% CO2. Sterility of the 
working environment was ensured by using Virkon and 70 % ethanol in cleaning all 
utensils used. Cultures were examined using an inverted microscope to observe the 
confluency and confirm the absence of contaminants (bacterial and fungal).   DMEM 
media were replaced every 3 d.  
 
2.17.2.3 Splitting Matured Confluent Cells 
Cell cultures were divided once 75 % confluence was reached. The cells were washed 
with pre-warmed (37°C) sterile phosphate-buffered saline (PBS; Sigma, UK) using a 
volume equivalent to half of the volume of cell culture medium. This step was 
repeated 3-4 times to remove the remaining media. Three mililitres of trypsin-EDTA 
solution at 0.25% (w/v) was added into the culture flask. Flasks were rotated to ensure 
that the walls were covered with trypsin, this was incubated for 2-5 minutes at 37 °C 
to ensure that cells were detached from the wall of the flask. The cells were then 
resuspended in 5 ml pre-warmed medium (37 °C) to dilute and inactivate the trypsin. 
Detached cells were split into 2 new culture flasks containing pre-warmed medium, 
and the flasks incubated in an incubator (37 ̊C with 5% CO2 environment)  
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2.17.2.4 Cell viability assay using MTT 
MTT (3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl tetrazolium bromide; (Sigma, UK) 
viability assay was conducted as described by Holst and Oredsso (2005). One hundred 
microlitres of cell suspension were seeded in 96 well microtitre plates to give 20,000 
cells/ well. Twenty-four hours after seeding, a concentration of compounds ranging 
from 3.13 to 100 μg/mL were diluted in appropriate DMSO was added to the wells. 
DMSO was used as the negative control, the treated cells were then left for 24 h. Five 
mg/mL MTT reagent (Sigma, UK) was dissolved in PBS and added unto the 96 well 
plates. Further incubation was done for 4 h. MTT was removed from the medium and 
cultures which had formed purple colour from the formazan in MTT were dissolved 
in DMSO (200 μl). A Thermo Labsystem Multiskan Ascent plate reader using Ascent 
software - (Labsystems Oy, Helsinki, Finland) was used to measure absorbance at 540 
nm and the inhibitory concentration (IC50) calculated. 
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Chapter 3   
Isolation and identification of antibiotic producing microorganisms 
from terrestrial invertebrates 
 
3.1 Introduction 
No single method has been discovered as the correct approach to selectively isolate 
organisms from environmental samples. Rather, various approaches of individual or 
collection of organisms are used to selectively isolate multiple types of fungi and 
actinomycetes from environmental samples. For example fungi have been enriched by 
plating serial dilutions of environmental samples onto potato dextrose media that 
contains compounds that inhibit unwanted bacterial growth but allows the growth of 
the target fungi. For example antibacterial agents can be added to the isolation media 
to prevent growth of bacteria that may overgrow fungal species (Awad et al., 2009). 
Recovery can be improved by enriching the environmental substrate before selective 
isolation or through chemical or physical treatment techniques (Ikechi–Nwogu and 
Elenwo, 2012) 
Many “non-selective” media have been recommended for the isolation of 
streptomycetes. In these media, carbon sources include glucose, glycerol, mannitol, or 
starch as the carbon source and arginine or asparagine as the nitrogen source. A 
source of both nitrogen and carbon is chitin, which is frequently used. Such “non-
selective” media are now known to favor the isolation of a narrow range of 
streptomycetes and\or fungi and do not support the growth of organisms with more 
exacting growth requirements (Sembiring and Goodfellow, 2008).  
 
Chemical screening 
Currently, the screening techniques available to detect antimicrobial activity of 
natural products are categorized into three groups: bio-autographic; diffusion and 
dilution techniques. The bio-autographic and diffusion approaches provide ideas of 
the presence or absence of substances with antimicrobial activity thus referred to as 
qualitative methods. However, through dilution techniques it is possible to determine 
minimal inhibitory concentration thus referred to as quantitative assays. Antimicrobial 
activities mentioned in the literature have been assessed using diverse collection of 
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methodologies, sensitivity degrees, amount of test compounds and microbial stains 
and are usually challenging to compare (Valgas et al., 2007).  
Three major factors need to be considered when screening for new bioactive 
microbial compounds: selection of producing organisms, culture methods and 
detection. The singularity of the microorganism and the novelty of both specific 
activity and chemical structure will increase the probability of success in the first 
stage (Sajid et al., 2009). In order to elucidate outstanding natural molecular 
diversity for drug development, various methods that have been developed are target-
directed biological, physicochemical and chemical screening strategies. To visualize 
the secondary metabolite pattern, a chemical screening using Thin-layer 
chromatography (TLC) with various staining reagents and HPLC-MS/MS enables 
the visualization of an almost complete picture of the secondary metabolites, also 
known as their metabolic ﬁngerprint (Taddei et al., 2006b).  
 
Maximization of antibiotic yield and manipulation of carbon and nitrogen 
sources. 
The manipulation of the type and concentration of nutrients formulating the culture 
medium can greatly affect antimicrobial production. The effect of carbon and nitrogen 
source has been the focal point of study for industries as well as research groups. 
Nitrogen is crucial in synthesizing enzymes that play a part in primary and secondary 
metabolism and may be part of the antimicrobial molecule (Merrick and Edwards, 
1995). Thus depending on the biosynthetic pathways involved, nitrogen may affect 
antibiotic formation. Tawiah et al., (2012) and Charyulu and Gnanamani, (2010) 
noted that the type of nitrogen source, whether organic or inorganic, was involved in 
the synthesis of secondary metabolites. They showed that using an organic nitrogen 
source Pseudomonas aeruginosa gave a higher yield of uncharacterized antimicrobial 
metabolites compared to inorganic sources. Specifically they showed that asparagine 
was better used for antibiotic production by P. aeruginosa rather than inorganic 
nitrogen sources such as sodium and potassium nitrates and ammonium salts.  
Production of penitrem B by P. aurantiogriseum also differed with different nitrogen 
sources with KNO3 giving greatest yield, followed by L-asparagine, NaNO3, glycine, 
DL-aspartic acid and L-tryptophan (Surekha and Reddy, 1992). Aspergillus flavus and 
Penicillium citrinum expressed higher levels of antibacterial activity with yeast 
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extract when compared to other nitrogen sources such as NH
4
Cl, (NH
4
)
2
SO
4 and 
NaNO
3 (Compaore et al., 2016a). In a study on the growth of Streptomyces 
hygroscopicus and biosynthesis of rapamycin using different nitrogen sources carried 
out by Lee et al., (1997), six non-amino acid nitrogen compounds were examined as 
nitrogen source. (NH
4
)
2
SO
4 was the best with respect to formation of rapamycin, and 
supported cell growth comparable to the organic nitrogen sources used. 
In study carried out by Khopade et al., (2012)  the production and properties of a 
biosurfactant isolated from a marine Streptomyces species B3 was reported as being 
best with yeast extract as a nitrogen source.  
In study carried on the effects of nitrogen compounds on production of L-
asparaginase by Streptomyces ginsengisoli by using different nitrogen sources, beef 
extract, yeast extract, and peptone were added at a concentration of 0.2% (w/v) to 
Asparagine Dextrose Salt Broth keeping other ingredients constant, Peptone gave 
maximum enzyme production by this strain (Deshpande et al., 2014). Soyabean was 
the best nitrogen source for Melanin production from a marine Streptomyces 
(Vasanthabharathi et al., 2013).  
Carbon sources are also important in optimizing yields of secondary metabolites and 
slowly utilised carbon sources such as lactose or glycerol have been shown to be 
optimal for secondary metabolite production than rapidly utilisable glucose (Jia et al., 
2009). P. aurantiogriseum responded differently to different carbon sources with D-
xylose found to be the best carbon sources for penitrem B production (Surekha and 
Reddy, 1992). The best carbon sources for production of antibacterial compounds 
appeared to be starch and glucose for Aspergillus flavus and starch and sucrose for 
Penicillium citrinum (Compaore et al., 2016a). 
Glucose is an excellent carbon source for growth of most actinomycetes, compared to 
glycerol. However, exceptions include for example Streptomyces clavuligerus, a 
cephamycin producer, which cannot utilize glucose, but glycerol favours its growth, 
while antibiotogenesis is inhibited (Khaliq et al., 2009). The regulation of carbon 
utilisation is of central importance in the gene expression pathways for both 
morphological development and antibiotic production in Streptomyces spp. as 
reported by Watve et al., (2001). In a study carried out by (Mehdi et al., 2006) the 
Streptomyces spp. TN97 strain showed that the highest biological activities were also 
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obtained when glycerol or fructose at 1% (w/v) was added in tryptic soy broth (TSB) 
medium after 72 h of incubation at 250 rpm. 
 
The aims of this part of the study were to isolate microorganisms from invertebrates 
to screen them for antibiotic activity and identify them to at least species level and to 
optimise antibiotic yields by culture selected organisms on different culture media. 
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3.2 Results 
 
3.2.1 Isolation of antibiotic producing microorganisms                
Twenty-one aquatic and 14 terrestrial invertebrates were investigated for the presence 
of Streptomyces-like organisms as described in section 2.1. A total of 125 microbial 
isolates were obtained and screened for antibiotic production.  
 
3.2.2 Primary screening 
3.2.2.1 Agar overlay technique 
Organisms isolated from the invertebrates were initially screened by streaking on AIA 
agar and screened for antimicrobial activity against Gram positive (S. aureus) and 
Gram negative bacteria (E.coli) using the agar overlay technique.  
 
3.2.2.2 Streak or single colony pattern on agar plates to detect antimicrobial 
activity 
All of the isolates were tested for their activity against five test microorganisms. 
Typical results are shown in Figures 3.1 and 3.2 and the results are summarised in 
Table 3.1. The test microorganisms included three Gram positive bacteria (S. aureus, 
S. aureus 2 and B. cereus) and two Gram negative bacteria (E. coli and P.  
fluorescens). The results showed that 47/125 (38%) isolates had promising 
antibacterial activity against one or more of the test organisms. 
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Table 3.1: Antibacterial activity against Gram positive and Gram negative bacteria 
Invertebrates Isolates 
 
E.c S. a S. a2 B. c P. f 
Black worm La1a ++ ++ ++ ++ + 
La2 + + ++ + - 
La4 ++ + ++ + - 
La5 + + ++ ++ - 
Whirligig Beetle Larva M35 1 ++ + ++ + + 
M35 4 ++ + ++ + - 
Sludge worm 
 
M35 5 + + ++ + + 
M35 9 ++ + ++ + + 
Biting midge larvae M35 11 + + ++ + - 
Swimming mayfly nymph M1 2 - + ++ + - 
M1 3 + + + + - 
M1 4 - + ++ ++ - 
M1 8 - + ++ ++ - 
M1 10 - + ++ ++ - 
M1 11 ++ ++ ++ ++ ++ 
Flattened mayfly nymph M1 13 - ++ ++ ++ - 
M1 14 + ++ ++ ++ - 
M1 15 - + ++ ++ - 
M1 16 - + ++ ++ - 
M1 18 - + ++ ++ - 
M1 20 - + ++ ++ - 
M1 22 + + ++ + - 
Red ant Antw1 + - - - - 
Antw2 + - - - - 
Antw3 + - - - - 
Yellow meadow ant Antb4 + - - - - 
Sea anemone Sa1 - - + - - 
Sa2 - - + - - 
Common wasps W 1 - - + + - 
W 2  + + ++ ++ - 
W 3 - + + + - 
W 6  - + ++ + - 
W 7 + + ++ + + 
W 9  + ++ ++ + - 
W 12 + + ++ + - 
W 13 + + ++ + - 
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Invertebrates Isolates E.c S. a S. a2 B. c P. f 
Great Ram's-horn snail 
 
Wata1  - + + - - 
Wata2  - + + - - 
Ram's horn snail 
 
p.p 1 - + + - - 
p.p 2 - + + - - 
p.p 3 + + + - - 
Black slug  
 
S 5 - + - - - 
S 6 - + - - - 
Garden snail Es 1 ++ ++ ++ ++ ++ 
Es 2 + ++ ++ + + 
Es 5 - + + - - 
Es 9 - + ++ + - 
- No inhibition zone, + inhibition zone less 5mm, ++ inhibition zone more than 5 mm 
E. c = E. coli ATCC10536, S. a = S. aureus MOH1, S. a 2 = S. aureus ATCC 25923, B. c = B. cereus 
ATCC 10876, P. f = P. fluorescens ATCC 13525. 
 
 
a                                                                       b 
Figure 3.1: Agar overlay technique showing Inhibitory zone activity of the strain 
isolated from Tubifex tubifex (M35 9) against S. aureus ATCC 25923 (a) and E. coli 
ATCC10536 (b). 
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Figure 3.2: Streak and single colony pattern on agar plates showing inhibitory 
activity of the strain (M1 11) against test organisms. 
The M1 11strain was isolated from Baetidae, Swimming mayfly nymph inhibited all 4 
test organisms and  showed inhibition of S. aureus AOH1 (Sa2), S.aureus ATCC 
25923 (Sa), E. coli ATCC10536 (Ec) and B. cereus ATCC 10876 (BC). 
 
Of the 47 isolates that showed antimicrobial activity, 28 were from aquatic 
invertebrates (Table 3.3) and 19 from terrestrial invertebrates (Table 3.4). Four strains 
were isolated from Lumbriculus variegatus (black worm), 2 from Actinia equine (sea 
anemone), 6 from Baetis spp. (swimming mayfly nymphs) 7 from Baetis spp. 
(flattened mayfly nymph), 2 from Gyrinidae Beetle Larva (whirligig), 2 from Tubifex 
tubifex (sludge worm), 1 from Culicoides spp. (biting midge larvae), 3 from Planoris 
planoris (ram's horn snail), 2 from Planorbis corneus (great Ram's-horn snail), 2 from 
Arion ater (black slug), 3 from Myrmica rubra (red ant), 1 from Lasius Flavus 
(yellow meadow ant), 4 from Helix aspersa (garden snail) and 8 from Vespula 
vulgaris (common wasp).  
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Table 3.2: Patterns of activity analysis 
Activity Isolates 
Broad spectrum high activity La1a1, M1 11, M1 14 and Es1  
Broad spectrum weak activity M35 5, M35 11, M1 3, M1 22, W7, W 12, 
W 13 and P.p3  
Broad spectrum variable activity La2, La4, La5, M35 1, M34 4, M35 9, W2, 
W9 and Es2  
Gram positive only high activity M1 4, M1 8, M1 10, M1 13, M1 15, M1 16, 
M1 18, and M1 20  
Gram positive only low activity Sa1, Sa2, W1, W3, Wata1, Wata 2, P.p1, 
P.p2, S 5, S 6, Es 5 
Gram positive only variable activity M1 2, W 6, Es 9 
Gram negative only high activity - 
Gram negative only low activity Antw1, Antw 2, Antw 3, Antb 4 
Gram negative only variable activity - 
Broad spectrum high activity (inhibition zone more than 5 mm against at least three of 
five test organisms) 
Broad spectrum weak activity (inhibition zone less 5 mm against at least four of five 
test organisms) 
Broad spectrum variable activity (inhibition zone more than 5 mm against two test 
organisms but less 5 mm against the other three test organisms) 
Gram positive only high activity (inhibition zone more than 5 mm against at least two 
of the three Gram positive test organisms) 
Gram positive only low activity (inhibition zone less 5 mm against the three Gram 
positive test organisms) 
Gram positive only variable activity (inhibition zone more than 5 mm against just one 
of the three Gram positive test organisms) 
Gram negative only low activity (inhibition zone less 5 mm against the Gram negative 
test organisms) 
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Table 3.3: Organisms isolated from the aquatic invertebrates 
Invertebrates 
Antibiotic producing isolates and strain 
designation 
Freshwater shrimp 0 
Water flea  0 
Bloodworm 0 
A leech 0 
Black worm 4 (la1a, la2, la4 and la5) 
Bristle worm 0 
Sea anemone 2 (Sa1 and Sa2) 
Swimming mayfly nymph 6 (m1 2,3,4,8,10 and 11) 
Flattened mayfly nymph 7 (m1 13,14,15,16,18,20 and 22)  
Whirligig Beetle Larva 2 (m35 1, and 4) 
Sludge worm 2 (m35 5 and 9) 
Biting midge larvae  1 (m35 11) 
Flatworm 0 
Flatworm 0 
Northern river crangonyctid 0 
Waterlouse 0 
Damselfly Nymphs  0 
Ram's horn snail 3 (p. p1, 2 and 3) 
Great pond Snail 0 
Great Ram's-horn snail 2 (water s 1 and 2) 
Waterlouse 0 
 
Table 3.4: Organisms isolated from the terrestrial invertebrates 
 
Invertebrates 
Antibiotic producing isolates and strain 
designation 
Roman snail 0 
Yellow mealworm 0 
Black slug  2 (S5 and S6) 
Red ant 3 (Antw1, 2 and 3) 
Yellow meadow ant 1 Antb4 
22-spot Ladybird 0 
Tiger worm 0 
Common shiny woodlouse 0 
Garden snail 4 (E.s1, 2,5 and 9) 
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Invertebrates 
Antibiotic producing isolates and strain 
designation 
Red flour beetle  0 
Common wasps 8 (W1, 2, 3, 6, 7, 9, 12 and 13) 
Yellow mealworm 0 
Black ants 0 
Common Earthworm  
Red tiger worm 
0 
0 
 
3.2.3 Secondary screening 
Isolate Es1 from Helix aspersa showed the highest antimicrobial activity against a 
range of bacterial test species during primary screening. For this reason, the study 
focused largely on ES1 for secondary screening and production, extraction of 
antibiotics. 
Comparative antibiotic production using different media 
A loopful of isolate Es1 isolated from Helix aspersa was inoculated into 50 ml 
aliquots of the following media in 250 ml Ehrlenmeyer flasks: SB with NaNO3 as 
source of nitrogen, SB with (NH4)2SO4 as source of nitrogen, SB2 with NaNO3 as 
source of nitrogen mixed with NB 2:1, SB2 with (NH4)2SO4 as source of nitrogen 
mixed with NB 2:1, GNB, MEB, YEB, TSB and AIB. The inoculated media were 
incubated on a rotary shaker at 28±2ºC and 120 rpm for 7 d. One millilitre of filtered 
medium was placed in wells cut in MHA plates seeded with test organisms, incubated 
for 24 h and zone size determined. The results are shown in Table 3.5. 
Filtered medium of SB with NaNO3, SB with (NH4)2SO4, MEB, YEB and AIB 
showed inhibition zones against E. coli ATCC10536 and S. aureus ATCC 25923. 
AIB, MEB and YEB promised to be the best media as they showed the largest 
inhibition zones. 
 
Table 3.5: Antibiotic production for isolate Es1 using different media. 
Test 
organism 
SB 
+NaNO3 
SB 
+(NH4)
2SO4 
SB2 
+NaNO3 
SB2 
+(NH4)
2SO4 
GNB MEB YEB TSB AIB 
S. aureus  4 3 - - - 14 12 - 14 
E. coli 3 2 - - - 10 11 - 11 
Inhibition zone diam. mm,  - No inhibition zone 
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Key to media: SB +NaNO3, Starch Broth with NaNO3 as source of nitrogen; 
SB+(NH4)2SO4, Starch Broth with (NH4)2SO4 as source of nitrogen; SB2+NaNO3 
Starch Broth and Nutrient Broth 2:1 with NaNO3 as source of nitrogen; SB2, Starch 
Broth and Nutrient Broth 2:1 with (NH4)2SO4 as source of nitrogen; GNB, Glucose 
Nitrate Broth; TSB, Tryptone Soya Broth; MEB, Malt Extract Broth; YEB, Yeast 
Extract Broth; AIB, Actinomycete Isolation Broth.  
 
3.2.4 Identification of isolates 
3.2.4.1 DNA extraction 
DNA was extracted from all isolates and tested for purity by using NanoDrop 
spectrophotometer. Six different DNA isolation kits (as described in section 2), were 
investigated for extraction of DNA from the isolates but the isolated DNA’s were of 
low concentration and purity from five kits, Typical results were those obtained using 
the Bioline ISOLATE kits which were used for 2 isolates Es1 and M1 11 (from broth 
and solid media). The absorbance spectrum of the DNA samples is shown in Figure 
3.3 and analysis details are shown in Table 3.6. The results show low purities and low 
concentrations. 
 
Table 3.6 and Figure 3.3: Raw spectroscopic data from NanoDrop 
spectrophotometer, showing absorbance at 260 and 280 nm for DNA extracted by 
Bioline kit. 
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However, when the FastDNA™ SPIN kit was used for DNA extraction for all isolates 
(from broth and solid media: Table 3.7 and Figure 3.4), the absorbance spectrum of 
the DNA samples showed acceptable purities and concentrations. Although not ideal, 
these extracts were found to be suitable for downstream applications such as PCR and 
sequencing.  
 
 
Table 3.7 and Figure 3.4: Raw spectroscopic data from NanoDrop 
spectrophotometer, showing absorbance at both 260 and 280 nm for DNA extracted 
using the FastDNA™ SPIN kit. 
 
3.2.4.2 Polymerase Chain Reaction 
PCR was performed using primers for 16S and 18S rDNA and examples of the 
agarose electrophoresis are shown in Figures 3.5 (18S primers) and 3.6 (16S primers).  
Bands of the expected size (240 for 18S and 1500 for 16S) were obtained.  
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Figure 3.5: Amplification of 18S rDNA of Penicillium sp.; Lane 1: Hyperladder 1kb; 
Lanes 2-7 representing the samples (Es1, Es9, La1a, La2, M1 11 and M35 9 
respectively); Lane 8-9: Negative control (no DNA). 
 
 
Figure 3.6: Amplification of 16S rDNA; Lane 1: Hyperladder 1kb; Lane 2 
Penicillium sp (Es1); Lane 3 Streptomyces sp (Pp1); Lane 4 Penicillium sp (La1a); 
Lane 5 Penicillium sp (M1 11); Lane 6: Negative control (no DNA). 
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3.2.4.3 Sequence alignment and identification 
 
The DNA from the 16S and 18S PCR experiments was sequenced and blast searched as described in section 2.11. The top 3 identification 
matches for each fungal isolate are shown in Table 3.8 and for bacterial isolates in Table 3.10.  
 
Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
LA1A 
Penicillium brevicompactum strain 
ATCC 16024 100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 100 
AF411201.1 
 
Published only in NCBI database 
2001 
Uncultured eukaryote 100 LC109063.1  Published only in NCBI database 
LA2 
Uncultured Penicillium CHiv76 18S 100 KP974229.1 
Published only in NCBI database 
2015 
Uncultured fungus clone 
Aerocomp_EO40 
100 FJ754892.1 (Le Goff et al., 2010) 
Penicillium commune strain IBT 
15141 
99 AF548089.1 (Wu et al., 2003) 
LA4 
Penicillium tardum strain 
KCTC16051 
100 AF245233.1 
Published only in NCBI database 
2000 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007)  
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
1999 
LA5 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007)  
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
M1 2 
Penicillium tardum strain 
KCTC16051 
100 AF245233.1 
Published only in NCBI database 
2000 
Penicillium brevicompactum strain 
ATCC 16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
M1 3 
Penicillium fimorum strain DTO 
159-F1 
98 KU904343.1 (Houbraken et al., 2016) 
Penicillium fimorum strain CBS 
140576 
98 KU904342.1 (Houbraken et al., 2016) 
Penicillium sp DR1 98 KT805951.1 
Published only in NCBI database 
2015 
M1 4 
Penicillium sp. 2 BRO-2013 97 KF367494.1 (Oliveira et al., 2013) 
Uncultured fungus clone 
T3_II_1a_04 
96 EF628511.1 (Poll et al., 2010) 
Penicillium sp HT-M15-LS 96 KJ527027.1 
Published only in NCBI database 
2014 
M1 8 
Penicillium roqueforti  ATCC 
10110 
99 GQ458035.1 (Arteau et al., 2010) 
Penicillium camemberti strain 
ATCC 10387 
99 GQ458039.1 (Arteau et al., 2010) 
Penicillium dipodomyicola strain 
ACBF 002-3 
99 GQ161752.1 
Published only in NCBI database 
2009 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
M1 10 
Penicillium tardum strain 
KCTC16051 
100 AF245233.1 
Published only in NCBI database 
2000 
Penicillium chrysogenum 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
1999 
M1 11 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007)  
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
Penicillium brevicompactum strain 
ATCC 16024 
100 KP981369.1 (Sharifirad et al., 2016) 
M1 13 
Penicillium brevicompactum ATCC 
16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
M1 14 
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
1999 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007) 
Penicillium tardum KCTC16051 100 AF245233.1 
Published only in NCBI database 
2000 
M1 15 
Penicillium solitum strain 20-01 99 JN642222.1 (Eldarov et al., 2012) 
Penicillium sp clone NJ-F4 18S 99 GU190185.1 
Published only in NCBI database 
2009 
Penicillium dipodomyicola strain 
ACBF 002-3 
99 GQ161752.1 
Published only in NCBI database 
2009 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
M1 16 
Penicillium roqueforti strain ATCC 
10110 
100 GQ458035.1 (Arteau et al., 2010) 
Penicillium sp BF79 100 AM901692.1 (Pitkäranta et al., 2008) 
Penicillium sp BF18 100 AM901680.1 (Pitkäranta et al., 2008) 
M1 18 
Penicillium sclerotigenum strain 
NRRL 22813 
100 DQ339574.1 (Dombrink-Kurtzman, 2007) 
PenicilliumvulpinumstrainNRRL10
02 
100 DQ339572.1 (Dombrink-Kurtzman, 2007) 
Penicillium vulpinum strain NRRL 
2031 
100 DQ339569.1 (Dombrink-Kurtzman, 2007) 
M1 20 
Penicillium clavigerum NRRL 1003 99 DQ339555.1 (Dombrink-Kurtzman, 2007) 
Penicillium griseofulvum NRRL 
3523 
99 DQ339549.1 (Dombrink-Kurtzman, 2007) 
Penicillium expansum strain NRRL 
35259 
99 DQ339548.1 (Dombrink-Kurtzman, 2007) 
M1 22 
Penicillium brevicompactum ATCC 
16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
1999 
ES1 
Penicillium brevicompactum strain 
ATCC 16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
ES2 
Penicillium brevicompactum strain 
ATCC 16024 
96 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
41H1 
96 
KX610138.1 
 
Published only in NCBI database 
2014 
Uncultured fungus clone CMH605 96 KF800692.1 (Rittenour et al., 2014) 
ES9 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007) 
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
2002 
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
ANT
W1 
Verticillium fungicola solate 
ARSEF 2065 
100 AF108487.1 (Bidochka et al., 1999) 
Simplicillium lamellicola isolate 
UAMH 2055 
100 AF108489.1 (Bidochka et al., 1999) 
Phytocordyceps ninchukispora 
strain CCRC 31900 
100 AJ242434.1 
Published only in NCBI database 
1999 
ANT
W2 
Lecanicillium sp strain CCF 5201 89 LT548278.1 
Published only in NCBI database 
2016 
Lecanicillium sp CCF 5233 89 LT548277.1 
Published only in NCBI database 
2016 
Fungal sp. SLZ14 89 KJ158154.1 
Published only in NCBI database 
2014 
ANT
W3 
Simplicillium lamellicola isolate 
UAMH 2055 
100 AF108489.1 (Bidochka et al., 1999) 
Cordyceps sp ATCC 36337 100 AJ242433.1 
Published only in NCBI database 
1999 
Fungal sp SLZ46 100 KJ183213.1 
Published only in NCBI database 
2014 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
ANTB
4 
Uncultured marine ascomycete 
clone PRTBE7359 
 
100 
HM800024.1 
 
(Eloe et al., 2011)  
Uncultured marine ascomycete 
clone PRTBE7237 
 
100 
HM799960.1 
 
(Eloe et al., 2011)  
Exophiala oligosperma strain CBS 
725.88 
 
99 
AY554287.1 
 
Published only in NCBI database 
2004 
M35 1 
Penicillium roqueforti strain ATCC 
10110 
100 GQ458035.1 (Arteau et al., 2010) 
Penicillium dipodomyicola strain 
ACBF 002-3 
100 GQ161752.1 
Published only in NCBI database 
2009 
Penicillium sp BF79 100 AM901692.1 (Pitkäranta et al., 2008) 
M35 4 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007) 
Penicillium expansum 100 AB028137.1 
Published only in NCBI database 
2002 
Penicillium tardum KCTC16051 100 AF245233.1 
Published only in NCBI database 
2000 
M35 5 
Penicillium brevicompactum strain 
ATCC 16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
M35 9 
Penicillium glandicola NRRL 985 100 DQ339573.1 (Dombrink-Kurtzman, 2007) 
Penicillium vulpinum strain NRRL 
1002 
100 DQ339572.1 (Dombrink-Kurtzman, 2007) 
Penicillium glandicola strain NRRL 
2036 
100 DQ339565.1 (Dombrink-Kurtzman, 2007)  
M35 
11 
Penicillium sp HT-M15-L 100 KJ527026.1 
Published only in NCBI database 
2014 
Uncultured fungus clone CMH605 100 KF800692.1 (Rittenour et al., 2014) 
Uncultured fungus clone CMH224 100 KF800315.1 (Rittenour et al., 2014) 
Pp3 
Penicillium commune strain MA09-
AL 
98 GQ458026.1 
Published only in NCBI database 
2009 
Penicillium coccotrypicola strain 
BRIP 59608 
98 KM605436.1 
Published only in NCBI database 
2014 
Penicillium glandicola strain NRRL 
985 
98 DQ339573.1 (Dombrink-Kurtzman, 2007) 
S 5 
Uncultured Penicillium clone USN5 100 JN397370.1 
Published only in NCBI database 
2011 
Penicillium sp strain Y12 EG-2010 100 HM161749.1 (Galiana et al., 2011) 
Penicillium glabrum strain 
KCTC16099 
100 AF245270.1 
Published only in NCBI database 
2000 
S 6 
Fungal sp Isolate nussu_195 100 KT714176.1 
Published only in NCBI database 
2013 
Fungal sp SLZ62 100 KJ183214.1 
Published only in NCBI database 
2014 
Hypocrea sp SP-4 100 HM152771.1 
Published only in NCBI database 
2010 
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Table 3.8: Sequence identification for fungal isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
Sa 1 
Penicillium expansum 100 AB028137.1 Ogawa.,  et al 2002 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007) 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
Sa2 
Trichocomaceae sp. LM196 100 EF060542.1 
Published only in NCBI database 
2006 
Uncultured ascomycete 100 AF290082.2 Lopez-Garcia.,  et al 2000 
Penicillium griseofulvum 100 DQ083547.1 
Published only in NCBI database 
2005 
W1 
Penicillium freii (IBT 3464) 99 AJ005446.1 (Skouboe et al., 2000) 
Penicillium dipodomyicola strain 
B64 
99 KX090305.1 
Published only in NCBI database 
2016 
Penicillium gladioli strain NRRL 
939 
99 DQ339568.1 (Dombrink-Kurtzman, 2007) 
W2 
Penicillium paneum strain NRRL 
25162 
99 DQ339571.1 (Dombrink-Kurtzman, 2007) 
Penicillium solitum strain 20-01 99 JN642222.1 (Eldarov et al., 2012) 
Penicillium echinulatum isolate 
00044 
99 DQ339568.1 (Dombrink-Kurtzman, 2007) 
W3 
Penicillium coccotrypicola strain 
BRIP 59608 
99 KM605436.1 
Published only in NCBI database 
2014 
Penicillium tardum strain 
KCTC16051 
99 AF245233.1 
Published only in NCBI database 
2000 
Penicillium griseofulvum 99 DQ083547.1 
Published only in NCBI database 
2005 
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Table 3.8: Sequence identification for fungi isolates 
Isolate ID 
Similarity 
% 
Accession Reference 
W6 
Penicillium brevicompactum strain 
ATCC 16024 
99 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 
99 AF411201.1 
Published only in NCBI database 
2001 
Eupenicillium crustaceum 99 D88324.1 (Ogawa et al., 1997) 
W7 
Penicillium vulpinum NRRL 1002 99 DQ339572.1 (Dombrink-Kurtzman, 2007) 
Penicillium paneum NRRL 25162 99 DQ339571.1 (Dombrink-Kurtzman, 2007) 
Penicillium gladioli strain NRRL 
939 
99 DQ339568.1 (Dombrink-Kurtzman, 2007) 
W9 
Penicillium sp clone NJ-F4 18S 99 GU190185.1 
Published only in NCBI database 
2009 
Uncultured fungus clone CMH067 99 KF800158.1 (Rittenour et al., 2014) 
Uncultured fungus clone CMH605 99 KF800692.1 (Rittenour et al., 2014) 
W12 
Penicillium expansum 100 AB028137.1 Ogawa.,  et al 2002 
Penicillium chrysogenum strain 215 100 GQ152991.1 (Davolos and Pietrangeli, 2007) 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
W13 
Penicillium brevicompactum strain 
ATCC 16024 
100 KP981369.1 (Sharifirad et al., 2016) 
Penicillium chrysogenum strain 
KCTC6052 
100 AF411201.1 
Published only in NCBI database 
2001 
Eupenicillium crustaceum 100 D88324.1 (Ogawa et al., 1997) 
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Thirty-seven isolates were confirmed as Penicillium spp. with similarities of 96-100% to previously published sequences. However, it was not 
possible to identify down to species level. The exceptions were Ant W1, 2 and 3, Ant B4 and S6.  Examples of sequence alignments for La1a 
isolate with the three closest identification strains are shown in Figures 3.8-3.10. The similarity between the isolates was determined using 
Clustal Omega and the results are shown in Figure 3.7. Cluster analysis of fungal strains showed four main four clusters, fungal isolated from 
ants formed a separate cluster, Es1 and La1a clustered very close together and in the same branch with M1 11.    
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Figure 3.7: Phylogenetic relationships of 42 isolates indicating four main clusters, sequences were aligned using Clustal Omega and then the 
concatenated tree was generated.  
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Figure 3.8: Penicillium brevicompactum strain ATCC 16024 
 
 
Figure 3.9: Penicillium chrysogenum strain KCTC6052 
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Figure 3.10: Uncultured eukaryote 
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ITS sequencing of the selected potent isolates for identification 
Three strains were also sent for identification to an external source for confirmation and identification for species status. 
Three plated culture chosen isolates (Es1, M1 11 and La1a) were sent to NCIMB LTD for ITS sequencing. 
 
Identification Summary 
 
Table 3.9: Result of ITS sequencing for potent isolates (Es1, M1 11 and La1a) 
Isolation Code  Identification % 
Similarity  
Match 
Es1 Penicillium species  100 Genus 
La1a Penicillium species 100 Genus 
M1 11 Penicillium chrysogenum 99.8 Species 
 
ITS sequencing was performed on the above isolates to distinguish between the suspected Penicillium group. Despite obtaining good sequences for all three isolates, only one 
isolate returned a species level match. An EMBL search was performed for all three isolates and the only published match to species level was to Penicillium chrysogenum 
for M1 11 (Appendix 1.43). There were Penicillium chrysogenum matches within the searches for La1a and Es1, but these were from unpublished sources. An alignment of 
all three isolates shows them to be very similar with no base differences (Appendix 1.45). Sample M1 11 was slightly longer, which may be the reason for the species level 
match. 
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Table 3.10: Sequence identification for bacterial isolates 
Isolate ID Similarity 
% 
Accession Reference 
Wata 1 
Streptomyces griseolus strain 11-11 99 KJ571072.1 
Published only in NCBI database 
2014 
Streptomyces verne strain: NBRC 3112 99 AB184727.2 
Published only in NCBI database 
2004 
Streptomyces sp NBRC 3111 99 AB301481.1 Tagawa et al., 2008 
Wata 2 Streptomyces sp SIA-Cu-E1 99 KX056510.1 Published only in NCBI database 
2016 
Streptomyces halstedii strain NRRL B-
1238 
99 NR_044148.1 Published only in NCBI database 
2011 
Streptomyces cyaneus strain ISP 5108 99 NR_114820.1 Published only in NCBI database 
2014 
Es5 
Streptomyces sp GS01 92 JX430438.1 
Published only in NCBI database 
2012 
Streptomyces fimicarius strain G8A-2 92 HQ238410.1 
Published only in NCBI database 
2010  
Streptomyces fimicarius strain G8A-17 92 HQ238384.1 
Published only in NCBI database 
2010 
Pp1 
Streptomyces sp GY2 95 AB907698.1 
Published only in NCBI database 
2014 
Streptomyces sp C3001 95 EU348370.1 
Published only in NCBI database 
2007 
Streptomyces parvulus strain K-15 94 KY038196.1 
Published only in NCBI database 
2016  
Pp2 Streptomyces sp. strain 194  99 KX641400.1 (Betancur et al., 2016) 
Streptomyces sp. strain 184 99 KX641399.1 (Betancur et al., 2016) 
Streptomyces sp. strain CAE3 
  
99 KX242156.1 Published only in NCBI database 
2016 
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The results confirmed that all 5 strains were Streptomyces spp..  Strains Wata1, Wata 2 and PP2 were 99% similar to previously sequenced 
strains but it was not possible to confirm the species. Strain Es5 was possibly S. fimicarius but the match was only 92%. 
Example sequence alignments for Wata 1 isolate with the three closest identification strains are shown in 3.11-3.13. All three sequences are 
identical and show a single mis-match at position 29. 
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Figure 3.11: Streptomyces griseolus strain 11-11  
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Figure 3.12: Streptomyces verne strain: NBRC 3112 
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Figure 3.13: Streptomyces sp NBRC 3111 
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3.3 Discussion 
 
The aims of the study were to examine terrestrial and aquatic invertebrates for the 
presence of antibiotic producing microorganisms in the hope that organisms 
producing novel compounds could be isolated. The results showed that it was possible 
to isolate antibiotic producing strains from organisms from both sources. In the last 
two decades, the rate of discovery of novel compounds from terrestrial 
microorganisms has declined significantly. Recently researchers have begun 
investigating unconventional sources due to lack of research within those particular 
areas. This includes terrestrial invertebrates (Madden et al., 2013). Antibiotic 
producers have previously been reported in terrestrial invertebrates. Antibiotic 
producing streptomycetes have been reported in wasps but these were from a different 
species of wasp which is thought to produce antibiotics (not yet characterized) that the 
wasp smears over brood cells prior to oviposition to protect eggs from a fungal 
parasite (Kaltenpoth et al., 2005). Antagonistic activity was reported in a new strain 
of Streptomyces tritolerans sp. isolated from earthworm gut. Ethyl acetate extract of 
these strain showed high antagonistic activity against Aspergillus flavus, Fusarium 
udum, Fusarium oxysporum, Rhizoctonia solani, Alternaria alternate and 
Colletotricum capscii (Aruna et al., 2008). Isolation of a Pseudomonas aeruginosa 
strain producing an uncharacterized antimicrobial agent with the broad spectrum 
activity against E. coli ATCC 25922, S. aureus ATCC 25923, B. subtilis ATCC 
465,E. faecalis   ATCC 29737, Candida albicans ATCC 10231 and   K. pneumoniae 
ATCC 10031, it has been reported from the digestive system of an Iranian endemic 
slug, Parmacella iberica (Ebrahimipour et al., 2011). Also, antibiotic producers have 
been reported in marin invertebrates, antibiotic producing bacterial strains (Bacillus 
megaterium, Vibrio sp., Idiomarina baltica, Dietzia sp., Bacillus marisflavi, 
Staphylococcus equorum, Salinicoccus roseus, Bacillus sp., Marinobacter sp., 
Bacterium K54, Pseudomonas sp., Ruegeria sp., Vibrio parahaemolyticus, Bacillus 
subtilis  , Vibrio fortis and   Vibrio sp.) associated with four species of sponges 
(Echinodictyum sp., Spongia sp., Sigmadocia fibulatus and Mycale mannarensis) 
were isolated from the Tuticorin coast, Gulf of Mannar region. The strain of Bacillus 
sp. was found to produce a highly active compound against B subtilis, E coli and 
Candida albicans but the structure of this compound has not been characterized 
(Anand et al., 2006). Three compounds (cottoquinazolines D, cottoquinazolines B and 
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cottoquinazolines C) were isolated from coral-associated fungus Aspergillus 
versicolor LCJ-5-4 (soft coral Cladiella sp., South China Sea). These compounds 
were evaluated in vitro for cytotoxicity against Hela (cervical carcinoma) and P388 
(murine leukemia) cells line and for antimicrobial activity against E. coli, S. aureus, 
Enterobacter aerogenes, B. subtilis, and Candida albicans. Cottoquinazolines D 
exhibited moderate antifungal activity against Candida albicans while other 
compounds did not show antimicrobial activity, the Three compounds showed no 
cytotoxicity against the tested Hela and P388 cell lines (IC50 > 50 μM) (Zhuang et 
al., 2011). Mayamycin was extracted from a Streptomyces sp. strain HB202 isolated 
from the Marine Sponge Halichondria panacea from the Baltic Sea showed activity 
against several bacteria including antibiotic-resistant strains (B. subtilis (DSM 347, 
Brevibacterium epidermidis (DSM 20660), Dermabacter hominis (DSM 7083), K. 
pneumoniae  (ATCC 700603; ESBL) Propionibacterium acnes (DSM 1897), P. 
aeruginosa (DSM 50071), S. aureus (ATCC 12600),   S. aureus  (ATCC 33593; 
MRSA), Staphylococcus epidermidis  (DSM 20044)  , Staphylococcus lentus (DSM 
6672) and Xanthomonas campestris (DSM 2405)) and exhibited potent cytotoxic 
activity against eight human cancer cell lines (HepG2 (hepatocellular carcinoma), 
  HT-29 (colon adenocarcinoma), GXF251L (gastric cancer)  ,   LXF529L (non-
small-cell lung cancer),   MAXF401NL (mammary cancer),   MEXF462NL 
(melanoma cancer),   PAXF1657L (pancreatic cancer) and RXF486L (renal cancer)   
(Schneemann et al., 2010). As far as the author is aware none of these has been 
commercially exploited so far, however, the results presented here support 
invertebrates as sources of antibiotic producing microorganisms which may give 
useful antibiotics. 
In this study and during the primary screening program, a total of 125 microbial 
isolates from 35 samples of different invertebrates were initially screened, by the 
overly-agar technique and agar-streak method for the ability to produce antibacterial 
metabolites. Whether the microorganisms were present in the invertebrates having 
been obtained from the environment e.g. from food or washed in from surrounding 
soils or whether they were there as part of a symbiotic or other association needs to be 
confirmed by further studies such as by trying to isolate organisms from same 
invertebrates to prove that producing organism were present in each time. The results 
revealed that 47 of the isolates (37.6 %) were active against the Gram positive and 
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Gram negative bacteria tested. This percentage seems encouraging as compared to 
some reports which quote a rather lower percent of active isolates from the total 
number isolated. For example (Zheng et al., 2005)
 
also reported that 8 out of 29 
strains, representing 28% of the isolates considered in their study produced 
antimicrobial activity against at least one of the test microorganisms. (Ivanova et al., 
1998) reported that, out of the 491 bacteria isolated from different marine sources, 
26% of the isolates were active. In contrast, (Motta et al., 2004)
 
found
 
86.6% active 
isolates out of 86 isolates from aquatic environment of Brazilian Amazon Basin. 
The antibacterial assay for isolates used two commonly used laboratory techniques, 
namely the overlay–agar technique and agar-streak method for comparative purposes 
and reliability of results. However, during this study, the streak assay technique 
showed more conclusive results and was relatively easier to use for primary screening 
of the biologically active metabolites of the isolates. 
Antimicrobial susceptibility has been evaluated by different qualitative and/or 
quantitative methods, but a reliable standardization for comparison is frequently 
missing (Wong et al., 2016). However, most of the common antimicrobial 
susceptibility assay methods require the purification of the antimicrobial substance or 
the use of an enriched fraction of it. Such a purified compound / fraction can then be 
tested by diffusion or dilution methods or other modern techniques (Finger et al., 
2013, Wang et al., 2014b)
 
Although 5 test organisms were used in the assay program representing both Gram 
positive (2) and Gram negative bacteria (3), most of the active isolates had activity 
against S. aureus which was the most sensitive test organism for all isolates (Table 
3.1) since about 31 isolates (~65.9 % of the total) were found to be active by showing 
a diameter of inhibition zone more than 5 mm. The limited number of test organisms, 
has previously been acceptable in primary screening programs (Svahn et al., 2012, 
Compaore et al., 2016a) for supplying sufficient and convenient results.  
 
This work represents just one ring of an endless chain of searching for novel 
antibiotics from nonconventional or uncovered sources and not fully studied 
(invertebrates). Fungi isolated from marine invertebrates are of substantial 
significance as novel promising sources of distinctive secondary metabolites with 
important biomedical potential (Yue et al., 2015). The estimated 100,000 species of 
fungi that are known today make up only about 10 percent of all fungal species that 
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are predicted to exist, implying that fungi are an unmapped and untapped source of 
secondary metabolites with bioactive potential (Scheffers et al., 2012). Thousands of 
Penicillium isolates have probably been screened in bioprospecting programs since 
the discovery of penicillin but new bioactive metabolites still continue to be 
discovered from these fungi (Larsen et al., 2007, Ge et al., 2008, Takahashi and 
Lucas, 2008) indicating their current importance as sources of novel bioactive 
molecules to be used by pharmaceutical industry (Petit et al., 2009). 
 
Comparative antibiotic production using different media 
 
The effect of carbon and nitrogen source has been the focal point of study for 
industries as well as research groups. In this study seven types of carbon and nitrogen 
containing media were tested for a maximizing the antibiotic production (SNB, SAB, 
GNB, YMB, YEB, TSB and AIB). Individual cultures of Es1 on YMB, YEB and AIB 
media, showed that the media which contained yeast extract as carbon and nitrogen 
sources, gave large zone sizes. Also, cultivation of Es1 on AIB gave good growth and 
antibiotic production; it contained carbon and nitrogen sources (glycerol as source of 
carbon and L-Asparagine as nitrogen source). However use of SNB and SAB, was not 
promising for getting better activity (inhibition less than 5 mm) when compared the 
YEB, YMB and AIB. 
Mycelium growth (biomass) of Es1 was similar to other media but with no 
appreciable antibiotic production in case of using mixed medium (SNB+NB; 2:1 and 
SAB+NB; 2:1 v/v), this may probably referred to some sort innate antagonism 
occurred between starch- containing media fortified with different nitrogen sources.  
(Tawiah et al., 2012) noted that asparagine gave better yield for antibiotic production 
by P. aeruginosa rather than inorganic nitrogen sources such as sodium and 
potassium nitrates or ammonium salts.  
(Lee et al., 1997) reported that ammonium sulfate was the best with respect to 
formation of rapamycin by S. hygroscopicus comparable to six non-amino acid 
nitrogen compounds were examined. Potassium nitrate, followed by L-asparagine, 
sodium nitrate, glycine, DL-aspartic acid and L-tryptophan were the best nitrogen 
sources for the production of penitrem B by P. aurantiogriseum (Surekha and Reddy, 
1992).  Streptomyces spp. TN97 strain showed that the highest biological activities 
were also obtained when glycerol or fructose at 1% (w/v) was added in tryptic soy 
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broth (TSB) (Mehdi et al., 2006). (Compaore et al., 2016a) reported that the best 
carbon sources for production of antibacterial compounds appeared to be starch and 
glucose for Aspergillus flavus and starch and sucrose for Penicillium citrinum. 
 
Identification of biologically active isolates by DNA plus PCR  
 
Different kits were used for DNA extraction the most satisfactory kit was FastDNA 
spin kit for both bacteria and fungi with acceptable purity and concentration for 
downstream application e.g. PCR and sequencing. Two genes were targeted for 
identification of the isolates, 16S for bacteria and 18S rDNA for fungi, Forty-two 
(89%) of the 47 isolates were fungi while the remaining 5 (11%) were Streptomyces 
spp.  
Although the initial methods were chosen to specifically isolate actinomycetes, there 
were only 5 Streptomyces spp. among the isolates and the majority were fungi, mostly 
Penicillium spp. Initially some of the isolated proved to be mixed cultures containing 
both a fungus and a streptomycete. This was demonstrated using whole genome 
sequencing using a MiSeq (data not shown). Although the antimicrobial activity could 
have been produced by the streptomycete or production could have been promoted in 
the mixed cultures as previously demonstrated (Schroeckh et al., 2009, Moody, 2014, 
Lim et al., 2012, Valayil, 2016), further subculturing led to a pure culture of the fungi 
which still produced the antimicrobial activity. The use of media for actinomycetes 
for growing the fungi may have enhanced the production of the antimicrobials or may 
have activated silent genes. 
Three strains (Es1, M1 11 and La1a) were also sent for identification to an external 
source for confirmation and identification under species status, the result of 18S 
rDNA sequencing for this isolates were identified as Penicillium species. For more 
identification of the under species status, the isolates were sent to NICMB Limited 
Company, to sequence ITS gene to distinguish between species because it has 
recently been accepted as the official sequence for identification of fungi (Schoch et 
al., 2012). The results identified M1 11 as P. chrysogenum but Es1 and La1a 
identified just as Penicillium spp. Depending on the obtained data, this level of 
identification of the spp. regarding the strains La1a and Es1, may be attributed to 
absence of sequencing ITS data in the gene bank or, may be, it is a new species and 
not discovered before.  
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Following completion of the work it was discovered that the ITS region has 
limitations for determining the species of Penicillium. The β-tubulin (BenA) gene has 
been proposed as a secondary identification marker although it too has its limitations 
(Visagie et al., 2014). 
Also, the use of BLAST searches against the Genbank database has problems as a 
large number of the sequences for Penicillium spp. have not been verified and some 
have been incorrectly identified (Kõljalg et al., 2005).  
 
The limitation of this part of the study were relatively small number of invertebrates 
screened but the result indicated that a larger study would be worthwhile.    
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Chapter 4 
Production and extraction of antibiotics 
 
4.1 Introduction 
 
4.1.1 Production 
As bioactive metabolites are typically generated in small quantities and production 
depends on the species and the growth parameters, optimisation of these factors is 
essential for maximum quantity and purity of secondary metabolites (Merlin et al., 
2013). Research in finding newer antibiotics and increasing the productivity of such 
agents has been a very important activity (Sundaramoorthi et al., 2011, Retinowati et 
al., 2010).  
Development of an efficient large scale production process to produce secondary 
metabolites by microorganisms requires examination of a diverse array of species-
specific features including nutritional factors such as carbon and nitrogen sources. 
These play key roles as structural and energy compounds in a cell (see chapter 3). 
Several cultivation parameters e.g. pH, incubation period, aeration rate and 
temperature play a significant role in the production of bioactive metabolites 
(Compaore et al., 2016a). A slight change in the culture medium will not only impact 
on the quantity of certain compounds but also the general metabolic profile of 
microorganisms (Scherlach et al., 2009, Wang et al., 2011).  
 
In the industrial setting, optimization of growing conditions can lead to the 
significantly increased production of a compound of interest. The manipulation of 
environment and nutrition has been shown to have substantial impacts on the quantity 
and diversity of secondary metabolite production (VanderMolen et al., 2013). 
Compaore et al. (2016a) reported that the antibacterial compound production started 
on the third
 
day by Aspergillus flavus and Penicillium citrinum, and the highest 
antibacterial compound production was between 7-9 days during the stationary phase. 
Tawiah et al., (2012) found that nine days incubation period was optimum for 
maximum antibacterial activity by Pseudomonas aeruginosa, an indication of 
maximum antibiotic production, after which there was no significant increase. Whilst, 
Compaoré et al. (2016b) reported that production of antimicrobial compound by 
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Aspergillus fumigatus started on the fourth day of fermentation and the optimum 
incubation period for the higher production of bioactive compound was 6-8 days (pH 
7, temperature 37 °C with rotary shaker 150 rpm). 
4.1.2 Extraction 
The initial step in isolating biologically active compounds is referred to as extraction. 
The compound extracted from any natural source as fungi, bacteria and plant is 
dependent on factors such as solvent type, extraction method and cultivation features. 
Methods used will depend on whether the desired compounds are endocellular or 
excreted into the medium. Extraction methods are a main consideration as they relate 
to efficiency in getting the highest yields of natural compounds from natural sources 
(Hip et al., 2009). 
To obtained new bioactive compounds from natural products, fractionation is usually 
required using multiple solvents with differing polarity (Cowan, 1999; Dinan et al., 
2001). Bioactive compounds are extracted from natural sources in small quantities 
and are present as conjugates or mixtures in extracts which may therefore require 
lengthy and intense purification processes. (Joana et al., 2013). 
Various techniques have been established to enhance the extraction of bioactive 
compounds from natural sources. The most common technique is referred to as 
Solvent Extraction (SE) used to obtain specific compounds from various materials 
such sediments, soil, bacteria, fungi and various plants (El Hattab et al., 2007; Plaza 
et al., 2010). The samples obtained are fed through various filtration processes such 
as centrifugation to filter unnecessary residues. Organic solvents have been used 
through time to extract bioactive compound from natural sources. From among the 
most common are hexane, ether, chloroform, acetonitrile, ethyl acetate, benzene and 
ethanol which are commonly used in various ratios with water. (Tokuoka et al.,2010, 
Plaza et al., 2010). These organic solvents can be used in the extraction of polar and 
non-polar bioactive compounds like fatty acids, phenols, aromatic hydrocarbons, 
alkaloids and the like (Szentmihalyi et al., 2002, El Hattab et al., 2007, Li et al., 
2006). Nevertheless, extra care should be practiced when handling certain solvents as 
they are harmful to not the person handling them but also to the environment; 
furthermore, it is important to note that extraction processes can be arduous (Miron et 
al., 2011, Li et al., 2006). 
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Solvent Extraction is one of the most convenient techniques compared to others as it 
is cheaper and easier to run, especially on an industrial scale if solvent recovery and 
reuse is practiced. Although, this technique uses potentially toxic and inflammable 
solvents to operate, involves an evaporation step and requires large quantity of 
solvents and is time consuming. Additionally, there is a risk of bioactive compound 
thermal degradation due to the hot temperature of solvents used during the long times 
of extraction. In general, extraction methods are constantly improving through the 
development of existing/new techniques such as Ultrasonic assisted extraction (UAE), 
Microwave-assisted extraction, Subcritical fluid extraction and Accelerated solvent 
extraction has been promoted (Szentmihalyi et al., 2002, Bendicho et al., 2012); The 
ultimate objective of these developments are to shorten the lengthy extraction time 
and energy consumed which would ultimately result in lowering costs. Therefore 
these techniques are sustainable in that they also minimize any harm to the persons 
handling and the environment, minimizing costs (Armenta et al., 2015). From the 
mentioned techniques UAE is the most efficient as it is safer to handle and 
economically advantageous and reproducible because the process involves 
atmospheric environments and ambient temperature (Soria et al., 2010, Vieira et al., 
2013).  
 
The aims of this part of the study were to culture one isolate (Es1) on one chosen 
medium (AIB), to extract the active compounds from culture medium, optimise 
maximum antibiotic yields using different solvent extraction systems and to test the 
spectrum of activity of the antibiotics against a range of test organisms. The spectrum 
was also determined for all antibiotic producing organisms isolated. The best three 
organisms were chosen on the basis of their activity and large scale culture used to 
prepare sufficient material for subsequent characterization. 
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4.2 Results 
 
4.2.1 Production, Extraction of antibiotics from broth medium 
4.2.1.1 Production of the antibiotics 
Isolate Es1was heavily inoculated into 250 ml sterile AIB in 1 L conical flasks and 
incubated for 7 d as described in section 2.12.1. The medium was filtered and 1 ml 
was placed in wells made in seeded MHA plates inoculated with a lawn of test 
organisms. The results (Table 4.1) showed that activity was secreted into the culture 
medium and both E. coli and S. aureus were inhibited. 
  
Table 4.1: Antibacterial activity result of filtered AIB of isolated Es1 against test 
organisms 
Test organism  Inhibition zone 
diam. mm 
E.coli ATCC10536 12  
S. aureus ATCC 25923 14  
 
4.2.1.2 Extraction of antibiotics 
The filtered medium was extracted with ethyl acetate; the organic layer was then 
separated and evaporated by rotary evaporation. The crude extract obtained was 
dissolved in ethyl acetate, and then tested using the paper disc diffusion method. The 
aqueous layer was tested by the agar well diffusion method. The results are shown in 
Table 4.2 and Figure 4.1. The organic layer showed antimicrobial activity but there 
was no residual activity in the aqueous layer. Mycelium extracts prepared with 
acetone had a much lower activity (Table 4.3) showing that most of the activity was 
secreted into the medium (the controls were paper discs loaded with acetone solvent).  
 
Table 4.2: Inhibitory activity of organic layer and aqueous layer of extracts from 
isolate Es1 against test organisms 
Test organism  Inhibition zone diameter mm 
Es1 organic layer Es1 aqueous layer Ethyl acetate (control) 
E.coli ATCC10536 12 mm - - 
S. aureus ATCC 25923 18 mm - - 
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A)                                                               B) 
Figure 4.1: Inhibitory activity of paper disc loaded with Es1 extracts of medium 
(A) S. aureus ATCC 25923 and (B) E. coli ATCC10536; (1) ethyl acetate 
control, (2) Es1 organic layer 
 
 
Table 4.3: Antibacterial activity of the Es1 mycelium extract prepared with acetone 
against S. aureus and E.coli after 12 d of incubation in AIB. 
 
Test organism  Inhibition zone diameter mm 
Es1 mycelium extract Acetone (control) 
E.coli ATCC10536 3 mm - 
S. aureus ATCC 25923 4 mm - 
- No inhibition zone 
 
4.2.1.3 Effects of incubation time on yield of antibiotics  
Isolate Es1 was grown in 300 ml portions of AIB in 1L conical flasks at 28±2ºC and 
120 rpm for 3, 7 and 12 d. Broth samples were filtered through cotton wool to remove 
mycelium and tested for their antimicrobial activity.  The results are shown in Table 
4.4 and Figure 4.2. The results showed that slight activity against S. aureus was 
apparent after 5 d but maximum activity against both organisms was obtained after 12 
d. 
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Table 4.4: Antibacterial activity of the Es1 extracts after three, five and twelve days 
of incubation on AIB  
Test organism Antibiotic activity after incubation time d  
 3 5 12 
S. aureus ATCC 25923 - 4 mm 17 mm 
E.coli      ATCC10536 - - 19 mm 
Inhibition zone diameter mm,  - No inhibition zone 
 
 
  
(A)                                                                 (B) 
Figure 4.2: Effects of incubation time in AIB on antimicrobial activity of extracts 
from isolate Es1  
Inhibition zone activity around the wells in seeded MHA plate with S. aureus ATCC 
25923 and E.coli ATCC10536 and filled with 1 ml of filtered AIB after 3, 5 and 12 d 
incubation. (A) MHA plate seeded with S. aureus ATCC 25923, (B) MHA plate 
seeded with E.coli ATCC10536. 
 
4.2.2 Production, Extraction of antibiotics from solid medium 
 
4.2.2.1 Extraction of antibiotic 
Strain Es1 was grown on two plates of AIA at 28°C for 7 d. The agar with the 
organism was then cut up into small pieces and placed into a flask with 40 ml ethyl 
acetate. Two different methods were used to extract the antibiotic, homogenising the 
agar with the ethyl acetate using a magnetic stirrer for 2 h and sonication for 1 h.  The 
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results are shown in Table 4.5 and Figure 4.3.The sonication method gave better 
extraction with a higher antibacterial activity and also took less time.  
 
Table 4.5: Antibiotic activity of extracts of isolate Es1 produced by different 
extraction methods  
 
Isolate Organism Zone of inhibition mm 
Extraction method  
Magnetic stirrer Sonicator 
Es1 E.coli ATCC10536 8  10  
S. aureus ATCC 25923 7  12 mm 
  
 
Figure 4.3: Antibiotic activity of extracts produced by different methods, 
Plate of MHA seeded with S. aureus ATCC 25923 showing clear inhibition zone, (A) 
magnetic stirrer method, (B) sonicator method. 
 
4.2.2.2 Effects of inoculation method on yield of antibiotics  
Average clear zones of antimicrobial activity of extracts were determined using three 
different inoculation methods as described in section 2.12.4.2 and the results are 
shown in Table 4.6. The results show that the zigzag method gave the largest 
inhibition zones. 
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Table 4.6: Effects of inoculation method on antibiotic activity of extracts  
Strain code  Test organism 
Zone of inhibition mm 
Inoculation Method  
Zigzag  Streak Individual 
colonies 
Es1 E. coli ATCC10536 
11 mm 9 mm 10 mm 
S. aureus ATCC 25923 13 mm 10 mm 11 mm 
 
4.2.2.3 Scale up number of plates extracted 
Six agar plates of Es1 incubated for 7 d were cut to small pieces, placed in a flask, 
120 ml ethyl acetate added and sonicated for 1 h then filtered. For scale up 14 plates 
were used, the agar was cut into small pieces and put in beaker. Ethyl acetate (280 ml) 
was added and sonicated for 1 h then filtered, Antibiotic activity was determined as 
before and the results are shown in Table 4.7. Activity was lower when 14 plates were 
used despite the volume of ethyl acetate being increased in proportion to the number 
of plates. 
 
 
Table 4.7: Effects of scaling up number of plates extracted on antimicrobial activity  
Strain code Test organism Zone of inhibition mm 
Number of Agar plates 
6  14  
Es1 E.coli ATCC10536 15  10  
S. aureus ATCC 25923 16  9  
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4.2.2.4 Time of incubation   
 
Isolate Es1 was inoculated onto 6 plates of AIA and incubated at 28°C for 7 d and a 
further 6 plates incubated for 21 d. Antibiotics were extracted and assayed as before 
and the results are shown in Table 4.8. Activity was higher after 21 d and all 
subsequent incubations were for 21 d unless otherwise stated. 
 
Table 4.8: Effects of incubation time on antimicrobial activity of extracts from isolate 
Es1 
Strain 
code 
Test organism Zone of inhibition mm 
Time of incubation d 
7  21 
Es1 E.coli ATCC10536 12  16 
S. aureus ATCC 25923 13  19 
 
 
4.2.2.5 Use of different solvents for antibiotic extraction  
Cultures of isolate Es1 grown on AIA were cut up into small pieces and extracted 
with 4 different solvents, filtered and assayed for antimicrobial activity. The results 
are shown in Figure 4.4, ethyl acetate gave the highest activity followed by acetone. 
Chloroform and chloroform-ethyl acetate gave the lowest activities. Ethyl acetate was 
used subsequently for extraction of the antibiotic activity. 
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Figure 4.4: Comparative analysis of solvent used for extraction of the antibiotic from 
cultures of the isolate Es1 grown on AIA. 
 
4.2.2.6 Antibacterial activity of ethyl acetate extracts of other isolates 
All isolates that showed antibacterial activity in the primary screen were grown on 
AIA at 28°C for 21 d, then 6 plates of each isolate were extracted with 120 ml ethyl 
acetate and antimicrobial activity determined as before and the results are shown in 
Table 4.9. The results showed that some isolates that showed some antibacterial 
activity in the primary screen had no inhibition zones for the ethyl acetate extracts. 
Only three extracts had inhibition zones against E. faecium (La1a, La2 and W12)  and 
one isolate against E. faecalis (W12). Most of the extracts isolates had activity against 
S. aureus2 which was the most sensitive test organism for the extracts, since about 25 
extracts isolates (~53% of the total) were found to be active by showing inhibition 
zones (between 4-18 mm). Twenty-two of the extracts isolates (48.8% of the total) 
showed activity against MRSA and gave inhibition zones of 2-13 mm, while 24 
extracts (~51% of the total) showed activity against ESBL E.coli with inhibition 
zones of 2-13 mm. Extracts from isolates Es1, M1 11 and La1a (shown in bold in 
Table 4.9) showed the best antibacterial activity compared to the other isolates and 
were chosen for further study. The appearance of these three organisms are shown in 
Figure 4.5. All three had similar colonies with a grey powdery appearance. Isolate 
Es1 had a filamentous colony edge and yellow pigmentation of the medium. Isolates 
M1 11 and La1a had more entire edges to the colony and M1 11 had a folded colony 
center.  
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Table 4.9: Inhibition zones of ethyl acetate extracts of cultures of microorganisms 
isolated from invertebrates. 
 
 
Zone of Inhibition (mm) against test organism 
Gram-positive Gram-negative Yeast 
Isolate B. c S. a S. a 2 MRSA E. f'm E. f's E. coli 
ESB
L E. 
coli 
P.a P.f K. P S. c 
Sa1 0 0 0 0 0 0 0 0 0 0 0 0 
Sa2 0 0 0 0 0 0 0 0 0 0 0 0 
La1a 9 11 14 9 2 0 12 9 9 7 0 5 
La2 7 7 8 5 1 0 8 5 7 6 0 6 
La4 4 5 6 6 0 0 5 7 6 4 0 4 
La5 7 8 11 4 0 0 8 6 8 6 0 7 
Es1 9 14 18 13 0 0 18 13 12 1 0 10 
Es2 0 0 0 0 0 0 0 0 0 0 0 0 
Es5 0 0 0 0 0 0 0 0 0 0 0 0 
Es9 0 0 4 0 0 0 0 0 0 0 0 0 
M1 2 9 10 12 8 0 0 10 10 3 6 6 0 
M1 3 10 10 13 12 0 0 3 10 6 9 8 0 
M1 4 10 9 13 11 0 0 10 12 6 7 7 0 
M1 8 8 9 10 11 0 0 9 9 0 12 1 0 
M1 10 9 10 12 12 0 0 10 10 3 7 7 0 
M1 11 10 14 15 12 0 0 16 10 6 8 6 0 
M1 13 8 8 11 12 0 0 7 8 3 6 5 0 
M1 14 9 9 9 11 0 0 10 9 5 6 5 0 
M1 15 8 10 12 12 0 0 9 10 4 7 5 0 
M1 16 8 9 13 11 0 0 10 10 6 6 4 0 
M118 8 9 10 8 0 0 9 0 2 6 3 0 
M1 20 4 6 12 12 0 0 10 11 1 3 6 16 
M1 22 6 7 11 8 0 0 8 7 2 4 5 0 
M35 1 0 5 1 0 0 0 0 2 0 1 1 9 
M35 4 0 3 0 0 0 0 0 2 0 0 0 8 
M35 5 9 8 9 7 0 0 8 5 2 3 3 0 
M35 9 2 15 6 8 0 0 7 7 1 6 7 20 
M35 11 0 3 0 0 0 0 0 0 0 1 1 6 
Pp1 0 0 0 0 0 0 0 0 0 0 0 0 
Pp2 0 0 0 0 0 0 0 0 0 0 0 0 
Pp3 0 0 0 0 0 0 1 6 0 0 0 0 
Wata1 0 0 0 0 0 0 0 0 0 0 0 10 
Wata 2 0 0 0 0 0 0 0 0 0 0 0 0 
W1 0 0 0 0 0 0 0 0 0 0 0 0 
W2 0 0 0 0 0 0 0 0 0 0 0 0 
W3 0 0 0 0 0 0 0 0 0 0 0 0 
W6 0 0 0 0 0 0 0 0 0 0 0 0 
W7 5 11 12 11 0 0 13 12 3 0 0 0 
W9 0 0 0 0 0 0 0 0 0 0 0 0 
W12 2 2 0 2 1 1 2 3 0 4 2 10 
W13 0 0 0 0 0 0 0 0 0  0 0 0 
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Key,: B. c = B. cereus, S. a = S. aureus, S. a 2 = S. aureus MOH1, E. f’m = E. faecium, E. f’s = E. 
faecalis, P. a = P. aeruginosa, P. f = P. fluorescens, K. p = K. pneumonia, S. c = S. cerevisiae. 
 
 
 
 
 
 
Zone of Inhibition (mm) against test organism 
Gram-positive Gram-negative Yeast 
Isolate B. c S. a S. a 2 MRSA E. f'm E. f's E. coli 
ESB
L E. 
coli 
P.a P.f K. P S. c 
Antw1 0 0 0 0 0 0 0 0 0 0 0 0 
Antw2 0 0 0 0 0 0 0 0 0 0 0 0 
Antw3 0 0 0 0 0 0 2 0 0 0 0 0 
Antb4 0 0 0 0 0 0 1 0 0 0 0 0 
S5 0 0 0 0 0 0 0 0 0 0 0 0 
S6 0 0 0 0 0 0 0 0 0 0 0 0 
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Figure 4.5: Single colonies of the three different isolates that showed best 
antibacterial activity on AIA 
A: La1a   
B: Es1  
C: M1 11 
 
4.2.3 Scale up of isolation of antibiotics produced by isolates Es1, M1 11, and 
La1a  
Isolates Es1, M1-11 and La1a were each inoculated onto 300 AIA plates. The plates 
were incubated, extracted with ethyl acetate as before and the solvent removed by 
rotary evaporation. The crude extracts were dissolved in HPLC grade methanol giving 
approximately 200 ml of extracts of each isolate. 
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All extracts were filtered through 0.22µm filters to prevent damage to the HPLC 
columns. Dry weights were determined by weighing of crude amount from 2 ml/vial 
after evaporation and were 7.8 mg ml
-1
 for Es1, 6 mg ml
-1
for M1-11 and 4.6 mg ml
-1
 
for La1a. 
All the extracts were tested for antibacterial activity before and after filtration. The 
result (Table 4.10 and Figure 4.6) showed that the extracts lost some activity on 
filtration but were still active.   
 
Table 4.10: Activity of crude extracts before and after filtration through 0.22µm 
filters 
Test organism Es1 extract M1 11 extract  
La1a extract 
Before After Before After Before After 
E. coli 19 14 19 12 13 9 
Inhibition zone diameter mm, 10 µl of each extract was assayed. 
 
 
 
 
Figure 4.6: Seeded MHA plate with E.coli showing clear inhibition zones around 
paper discs loaded with 10 µl extracts before and after filtration (Es1, M1 11 and 
La1a)  
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4.2.4 Quantitative antibacterial activity of extracts 
To test quantitative activity of the extracts, each extract was diluted to 1 mg ml
-1
.and 
antibiotic activity determined (Table 4.11). The results showed that Es1 extracts were 
the most active followed by M1 11 then La1a extracts. The results also showed that S. 
aureus was more susceptible than E. coli. 
 
Table 4.11: Comparison of antimicrobial activity of ethyl acetate extracts from 
different isolates 
Test organism 
Zone of inhibition of extract mm 
Es1 M1 11 La1a 
E. coli 13  13  10  
S. aureus 21  15  12 
All isolates were adjusted to 1 mg ml
-1
 dry weight and 10 µl assayed 
 
 
4.2.5 Calibration Graph  
Aliquots (5 µl, 10 µl, 15 µl, 20 µl, and 25 µl) of the 1 mg ml
-1
 extracts were loaded 
onto 6 mm filter paper disks and allowed to dry. Antibiotic activity was determined as 
before and the results are shown in Table 4.12 and Figures 4.7 and 4.8, the result 
showed the three extracts were more active against S.aureus than E.coli, the Es1 
extract had the strongest activity followed by M1 11 and La1a respectively against 
both test organisms. 
 
Table 4.12: Calibration curve of zone diameter vs concentration for crude extracts 
from three isolates  
Test 
organism 
 
Es1 isolate M1 11 isolate  La1a isolate 
5 µg 10 
µg 
15 
µg 
20 
µg 
25 
µg 
5 µg 10 
µg 
15 
µg 
20 
µg 
25 
µg 
5 
µg 
10 
µg 
15 
µg 
20 
µg 
25 
µg 
Inhibition zone mm 
E. coli 10  13  14  15  15  9 
 
12 13  13 
 
13 5  10  11  11  11  
S. aureus 18  21  22  23  23  9  12 13 16 
 
17  7  12  13  15  15  
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Figure 4.7: calibration curve for amount of antibiotic vs zone size   
Antimicrobial activity of antibiotic extracts  Es1, M1 11 and La1a against E.coli. 
 
 
 
Figure 4.8: Calibration curve for antimicrobial activity of extracts from isolates Es1, 
M1 11 and La1a against S. aureus. 
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4.3 Discussion 
 
Initially, production, extraction of the biologically active components synthesized by 
the isolate Es1 was by using broth medium. AIB medium, although designed for 
streptomycetes, was chosen as the growth medium as it had given good growth. The 
pH of this medium (7.0) was higher than standard media for fungi (pH 5-6) (Rahman 
et al., 2012, Gordon et al., 1947) and penicillin production in immobilized cells of P. 
chrysogenum was also optimum at an initial pH of 4 (Nagamune et al., 1988). Despite 
this the organism produced and an acceptable antibiotic yield. 
The assay results were obtained after cultivation of the target organism (Es1) for 7 d, 
after which the culture was filtered then bio-assayed and showed activity against E. 
coli and S. aureus (inhibition zones of more than 5 mm). A further extraction step was 
accomplished using ethyl acetate: broth filtrate (1:1, v/v), after which, solvent was 
evaporated to dryness and the dark brown residual crude extract was eluted then bio-
assayed with paper disc assay against the same organisms. The result showed more 
than 5 mm zones against test organisms; this result indicated that ethyl acetate 
succeeded in extracting the antimicrobial material from broth filtrate.  
 
Time optimization for enhancement of antibiotics yield 
 
Assay of the antibacterial activity in filtrates after 3, 5 and 12 days of incubation 
showed no activity after 3 days, after 5 days the bioactive material were only active 
against S. aureus (less than 5 mm).  Extension of the incubation period up to 12 days 
improved the yield and spectrum of the antibiotic (more than 5 mm on both test 
organisms). The 12-day mycelium acetone extract also showed the highest antibiotic 
activity as tested by disc diffusion method on both test organisms (more 5 mm). 
(Compaore et al., 2016a) reported that the antibacterial compound production by the 
fungi they isolated was monitored over two weeks in synthetic broth. The course of 
antibacterial compound production and growth by the isolates showed the production 
started only after 48 h for both isolates. The highest rate of antimicrobial activity by 
the isolates was observed from days 7 up to 9 after its subculture into fermentation 
broth. There was an increase in the antibacterial activity produced by Pseudomonas 
aeruginosa metabolites up to the ninth day of incubation after which there was no 
significant increase (Tawiah et al., 2012). (Merlin et al., 2013) reported bioactive 
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metabolite production by endophytic fungi was monitored 15 days in synthetic broth, 
incubation period for 9 days was observed to be optimum for maximum production. 
(Tayung et al., 2011)
 
also reported that incubation of endophytic fungi for 10–12 days 
was optimum for metabolite activity. In the present study, the maximum production 
of the antibiotic was at 12 days of incubation.  
However, due to the lack of fermentation facilities in the School or in other Northern 
Universities to cultivate cultures of relatively large volumes of 10 L+ / run, it was 
decided to use an alternative method, that is the cultivation and extraction from a solid 
AIA medium to scale up the antibiotic(s) production. This made the fractionation 
more difficult as components from the cells and the culture medium would be co-
extracted. This switch was necessary to save time and material and studies were 
performed to try to optimize the yield of antibiotics. Solid state culture has previously 
been used with success for a number of products including antibiotics using a variety 
of media (Pandey et al., 2000). For example penicillin has been produced from P 
chrysogenum using bagasse impregnated with growth medium (Barrios-Gonzalez et 
al., 1988). Svahn et al. (2015) reported the isolation of amphotericin from a fungus 
isolated from an extremely cold zone, they compared between extraction efficacy of 
solvents and procedure.  The major extracts were, the filtrate of the liquid culture, the 
mycelial growth in the liquid culture, and the cultures growing on solid medium were 
also analyzed. They reported that, during amphotericin B production, cultures on solid 
medium proved to be a more reliable and favorable choice compared to liquid 
medium. Lamrani et al. (2008)
 
similarly reported that various isolated fungi   had 
increased antimicrobial production using media such as Sabouraud Agar, PDA 
(Potato Dextrose Agar), or MEA (Malt Extract Agar). These results agree with the 
results obtained here concerning the optimization of the antibiotic yield by growing 
the fungal spp. on solid medium. 
Initial studies were on isolate Es1 but the same methods were also used for large-scale 
extraction from isolates M1-11 and La1a. Sonication and stirring methods for 
extraction into ethyl acetate were compared and the sonication method was better than 
stirring. (Kothari et al., 2012) also reported that sonication assisted extraction proved 
good at extracting antibacterial compounds.  
Another pilot experiment was carried out in which Es1 inoculum was spread in three 
different ways (separate colony, streak, and zigzag), incubated and extracted. The 
highest yield was obtained from the zigzag method rather than separate colony and 
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streak methods. This was probably because the organism did not spread far from the 
inoculation sites and the zigzag method spread the organism out on the medium 
leading to better growth and increased yield. Initial experiments (data not shown) in 
which the whole plate was covered by spreading the inoculum gave a lower yield. It is 
likely that with the zig-zag method nutrients were able to diffuse into the colony from 
the uninoculated areas providing nutrients for antibiotic synthesis whilst not causing 
catabolite repression of secondary metabolite production. 
 
Culture study for optimizing antibiotic yield on solid medium 
 
1. Effect of   incubation period on antibiotic yield 
Two incubation periods (7 and 21 d) were used to cultivate isolate Es1, under the 
previously described conditions and the antibiotics produced were extracted of with 
ethyl acetate. For these experiments isolate Es1 was inoculated on plate surface and 
incubated at 28ºC, although some reports used a temperature of 25ºC for fungi (Petit 
et al., 2009).  The results showed that the best incubation period was 21d and this was 
used in subsequent experiments. This taken with the results from broth medium 
suggest that the antibiotic activity was produced in the stationary phase of growth 
which is common for most fungi. 
 
2. Effect of solvent type on extraction  
Three organic solvents were utilized individually for extraction of the bioactive 
metabolites secreted from Es1. They included ethyl acetate, acetone, and chloroform, 
and a mixture of ethyl acetate and chloroform (1:1; v/v). The results revealed that the 
best solvent was ethyl acetate. Ethyl acetate was reported as the best solvent used for 
extraction of active metabolites from Penicillium species (Petit et al., 2009).
 
 In 
contrast Svahn et al. (2015) used methanol to extract active fractions of bioactive 
compounds from the solid medium cultures of Penicillium nalgiovense Laxa and was 
fractionated with HPLC as they described. Choice of solvent depends on the chemical 
nature of the antibiotics. 
Collectively, the 47 active isolates were screened using 6 Gram positive and 5 Gram-
negative test pathogens including MRSA, ESBL E. coli and a yeast (Saccharomyces 
cerevisiae). The number of isolates showing activity using ethyl acetate extraction 
was less than those in the initial screening. This suggests that studies on the other 
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isolates should use different solvents. Three isolates (Es1, M1 11 and La1a) were 
finally chosen according their spectra of activity. These isolates were further 
subjected to scale up procedure to obtain sufficient crude antimicrobial materials for 
further purification and chemical identification using HPLC, NMR, MS and FTIR.  
 
Scale up of isolation of antibiotics production by the isolates Es1, M1 11, and 
La1a 
 
Extracts from 300 petri dishes were pooled, rotary evaporated and redissolved in ethyl 
acetate. When filtered through 0.22µm filters for HPLC use, some activity was lost 
after filtration the crude extracts through 0.22µm filters, this loss was probably due to 
part of antimicrobial compounds being caught in the filter as the compounds were not 
dissolved totally in the solvent.  
Reasonable yields were obtained as crude bioactive materials from Es1 200 ml 7.8 
mg/mL (1.650 g from 7.5 L medium), M1 11 200 ml 6.0 mg/mL (1.2g from 7.5 L 
medium) and from La1a 200 ml 4.6 mg/mL (0.920 g from 7.5 L medium). 
A quantitative comparison of the efficacy of the active compounds produced by the 
three organisms was carried out using paper disc assay method on E. coli and S. 
aureus. The results indicated that the active extracted components from Es1 and M1 
11 were more active than La1a against E. coli and S. aureus and Es1 and M1 11 
extracts were chosen for further study. 
 
The limitation of this part of the study was that the antibiotics were extracted from 
just three isolates (Es1, M1 11 and La1a) with broad spectrum activity but in term of 
commercial potential those producing narrow spectrum antibiotics maybe more 
applicable to the clinical situation. Also it was not possible to produce a large liquid 
scale culture which would facilitate production of the crude extract and make the 
fractionation easier as there would probably be fewer contaminants when using cell 
free filtered medium than extraction from solid culture. This limitation on the study 
would need to be overcome if these study to be taken any further.     
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Chapter 5  
 
Purification and determination of structure of antibiotics 
 
 
5.1 Introduction 
 
5.1.1 Purification - application of High performance liquid chromatography 
HPLC 
High performance liquid chromatography (HPLC) is a chromatographic technique 
that is used to separate a mixture of compounds and is applied in biochemistry and 
analytical chemistry to identify, quantify and purify the individual components of the 
mixture (Malviya et al., 2010). In the early 1970’s several reliable separation 
techniques such as paper chromatography, thin-layer chromatography and open-
column chromatography were commonly used in the laboratory. High performance 
liquid chromatography emerged in the mid 1970’s and was widely used in industry as 
a reliable and efficient separation technique. The technique further progressed with 
the development of column packing materials and the development of on-line 
detectors. 
In the late 1970's, new methods such as the reverse phase liquid chromatography 
allowed for further development in separation between compounds with similar 
properties (Lee, 2009). New techniques were introduced to develop the separation, 
identification, purification and quantification of HPLC with the addition of computers 
and automation. The developments of the different types of columns including micro-
column and affinity columns have further lead to the improvement of the 
reproducibility and reliability and eventually fast HPLC made an appearance (Sailaja 
et al., 2014). The HPLC is made up of multiple parts including a computer, mobile 
phase reservoirs, pump, injector, column, detector and fraction collector (Figure 5.1). 
The most vital part of the instrument is the column where the separation happens. The 
components are separated when the analytes and mobile phase are pumped through 
the column (Kupiec, 2004).  
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Figure 5.1: The HPLC system and its components, modified from (Bhardwaj et al., 
2015b) 
 
The types of HPLC are commonly dependent upon the phase system used in the 
method, these include; normal phase HPLC (NP- HPLC), this approach uses a polar 
stationary phase and a non-polar mobile phase. The reversed phase HPLC (RP- 
HPLC) is the most preferred technique for the analytical and preparative separations 
of desired compound in chemical, biological, pharmaceutical, food and biomedical 
sciences. In this technique the stationary phase is made up of non-polar hydrophobic 
molecules with a functional group octyl or octa-decyl attached to the silica gel, the 
mobile phase is a polar solvent, the polar compounds get eluted first in this mode 
whereas the non-polar compounds are retained for longer periods; because the 
majority of the drugs and pharmaceuticals are naturally polar, it means they are not 
retained for longer periods and thus elute quicker (Husain et al., 2011). Size exclusion 
chromatography (SEC), also known as gel permeation chromatography is commonly 
used to separate particles based on their size, this is a powerful method for protein 
purification and polymer characterization (Khodabandehloo et al., 2017).  
In ion-exchange chromatography, retention is dependent upon the interactions 
between solute ions and charged sites that are bound to the stationary phase, similarly 
charged ions are excluded, this technique is more appropriate for separating 
molecules with a charge only such as proteins, enzymes, peptides, amino acids by 
itself or in combination with other chromatographic techniques (Acikara, 2013). Bio-
affinity chromatography is a technique based on particular reversible interaction of 
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proteins with ligands, due to the specificity of interaction can lead to very high 
purification in a single step, this technique is preferably used to isolate proteins and 
enzymes from complex mixtures (Verma, 2014, Malviya et al., 2010, Sabir et al., 
2013). 
Among all the different modes, the reversed-phase chromatography is the most 
widely used because of its extensive application range, particularly when separating 
natural products from plant materials. This mode is popular for its simplicity, 
versatility and range as it can be used with compounds in a broad range of polarity 
and molecular mass. The separation device of reverse phase chromatography is reliant 
upon the hydrophobic binding interaction between the solute of the mobile phase and 
the immobilized hydrophobic material of the stationary phase (Prathapa et al., 2013)
 
 
5.1.2 Characterisation 
5.1.2.1 Nuclear Magnetic Resonance Spectrometry (NMR) 
NMR spectroscopy is an analytical technique that involves the application of a 
magnetic field to a chemical compound and measurement of the spin state of nuclei in 
the molecule. It gives information on the types of atoms in the compound, the relative 
amounts of different atoms and information about the structure of the compound. 
Over the years the use of nuclear magnetic resonance (NMR) has grown 
exponentially as a spectroscopic instrument and its applications. Now, the use of 
NMR is applied over a wide range of scientific disciplines including biology, physics 
and medicine. Due to greatly increased resolution in NMR spectrometers, NMR 
spectra have become a vital instrument in the study of newly synthesized as well as 
natural products derived from plants and microorganisms. Since the invention of 
superconducting magnets together with recently developed, highly complex pulse 
methods have provided chemists with the ability to define 3-dimentional structures of 
large molecules in solutions. NMR techniques are increasingly used as a quantitative 
analysis for multiple purposes including: to analyze impurities in drugs; to distinguish 
the composition of drug products; and to study metabolites of drugs within body 
fluids (Holzgrabe et al., 1998). 
NMR spectroscopy has become a vital instrument to chemists and is used regularly to 
analyze the chemical structure of basic molecules using 1-dimensional methods (1D-
NMR), whereas 2-dimensional methods (2D-NMR) are used to define the structure of 
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more complex molecules (Webb, 2009). The nuclei of multiple elemental isotopes 
have a particular spin with the most common isotopes used in organic chemistry being 
C and H. The NMR behaviour with regards to the nuclei of these two particular 
elements has been utilized by organic chemist as they yield crucial information that 
can be used to determine the structure of organic compounds. The analysis of 1D 
proton spectra (
1
H NMR) e.g. in the study of plant products is complicated due to 
majority of the signals overlapping. However the establishment of additional spectral 
dimensions has made it possible to simplify these spectra and acquire more 
information, thus the development of 2D NMR was a crucial step in the advancement 
of NMR spectroscopy. There are multiple forms of 2D NMR experiments; these 
include Correlation Spectroscopy (COSY, correlation between protons that are 
coupled to each other), Heteronuclear Multiple Quantum Correlation Spectroscopy 
(HMQC, used to correlate proton and carbon signals using either one bond or longer 
range couplings) and Heteronuclear Multiple-bond Correlation Spectroscopy 
(HMBC). This technique is similar to HMQC, but it is optimized to detect proton-
carbon correlation over 2 and/or 3 bonds (Timothy and Claridge, 2009).  
NMR provides valuable information in identifying the molecular structure of 
particular compounds, for example, the number as well as types of protons in the 
desired molecule. These protons are represented as a NMR signal and give data as it 
relates to the proton environment and coupling partners. Regardless, this data requires 
a precise analysis before settling for a final structure. This can be acquired through 
multiple automated structure elucidation software, which has been developed to 
clarify the structure of the interpretation methods (Heftmann, 2004, Queiroz et al., 
2002)
 
 
5.1.2.2 Fourier-transform infrared spectroscopy (FTIR) 
FTIR is most useful for identifying chemicals that are either organic or inorganic 
(Grumezescu, 2017). FTIR has been recognized as a crucial instrument for the 
classification and identification of compounds or functional groups (chemical bonds) 
existent in an unidentified mixture of compounds (Eberhardt et al., 2007). The 
wavelength of light absorbed is characteristic of the chemical bonds. By interpreting 
the infrared absorption spectrum, the chemical bonds in a molecule can be 
determined. Additionally, the FITR spectra of pure compounds are typically 
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distinctive that they are recognized as molecular “fingerprint”. For majority of the 
materials the spectrum of an unknown compounds are recognized when they are 
compared to a library of known compounds (Upadhyay, 2011, Sasidharan et al., 
2011). To identify less common materials, IR will need to be combined with NMR, 
mass spectrometry (MS), and/or other techniques (Upadhyay, 2011).  
 
5.1.2.3 Mass spectroscopy 
Mass spectrometry (MS) contributes a vital role in the research work relating to 
phytochemical and small molecules. MS typically provides data as it relates to 
molecular mass/formula and fragmentation patterns. MS is commonly considered as 
the most sensitive and precise multipurpose analytical technique and it is an 
impressive analytical technique with multiple functions such as to quantify known 
materials, to identify unknown compounds, and discovering molecular structures 
(Silberring, 2002).  
Mass spectrometers are used in a broad range of applications in multiple discipline 
including chemical, electronics, food processing, petroleum, and pharmaceutical 
industries. Mass spectrometers examine materials based on their mass-to-charge ratio 
(m/z) of constituent molecules. To accomplish this, chemical compounds are initially 
ionized, then separated based on m/z ratio, and lastly detection to produce a 
significant output for the user (Figure 5.2). The separation and ionization processes 
occur in a vacuum. Ideally, samples are introduced into the vacuum system of the MS 
instrument; the neutral molecules are ionized and then carried on towards the mass 
analyzer. The analyzer runs on a low pressure (~10
-4–10-8 Torr) whereby the ions are 
separated based on their mass-to-charge ratio, using electric or magnetic fields or a 
combination of both. The separated ions are then detected and generated signals are 
processed and displayed on a screen as a mass spectrum. A mass spectrum is a plot of 
relative abundance (signal intensity) against m/z ratio. The most common ionization 
techniques used with molecular MS are Electron impact ionization, Chemical 
ionization, Desorption ionization, Electrospray ionization and Ambient ionization 
(Maher et al., 2015).  
Electron impact ionization (EI), in the early stages of mass spectrometry EI was the 
oldest of ionization methods used and it was the first molecular ionization method 
used create gas-phase ions for a wide range of organic molecules. This method can be 
applied to compounds which are easily vaporized. EI generates positive ions due to 
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electron ejection from the sample (Maher et al., 2015) 
Chemical ionization (CI), this method uses gas-phase chemical reactions to ionize 
molecules via charge exchange or proton transfer with little or no fragmentation 
compared to EI so it is considered a soft ionization methods (Munson and Field, 
1966).  Both of methods mentioned above (EI and CI), the sample molecule is 
originally in the gas phase. These gas-phase sample molecules created by the 
volatilization process must not decomposition or reorganization the sample. 
Due to the limitation of EI and CI just for volatile compounds this limitation led to the 
evolution of desorption ionization methods to create ions from non-volatile sample 
molecules and more delicate biological molecules (Busch, 1995).     
Desorption ionization (DI) such as photoionization. Photoionization is independent of 
surrounding molecules and involves photon absorption followed by ejection of an 
electron. Accordingly probing of state-selected molecular fragmentation dynamics 
can be achieved by coincidence measurements of several particles (Miron and Morin, 
2009). This has led to ultrafast molecular dissociation mechanisms being proposed 
(Travnikova et al., 2013).  
Electrospray ionization (ESI), the molecular- weight range of MS increased by this 
method, making it achievable to ionize a wide range of compounds including large 
molecular-weight bio- molecules that had before been difficult to analyze (Heck and 
Van den Heuvel, 2004). 
Ambient ionization method, this method has attracted much attention in many fields 
as pharmaceuticals, food safety and biomedicine, in this method requires minimal or 
no sample pretreatment. It usually involves separate ionization and sample-
introduction events, allowing independent control over each set of conditions. 
Ionization is typically achieved under ambient environments through use of existing 
electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI) 
techniques. Rabid analyses possible to the gas, liquid, and solid samples with the 
adoption of various sample-introduction methods (Huang et al., 2010). 
 
The aims of this part of the study were to fractionate and purify the active compounds 
from crude extracts and to determine their chemical structure.  
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Table 5.1: Ionization methods commonly used for molecular MS.  
Method  Agent(s) Sample phase  Hard or soft  
Electron impact 
ionization   
Energetic 
electrons   
Gas  
 
Hard 
Chemical 
ionization   
Reagent gas-phase 
ions  
Gas Soft 
Desorption 
ionization (e.g., fast 
atom bombardment, 
photoionization, 
plasma desorption)   
Energetic ions, 
photons, plasma  
 
Solid, liquid, gas  Soft 
Electrospray 
ionization   
Highly energetic 
charged droplets  
Liquid   Soft 
Ambient ionization 
(e.g., direct analysis 
in real time, 
desorption 
electrospray 
ionization)  
Highly energetic 
charged droplets, 
photons, plasma  
 
Solid, liquid, gas  Soft 
“Soft” ionization means to the formation of a large proportion of ions without 
breaking chemical bonds. “Hard” ionization results in chemical bonds being broken 
and formation of a large proportion of fragment ions. 
Modified from Maher et al. (2015).  
 
 
Figure 5.2: Mass spectroscopy instrument, modified from (Maher et al., 2015) 
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5.2 Results 
 
 
5.2.1 Optimization of fractionation by HPLC 
 
The separations were conducted by injecting 20 µl of the extract (from isolates Es1 
and M1 11) onto the analytical column. Six solvent systems were used for 
optimisation of the analytical RP-HPLC parameters using isocratic elution with 
different mobile phases as described in section 2.17.1. 
 
Es1 extract 
The resultant chromatograms are shown in Figures 5.3 to 5.7. The result showed that 
the crude extract could be bound to the column and not eluted (an isocratic mobile 
phase of water: methanol 70:30 (v/v) Figure 5.3, an isocratic mobile phase of water: 
methanol 50:50 (v/v) Figure 5.4 and an isocratic mobile phase of water: methanol 
40:60 (v/v) Figure 5.5) or could be resolved into 5 components with RT of 1.055, 
2.971, 3.157, 3.291 and 5.620, arrows in the Figure 5.7 (an isocratic mobile phase of 
water: methanol 10:90 (v/v) Figure 5.7) to 19 components (an isocratic mobile phase 
water: methanol 30:70 (v/v) Figure 5.6). The 30:70 (v/v) of water: methanol isocratic 
system gave a better separation than the other mobile phases, their was no further 
improvement by adding TFA in separation see Appendix 2.1  
   
  
 Figure 5.3: Fractionation of Es1 extracts by HPLC on Spherisorb, using a mobile 
phase of water: methanol 70:30 (v/v) 
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Figure 5.4: Fractionation of Es1 extracts by HPLC on Spherisorb, using an isocratic 
mobile phase of water: methanol 50:50 (v/v) 
 
 
Figure 5.5: Fractionation of Es1 extracts by HPLC on Spherisorb using an isocratic 
mobile phase of water: methanol 40:60 (v/v) 
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Figure 5.6: Fractionation of Es1 extracts by HPLC on Spherisorb using an isocratic 
mobile phase water: methanol 30:70 (v/v) 
 
 
 
 
Figure 5.7: Fractionation of Es1 extracts by HPLC on Spherisorb, using an isocratic 
mobile phase of water: methanol 10:90 (v/v) 
 
The different scales used on the y axes is due to differences in the elution and 
fractionation of the material, Figure 5.7 the crude extract eluted, fractionated and 
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resolved into five peaks (fractionation of the crude extract was not successful), Figure 
5.6 the crude extract eluted, fractionated and resolved into 19 peaks (better 
fractionation).   
The fractions from the better separation mobile phases (water: methanol 30:70 (v/v)) 
were tested for antibacterial activity and one fraction (with a retention time 13.496 
min: Figure 5.6) gave a large inhibition zone on plates seeded with E.coli and S. 
aureus. 
 
M1 11 extracts 
 
The resultant chromatograms are shown in Figures 5.8 to 5.11. The 30:70 (v/v) of 
water: methanol isocratic system gave a better separation than the other mobile 
phases. The results showed that the crude extract was not well resolved (Figures 5.8 
to 5.10) but with an isocratic mobile phase water: methanol 30:70 (v/v) resolved into 
15 components (Figure 5.11).  
 
 Figure 5.8: Fractionation of M1-11 extracts by HPLC on Spherisorb, using an 
isocratic mobile phase of water: methanol 70:30 (v/v). 
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Figure 5.9: Fractionation of M1-11 extracts by HPLC on Spherisorb, using an 
isocratic mobile phase of water: methanol 50:50 (v/v). 
 
 
Figure 5.10: Fractionation of M1-11 extracts by HPLC on Spherisorb, using an 
isocratic mobile phase of water: methanol 40:60 (v/v) 
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Figure 5.11: Fractionation of M1-11 extracts by HPLC on Spherisorb, using an 
isocratic mobile phase of water: methanol 30:70 (v/v). 
 
The fractions of the 30:70 (v/v) of water: methanol isocratic system were collected 
and tested for antibacterial activity, one fraction with a retention time of 13.586 min 
(Figure 5.11) gave large inhibition zones on plates seeded with E.coli and S. aureus. 
 
Purification of the antibiotics from Es1 extracts 
 
Use of different HPLC columns for purification of Es1 extracts 
 
Three analytical columns, ACE Excel 5 C-18 amide, ACE Excel 5 SuperC18 and 
ACE Excel 5 CN-ES were tried using isocratic elution with a mobile phase of water: 
methanol 30:70 (v/v), flow rate 1 ml/min. Twenty microlitres of Es1 extract was 
injected the onto each column. The chromatograms are shown in Figures 5.12 to 5.14. 
The column that gave the best separation was ACE Excel 5 C-18 amide column. The 
fractions of ACE Excel 5 C-18 amide column were collected separately and tested for 
antibacterial activity. Three fractions with retention times of 12.230 (F3), 27.272 (F5) 
and 46.390 (F6) min (Figure 5.14) gave inhibition zones around 6 mm filter paper 
disks on plate seeded with S. aureus ATCC 25923 (F3 4mm, F5 5mm and F6 11mm), 
rest of the fractions showed no inhibition zones (Figure 5.15). 
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Figure 5.12: Fractionation of ES1 extract by HPLC, 20 µl Es1 extract was injected 
into ACE Excel 5 SuperC18, the solvent system was isocratic mobile phase water: 
methanol 30:70 (v/v). 
 
 
 
Figure 5.13: Fractionation of ES1 extract by HPLC, 20 µl Es1 extract was injected 
into ACE Excel 5 CN-ES, the solvent systems was isocratic mobile phase water: 
methanol 30:70 (v/v). 
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Figure 5.14: Fractionation of ES1 extract by HPLC, 20 µl Es1 extract was injected 
into ACE Excel 5 C-18 amide, the solvent systems was isocratic mobile phase water: 
methanol 30:70 (v/v) 
         
 
 
 
Figure 5.15: MHA plate seeded with S. aureus ATCC 25923 showing inhibition 
zones around 6 mm filter paper disks loaded with fractions collected from Es1 extract 
separated by ACE Excel 5 C-18 amide, the solvent systems was isocratic mobile 
phase water: methanol 30:70 (v/v). Three fractions showed inhibition zones (F3 4mm, 
F5 5mm and F6 11mm) 
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Comparison of fractions prepared by HPLC of Es1 extracts from solid medium 
(AIA), broth medium (AIB) and mycelium obtained from cells grown AIB. 
Analytical ACE Excel 5 C-18 amide was used with a mobile phase of water: 
methanol 30:70 (v/v). The chromatogram was conducted by injecting equal amounts 
of the three extracts 9AIA, AIB and mycelium extracts) and the peaks of the 
chromatogram were collected separately and tested for antibacterial activity. The 
results showed that three biological active fractions were present in all extracts with 
different concentrations, considering the area under the peaks as an indicator of 
concentration (Tables 5.2 to 5.4).  
Three fractions with retention times of 11.382 (F3), 23.182 (F5), 39.122 min (F6) 
were obtained from AIA extract, three fractions with retention times 11.316 (F3), 
23.122 (F5) and 39.415 min (F6) from AIB extract and three fractions with retention 
times of 11.298 (F3), 23.084 (F5) and 39.245 min (F6) from mycelium extract gave 
inhibition zones in plates seeded with E.coli and S.aureus (Figures 5.16 to 5.18). The 
retention times were very similar suggesting that the same compounds were present in 
each of the extracts. Quantitatively fraction F3 was lowest in the AIB extract but 
higher in the AIA and mycelium extracts whereas fraction F6 was highest (>50%) in 
the AIB extract but lower in the other two extracts. Fraction F5 was of relatively low 
abundance in all three extracts (Tables 5.2 to 5.4). 
 
 
Figure 5.16: Fractionation of injecting 20 µl Es1 extracts from AIA into ACE Excel 
5 C-18 amide, flow rate 2ml/min, the solvent systems was isocratic mobile phase 
water: methanol 30:70 (v/v). 
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Table 5.2: Showing concentration of the three biological fractions indicated by the 
area under the peaks (Es1 extracts from AIA) 
 
Peak labels as: BB indicates a baseline-resolved peak, BV indicates a peak that starts 
a cluster, VB indicates a peak that ends a cluster, VV indicates a peak within a cluster, 
E is for estimated peak and R is rounded peak. 
 
Figure 5.17: Fractionation of injecting 20 µl Es1 extracts from AIB into ACE Excel 5 
C-18 amide, flow rate 2 ml/min, the solvent systems was isocratic mobile phase 
water: methanol 70:30 (v/v) 
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Table 5.3: Showing concentration of the three biological fractions indicated by the 
area under the peaks (Es1 extracts from AIB) 
 
 
 
Figure 5.18: Fractionation of injecting 20 µl mycelium extracts from AIB into ACE 
Excel 5 C-18 amide, flow rate 2 ml/min, the solvent systems was isocratic mobile 
phase water: methanol 30:70 (v/v). 
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Table 5.4: Showing concentration of the three biological fractions indicated by the 
area under the peaks (Es1 extracts from mycelium obtained from cells grown AIB) 
 
Preparation of the fractions with antimicrobial properties from Es1 extracts. 
The semi-preparative ACE Excel 5 C-18 amide column was used for collecting the 
fractions with antimicrobial properties. The results are shown in Figure 5.19 
 
Figure 5.19: Fractions obtained by injecting 500 µl Es1 extracts on to semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems 
was Gradient mobile phase water: methanol 30:70 (v/v). 
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Three fractions gave inhibition zone on MHA pates seeded with (E.coli and S. aureus) 
at retention times of  8.547 (F3), 16.688 (F5) and 26.271 min (F6). 
The whole ES1 extract from 300 plates (200 ml) was injected, 500 µl at a time and the 
three fractions were collected, pooled, the solvent was removed by rotary evaporation 
and a brown oil residue obtained, the residue was eluted in methanol-d4, than each 
fraction analyzed by NMR. More than one compound was present in the proton 
spectrum in each fraction (data not shown).   
Therefore different solvent systems were used to purify the antibiotic from impurities, 
the best solvent system was isocratic mobile phase water: acetonitrile 33:67 (v/v).  
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Fraction 3 
The results of fractionation of fraction F3 are shown in Figure 5.20. All the peaks 
were collected separately and the results of antibacterial screening assay indicated that 
two sub-fractions were active against the test strains and had retention times of 8.405 
(F3/1) and 16.139 (F3/3) min.     
 
 
Figure 5.20: Fractions obtained by injecting 250 µl of fraction F3 on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems 
was isocratic mobile phase water: acetonitrile 33:67 (v/v) 
 
Fraction 5  
The results of fractionation of fraction F5 are shown in Figure 5.21. There was one 
major peak with a retention time of 10.159 min and a number of smaller peaks. All 
low intensity peaks were pooled together and together with the strong peak were and 
tested for antimicrobial activity.  The results showed that the strong peak (F5) 
demonstrated inhibitory effects against the tested strains. 
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Figure 5.21: Fractions obtained by injecting 250 µl of Fraction F5 on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems 
was isocratic mobile phase water: acetonitrile 33:67 (v/v). 
 
Fraction 6 
The results of fractionation of fraction F6 are shown in Figure 5.22. There were two 
major peaks with retention times of X and 18.706 min. The results showed that the 
fraction with a retention time at 18.708 min (F6) had inhibitory effects against the 
tested strains. 
   
Figure 5.22: Fractions obtained by injecting 250 µl of fraction F6 on to semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems 
was isocratic mobile phase water: acetonitrile 33:67 (v/v).  
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Fractionation was repeated for all the extracts and the four fractions were pooled and 
dried by rotory evaporation and weighed. Yields of the purified fractions were F3/1, 
3.5 mg; F3/3, 3.7 mg; F5, 10 mg F6, 24 mg. These were then subjected to further 
analysis by NMR, IR spectroscopy and accurate MS to try to determine the chemical 
nature and structures of the compounds. The purification procedure is summarised in 
Table 5.5) 
 
Table 5.5: Summary of purification of the antibiotics for Es1 extraction by HPLC 
(each step of purification all the fractions collected separately and tested for 
antimicrobial activity) 
 
Crude extract First step of the 
purification, the solvent 
systems was water: 
methanol 30:70 (v/v) 
 
Second step of the 
purification, the solvent 
systems was water: 
acetonitrile 33:67  
(v/v) 
Injecting Es1 crude extract 
on to reverse phase HPLC  
 
F3 at RT 8.547 min, semi 
pure fraction 
F3/1 (3.5 mg) at RT 8.405 
min, pure fraction 
F3/3 (3.7 mg) at RT 16.139 
min, pure fraction 
F5 at RT 16.688 min, semi 
pure fraction 
F5 (10 mg) at RT 10.195 
min, pure fraction 
F6 at RT 26.271 min, semi 
pure fraction 
F5 (10 mg) at RT 10.195 
min, pure fraction 
F6 (24) mg at RT 18.708 
min, pure fraction 
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Purification of the antibiotics for M1 11 extracts 
A semi-preparative ACE Excel 5 C-18 amide column with two different solvent 
system was used. The first solvent system was an isocratic elution using a mobile 
phase of water: methanol 30:70 (v/v) Figure 5.23, the second was an isocratic elution 
run using water: acetonitrile with a ratio of 33:67 (v/v) Figure 5.24, both with flow 
rate 5 ml/min. The second solvent system gave better separation.  
 
 
Figure 5.23: Fractions obtained by injecting 250 µl M1 11 extracts on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems 
was isocratic mobile phase water: methanol 30:70 (v/v).  
 
 
 
Figure 5.24: Fractions obtained by injecting 250 µl M1 11 extracts on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems 
was isocratic mobile phase water: acetonitrile 33:67 (v/v). 
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Collecting the fractions with antimicrobial properties from M1 11 extracts. 
Solvent system water: acetonitrile 33:67 (v/v) was used to collecting fractions with 
antibacterial activity. 
 
 
Figure 5.25: Fractions obtained by injecting 500 µl M1 11 extracts on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems 
was Gradient mobile phase water: acetonitrile 33:67 (v/v). 
 
The fractions were collected separately and tested for antibacterial activity, three 
fractions gave inhibition zone in seeded plates (E.coli and S. aureus) at retention 
times of 8.279 (M1 F1), 10.937 (M1 F2) and 15.205 (M1 F3) mins (Figure 5.25). 
 
All M1 11 extract (200 ml) was injected 500 µl at a time and the three fractions were 
collected, pooled, solvent removed by rotary evaporator and yellowish 
brown oil residues obtained.  The residues were then dissolved in methanol-d4. Each 
fraction was analysed by NMR, however the proton spectra showed more than one 
compound in each fraction.   
Different solvent system were used for each fraction to purify the antibiotic from 
impurities, three solvent systems were used, an isocratic elution using a mobile phase 
of water: methanol 30:70 (v/v; Figures 5.26, 5.29, 5.32), an isocratic elution run using 
water: methanol: acetonitrile with a ratio of 35:35:30 (v/v; Figures 5.27, 5.30, 5.33) 
and an isocratic elution run using water: methanol: acetonitrile with a ratio of 
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40:40:20 (v/v; Figures 5.28, 5.31, 5.34). The peaks of the chromatogram of the best 
solvent systems were isocratic mobile phase water: methanol: acetonitrile with a ratio 
of 30:35:35 (v/v) gave better separation.  
Samples (250 µl) of each fraction (M1 F1, M1 F2 and M1 F3) were therefore injected 
on to a semi-preparative ACE Excel 5 C-18 amide column using an isocratic mobile 
phase water: methanol: acetonitrile with a ratio of 30:35:35 (v/v).  Each peak was 
collected separately assayed for antimicrobial activity. The results showed that there 
were four peaks with antibacterial activity from M1 F1, retention time at 4.162 min 
(F1 1 p3), 7.570 min (F1 2 p4), 9.246 min (F1 3 p5) and 17.529 min (F1 4 p6; Figure 
5.27), one peak with antibacterial activity from M1 F2 retention time at 7.660 min (F2 
2 p2; Figure 5.30), five peaks with antibacterial activity from M1 F3 retention times 
at 3.974 min (F3 1 p2), 5.360 min (F3 2 p3), 6.882 min (F3 3 p4), 8.282 min (F3 4 p5) 
and 14.966 min (F3 5 p6; Figure 5.33).   
 
M1 F1 
 
 
Figure 5.26: Fractions obtained by injecting 250 µl M1 F1 on to a semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
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Figure 5.27: Fractions obtained by injecting 250 µl M1 F1 on to a semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 30:35:35 (v/v) 
 
Figure 5.28: Fractions obtained by injecting 250 µl M1 F1 on to a semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 20:40:40 (v/v) 
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M1 F2 
 
  
Figure 5.29: Fractions obtained by injecting 250 µl M1 F2 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
 
 
Figure 5.30: Fractions obtained by injecting 250 µl M1 F2 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 30:35:35 (v/v) 
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Figure 5.31: Fractions obtained by injecting 250 µl M1 F2 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 20:40:40 (v/v) 
 
 
M1 F3 
 
 
Figure 5.32: Fractions obtained by injecting 250 µl M1 F3 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
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Figure 5.33: Fractions obtained by injecting 250 µl M1 F3 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 30:35:35 (v/v) 
 
 
Figure 5.34: Fractions obtained by injecting 250 µl M1 F3 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems was 
isocratic mobile phase water: methanol: acetonitrile with a ratio of 20:40:40 (v/v) 
 
Each peak with antibacterial activity was collected separately and fractions from 
different runs were pooled. 
M1 F1 (F1 1 p3, F1 2 p4, F1 3 p5 and F1 4 p6) 
M1 F2 (F2 2 p2) 
M1 F3 (F31 p2, F32 p3, F3 3 p4, F3 4 p5 and F3 5 p6)  
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The solvent was removed by rotary evaporation and the yellowish brown residue 
eluted in methanol-d4, each peak was analysed by NMR and the proton spectrum 
showed that more than one compound was present in M1 F1 (F1 1 p2, F1 2 p3, F1 3 
p5 and F1 4 p6), M1 F2 (F2 2 p2) and M1 F3 (F3 1 p2, F3 2 p3 and F3 4 p5), but M1 
F3 (F3 3 p4, F3 4 p5 and F3 5 p6) did not need further purification. 
To purify the fractions that showed more than one compound on proton spectrum (see 
Figure 5.73 and Appendix 3.56, 3.65, 3.74, 3.82, 3.88 and 3.96) different solvent 
system used, solvent system was an isocratic elution using a mobile phase of water: 
methanol 30:70 (v/v; Figures 5.35-5.41). All the peaks of each fraction were collected 
separately and assayed for antimicrobial activity. The results showed that there was 
one peak with antibacterial activity from each fraction, the retention time of the 
peaks that showed antibacterial activity are summarised in Table 5.6. 
 
 
 
Figure 5.35: Fractions obtained by injecting 250 µl F1 1 p3 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
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Figure 5.36: Fractions obtained by injecting 250 µl F1 2 p4 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
 
 
Figure 5.37: Fractions obtained by injecting 250 µl F1 3 p5 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
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Figure 5.38: Fractions obtained by injecting 250 µl F2 2 p2 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
 
 
Figure 5.39: Fractions obtained by injecting 250 µl F3 1 p2 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
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Figure 5.40: Fractions obtained by injecting 250 µl F3 2 p3 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
 
 
 
Figure 5.41: Fractions obtained by injecting 250 µl F3 4 p5 on to semi-Preparative 
ACE Excel 5 C-18 amide column, flow rate 5ml/min, the solvent systems was 
isocratic mobile phase water: methanol 30:70 (v/v). 
 
Table 5.6: Summary of retention time for the peaks with antibacterial activity from 
the fractions from M1 11 extracts that showed more than one compound on proton 
spectrum     
 
Peak F1 1 p3 F1 2 p4 F1 3 p5 F2 2 p2 F3 1 p2 F3 2 p3 F3 4 p5 
Retention 
time 
6.660 
min  
16.822 
min  
17.201 
min  
10.082 
min  
 
7.016 
min 
21.288 
min 
10.684 
min 
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The HPLC was repeated for all the extracts and the active fractions pooled, 
concentrated by rotary evaporation and weighed The following amounts were 
obtained: M1 F1 (F1 1 p3 0.9 mg, F1 2 p4 1.8 mg, F1 3 p5 1.5 mg and F1 4 p6 
3 mg), M1 F2 (F2 2 p2 0.8 mg) and M1 F3 (F3 1 p2 0.9 mg, F3 2 p3 0.9 mg, 
F3 3 p4 3 mg, F3 4 p5 8 mg and F3 5 p6 4 mg). The purification scheme is 
summarized in Table 5.7. Further analysis of the fractions including NMR, IR 
and accurate MS was done to obtain the chemical elements of the compound 
and the possible structure of the antibiotics. 
 
Table 5.7: Summary of purification of the antibiotics for M1 11 extraction by HPLC 
(each step of the purification all the fractions collected separately and tested for 
antimicrobial activity) 
 
Crude extract First step of the 
purification, the solvent 
systems was water: 
acetonitrile 33:67 (v/v) 
Second step of the 
purification, the solvent 
systems water: 
methanol: acetonitrile 
30:35:35 (v/v) 
Third step of the 
purification, the solvent 
systems was water: 
methanol 30:70 (v/v) 
Injecting M1 11 crude 
extract on to reverse 
phase HPLC  
 
F1 at RT 8.547, not 
pure fraction 
 
 
F1 1 p3 at RT 4.162 
min,  
Semi-pure fraction 
F1 1 p3 (0.9 mg) at RT 
6.660 min  
Pure fraction 
F1 2 p4 at RT 7.570 
min,   
Semi-pure fraction 
F1 2 p4 (1.8 mg) at RT 
16.822 min   
Pure fraction 
F1 3 p5 at RT 9.246 
min,  
Semi-pure fraction 
F1 3 p5  (1.5 mg) at RT 
17.201 min  
Pure fraction 
F1 4 p6 (3 mg) at RT 
17.529 min, did not 
need further 
purification 
 
F2 at RT 16.688, not 
pure fraction 
  
F2 p2 at RT 7.660 min, 
semi-pure fraction 
F2 p2 (0.8 mg) at RT 
10.082 min  
Pure fraction 
F3 at RT 26.271, not 
pure fraction 
 
 
F3 1 p2 at RT 3.974 
min, semi-pure fraction 
F3 1 p2 (0.9 mg) at RT 
7.016 min  
Pure fraction 
F3 2 p3 at RT 5.360 
min, semi-pure fraction 
F3 2 p3  (0.9 mg) at RT 
21.288 min  
 
F3 3 p4 (3 mg) at RT 
6.882 min, did not need 
further purification  
 
F3 4 p5 at RT 8.282 
min, semi-pure fraction 
F3 4 p5  (8 mg) at RT 
10.684 min  
Pure fraction 
F3 5 p6 (4 mg) at RT 
14.966 min, did not 
need further 
purification  
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5.2.2 Identification of Chemical Structures 
 
5.2.2.1 Es1 Fractions 
 
NMR: Spectroscopy and Interpretation 
All NMR measurements were performed on a Bruker Ultra-shield Avance AMX 400 
MHz spectrometer as described in section 2.17.4 
 
Es1 Fraction 6 
The NMR results of Es1 Fraction 6 are shown in Figures 5.43-5.48 Appendix 3.1 to 
3.13.
 1
H NMR showed peaks at 7.75ppm, 7.05ppm and 6.90ppm which are 
characteristic of protons found in aromatic rings (Figure 5.43), the 2D g-COSY 
showed that the signals at 7.75ppm and 6.90ppm were adjacent to each other on the 
ring system, and is consistent with the peak splitting seen as a doublet (number of 
peaks = n+1 where n is the number of protons on the adjacent carbon; Figure 5.44). 
The signal at 7.05ppm was a singlet so has no adjacent carbons with protons and was 
not correlated with other protons on the COSY. The alcohol groups are not present 
due to deuterium exchange of the hydroxyl group. The signal at 3.4ppm shows 
hydrogen deuterium oxide (DOH) produced by the deuterium exchange and the signal 
at 2.50ppm was from the solvent (Figure 5.43). The 
13
C NMR had seven signals, the 
signal at 172.6ppm corresponding to a carboxyl group and that at 159.6ppm with an 
enol group. The five remaining signals 131.8ppm, 127.5ppm, 122.8ppm, 114.6ppm, 
115.9ppm all fall into the aromatic region and, due to the low number of signals 
present, indicated that the molecule had some symmetry involved as the signals would 
overlap and be seen as a single signal, or due to the low concentration of the molecule 
some peaks may not be present (Figure 5.47). The JMOD 
13
C NMR showed that the 
signals at 172.6ppm, 159.6ppm, 122.8ppm and 114.6ppm were ether non protonated 
carbons or di-protonated carbons, as the splitting from the 1H NMR indicates the 
liklihood of these being di-protonated is minimal (Figure 5.48).  
The 2D g-HMQC and 2D g-HMBC NMR showed that the linked signals at 7.75ppm 
and 6.90ppm on the 
1
H NMR were associated with the signals 131.8ppm and 
115.9ppm respectively (Figures 5.45 and 5.46). The difference in the 
1
H NMR ppm is 
due to the deshielding effect of a hydroxyl group in addition to the anisotropy effect 
of the aromatic ring which indicated that the 7.75 ppm proton was next to a carbon 
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with a hydroxyl group attached. This indicated an aromatic ring which has two 
adjacent protons with no protons on the next carbons along in the ring. The 
1
H NNR 
signal at 7.05ppm was correlated with the 
13
C NMR signal at 127.5ppm which is 
indicative of a aromatic carbon with a hydroxyl group attached to the 
1
H NMR 
7.05pmm.  
The FTIR spectrum is shown in Figure 5.49 and showed transmission bands 
associated with alcohol groups at 3300 cm 
-1
, aromatic groups at 2452 cm 
-1
, carbonyl 
group at 1602 cm 
-1
 and enol / ether group at 1510 cm 
-1
. These bands correlate with 
the structure suggested by the NMR data (Figures 5.43-5.48).  
Using this information gained from the FTIR and NMR (Table 5.8) it was possible to 
build a picture of the molecule. This gave a molecule with the chemical formula 
C15H10O6 which has a mass of 286.05 da. The mass spectrum of the compound 
showed a peak at 287.08 which corresponds to the [M+H]
-
 ion which helps to confirm 
the structure proposed (3, 4’, 7, 8 tetrahydroxyflavone; Figure 5.45).  
 
Table 5.8: Summarised of NMR and FTIR data. 
Atom Number 
1H 
NMR 
13C 
NMR FTIR 
1 - - 1510 
2 - 122.8 1510 
3 - 159.67 1510 
4 - 172.63 1602 
5 - 127.53 2452 
6 7.05 114.6 2452 
7 - 127.53 3300 
8 - 127.53 3300 
9 7.05 114.6 2452 
10 - 127.53 2452 
1* - 122.8 2452 
2* 6.9 115.9 2452 
3* 7.75 131.8 2452 
4* - 122.8 3300 
5* 7.75 131.8 2452 
6* 6.9 115.9 2452 
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Figure 5.42: The chemical structure of compound Es1 F6 build by NMR, FTIR and 
MS (C15H10O6) 
 
 
 
 
Figure 5.43: 
1
H NMR Spectrum of ES1 F6 in D6DMSO+TMS  
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Figure 5.44: 2D g-COSY NMR Spectrum of Es1 F6 (expansion) in D6DMSO+TMS 
 
 
 
Figure 5.45: 2D g-HMQC NMR Spectrum of Es1 F6 (expansion) in D6DMSO+TMS 
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Figure 5.46: 2D g-HMBC NMR Spectrum of Es1 F6 (expansion) in D6DMSO+TMS 
  
 
 
Figure 5.47: BB H1 Decoupled C13 NMR Spectrum of ES1 F6 (expansion) in 
D6DMSO  
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Figure 5.48: JMOD C13 Spectrum of Es1 F6 (expansion) in D6DMSO+TMS 
 
 
Figure 5.49: The FTIR spectrum (ATR) 4 cm 
-1
 (16 Scans) of F6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 159 
Mass Spectroscopy (MS) of the compound Es1 F6.  
Samples of Es1 F6 were sent to the Cambridge University Chemical Laboratory for 
accurate mass analysis and the results are shown in Figure 5.50 and Appendix 3.14 to 
3.16 (similar MS results were obtained from LC MS at University of Salford 
University Appendix 3.17). The results gave a MZ of 286.  The results are 
summarised below. All the data supports the structure shown in Figure 5.51 (3, 4′, 6, 
7-tetrahydroxyflavone. 
 
Figure 5.50: The negative ion spectrum from LC MS-TOF of Es1 F6 
 
Summary of spectral data of compound Es1 F6 
1 
H-NMR (400 MHz, CD3OD):  H 7.75 doublet of doublet (d of d), 7.06 singlet (s) 
and 6.9 doublet of doublet (d of d) 
13
C NMR (400 MHz, CD3OD):  13C 172.58, 159.70, 131.81, 127.50, 122.82, 
115.97 and 114.58 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3300 broad (br), 2452 small broad (sbr), 
2108 medium sharp (ms), 1602 sharp (s), 1510 sharp (s), 1436 small medium sharp 
(sms), 1346 small broad (sbr), 1277 sharp (s), 1174 sharp (s), 1113 small sharp (ss), 
973 small broad (sbr), 882 small sharp (ss) and 829 small sharp (ss)  
MS: MZ=287 (M+H)
-
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Figure 5.51: The confirmed chemical structure of compound Es1 F6 (C15H10O6, MW 
MZ=287 (M+H)-). 
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Es1 Fraction 3/1 
The NMR results of Es1 Fraction 3/1 are shown in Figures 5.52 and 5.53, Appendix 
3.18. The 
1
H NMR spectrum showed a strong signal in the aromatic region (between 
6.8 to 8 ppm; Figure 5.52). 2D g- COSY spectra showed two different aromatic rings 
not next to each other (Figure 5.53). The NMR spectrum showed peak at 6.9ppm 
(2H), 7.75ppm (2H) and 6.9ppm (1H), 7.15ppm (1H), 7.4 ppm (1H) showing 
presence of two benzene rings, 1,4-disubstituted and 1,2,4-trisubstituted respectively 
(Figure 5.52). This was confirmed by the 2D COSY spectrum. The 
1
H NMR and 2D 
g-Cosy spectra did not show protons on the alcohols due to exchange with deuterium 
(Figures 5.52 to 5.53). The FTIR spectra showed alcohol group (3397 cm 
-1
), aromatic 
group (2255 cm 
-1
), carbonyl group (1659 cm -1) and enol groups (1437 cm -1; Figure 
5.54). The range of MS showed too many signal on positive and negative mode due 
the compound not being stable at the temperature used (Appendix 3.19 to 3.21) and 
the MS of the compound showed a peak at 319.07 which corresponds to the [M+H]
-
 
ion in negative mode (Figure 5.55). 
 
 
 
 
 
Figure 5.52: 
1
H NMR Spectrum of Es1 F3/1 in D6DMSO+TMS 
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Figure 5.53: 2D g-COSY NMR Spectrum of Es1 F3/1 (expansion) in CD3OD 
 
 
 
Figure 5.54: The FTIR spectrum (ATR) 4 cm 
-1
 (16 Scans) of Es1 F3/1 
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Figure 5.55: The negative ion spectrum from LC MS-TOF of Es1 F3/1 
 
Summary of spectral data of compound Es1 F3/1 
1 
H-NMR (400 MHz, CD3OD):  H 7.75(d of d), 7.39(d), 7.15(d of d), 7.06(s), 
6.92(s), 6.91(d of d) and 6.84(d)  
13
C NMR (400 MHz, CD3OD): 
Due limited amount of material 
13
C NMR was not be obtained. 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3397 (br), 3003 (sms), 2255 (sms), 1659 
(s), 1406 (s), 1314 (ss), 1020 (s), 952 (s), 824 (ss) and 761(ss) 
MS: M/Z=319 (M-H)
-
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The FTIR, NMR and MS data are consistent with the structure shown in Figure 5.56 
(2′, 4′, 6′, 3, 6, 8- hexahydroxyflavone). 
 
 
 
 
 
 
Figure 5.56: The proposed chemical structure of compound Es1 F3/1 (C15H10O8, MW 
MZ=318 (M-H)-). 
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Es1 Fraction 3/3 
 
The NMR results of Es1 Fraction 3/3 are shown in Figure 5.57 and 5.58 Appendix 
3.22 to 3.24. The 
1
H NMR Spectrum was very similar to the one obtained from Es1 
F6, the 
1
H NMR spectrum showed two aromatic rings (Figure 5.57). The 
1
H NMR 
spectrum and 2D COSY had peaks at 7.63ppm (2H), 6.78pp (2H) and 6.9ppm (1H), 
indicating presence of possibly two benzene rings, 1,4-disubstituted and pent 
substituted (or olefinic hydrogen) respectively (Figure 5.57 and 5.58). The 2D g-
COSY showed a similar spectrum to fraction Es1 F6 (Figure 5.58). Unfortunately the 
13
 C spectrum was too weak due to lack of material and did not show all signals 
(Appendix 3.23). The FTIR spectrum showed the same groups as Es1 F6 (Figure 
5.59). The range of MS showed too many signal on positive and negative mode 
(Appendix 3.25 to 3.27) and the MS of the compound showed a peak at 287 which 
corresponds to the [M+H]
-
 ion in negative mode (Figure 5.60). 
 
 
 
Figure 5.57: 
1
H NMR Spectrum of Es1 F3/3 in D6DMSO+TMS 
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Figure 5.58: 2D g-COSY NMR Spectrum of Es1 F3/3 (expanded) in CD3OD 
 
 
 
 
Figure 5.59: The FTIR spectrum (ATR) 4 cm 
-1
 (16 Scans) of Es1 F3/3 
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Figure 5.60: The negative ion spectrum from LC MS-TOF of Es1 F3/3 
 
             
 
Summary of spectral data of compound Es1 F3/3   
1 
H-NMR (400 MHz, CD3OD):  H 7.63(d of d), 6.9(s) and 6.78(d of d) 
13
C NMR (400 MHz, CD3OD): 
Due limited amount of material 
13
C NMR was not obtained 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3426 (br), 2252 (ss), 2126 (ss), 1660 (sbr), 
1050(ss), 1023(s), 1003(s), 822 (ss) and 759 (ss) 
MS: M/Z=287 (M+H)
-
   
The IR, NMR and MS data are consistent with the structure shown in Figure 5.61 (1, 
3′, 6, 7, tetrahydroxyisoflavone). 
 
 
 
 
Figure 5.61: The proposed chemical structure of compound Es1 F3/3 (C15H10O6, MW 
MZ=287 (M-H)
-
). 
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Stack plots of 
1
H NMR spectra from F6 and F3/3 showed very similar spectra (Figure 
5.62).  
 
 
Figure 5.62: Comparisons of 
1
H NMR spectra for Es1 F3.3 (A) and Es1 F6 (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Es1 Fraction 5 
 
The NMR results of Es1 Fraction 5 are shown in Figures 5.63 to 5.68, Appendix 3.28 
to 3.45. The 
1
H NMR Spectrum was very similar to the one obtained from F3/1 
(Figure 5.63) but this fraction had less impurities. The 
1
HNMR spectrum and 2D 
COSY showed peaks at 7.73ppm (2H), 7.39pp (2H) and 7.14ppm (1H), 7.01ppm 
(1H), 6.93 ppm (1H), 6.9ppm (1H), 6.8ppm (1H) showing presence of two benzene 
rings, 1,4-disubstituted and 1,2,4-trisubstituted respectively (Figure 5.63 and 5.64). 
The 
13
C NMR had fourteen signals, the signals at 175.03ppm, 174.85ppm 
corresponding to a carboxyl group and that at 161.32ppm with an enol group, the 
elven remaining signals 149.78ppm, 147.04ppm, 133.26ppm, 129.19ppm, 
128.80ppm, 125.78ppm, 125.32ppm, 125.06ppm, 117.53ppm, 117.19ppm, 116.88 all 
fall into the aromatic region Figure 5.67. The JMOD 
13
C NMR (Figure 5.68), 2 D g-
HMQC (Figure 5.65) and 2 D g- HMBC spectra (Figure 5.66) were determined to aid 
structure determination. The FTIR spectrum is shown in Figure 5.69 and showed the 
same groups as F3/1. The range of MS showed too many signal on positive and 
negative mode (Appendix 3.46 to 3.48) and the MS of the compound showed a peak 
at 301 which corresponds to the [M+H]
-
 ion in negative mode (Figure 5.70). A similar 
MS result was obtained from LC MS at University of Salford (Appendix 3.49). 
 
 
 
Figure 5.63: 
1
H NMR Spectrum of Es1 F5 in CD3OD+TMS 
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Figure 6.64: 2D g-COSY NMR Spectrum of Es1 F5 (expansion) in CD3OD 
 
 
Figure 5.65: 2D g-HMQC Spectrum of Es1 F5 (expansion) in CD3OD 
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Figure 5.66: 2D g-HMBC Spectrum of Es1 F5 (expansion) in CD3OD  
 
Figure 5.67: BB H1 Decoupled C13 NMR Spectrum of Es1 F5 (expansion) in 
CD3OD  
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Figure 5.68: JMOD C13 Spectrum of Es1 F5 (expansion) in CD3OD  
 
 
 
Figure 5.69: The FTIR spectrum (ATR) 4 cm 
-1
 (16 Scans) of Es1 F5 
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Figure 5.70: The negative ion spectrum from LC MS-TOF of Es1 F5 
 
 
Summary of spectral data for compound of Es1 F 5 
1 
H-NMR (400 MHz, CD3OD):  H 7.73(d of d), 7.39(d), 7.14(d of d), 7.01(s), 
6.93(s), 6.9(d of d) and 6.8(d)  
13
C NMR (400 MHz, CD3OD):  
13
C 175.03, 174.85, 161.32, 149.78, 147.04, 
133.26, 129.19, 128.80, 125.78, 125.32, 125.06, 117.53, 117.19 and 116.88 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3333 (br), 2114 (s), 1599 (s), 1509 (s), 
1443 (ss), 1358 (ss), 1292 (br), 1176 (s), 1118 (ss), 1003 (ss), 962 (ss), 879 (ss) and 
828 (sbr) 
MS: MZ=301 (M-H)
-
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The IR, NMR and MS data are consistent with the structure shown in Figure 5.71  
 (2, 2’, 4′, 6, 8, pentahydroxyisoflavone). 
 
 
Figure 5.71: The confirmed chemical structure of compound Es1 F5 (C15H10O7, MW 
MZ=301 (M-H)-). 
 
Stack plots of 
1
H NMR spectra from Es1 F5 and Es1 F3/1 showed very similar 
spectra with different shifts on some peaks (arrows Figure 7.72). 
 
 
 
 
Figure 5.72: Comparison of 
1
H NMR spectra for Es1 F3/1 (A) and F5 (B) 
 
 
 
 
A 
B 
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5.2.2.2 M1 11 Fractions 
 
NMR: Spectroscopy and Interpretation  
 
M1 Fraction1 2 p4 
The NMR results of M1 F1 2 p4 are shown in Figures 5.73 to 5.74, Appendix 3.50 to 
3.52. The NMR data showed the sample to be impure
 
(Figure 5.73), As a result the 
sample was purified by HPLC to obtain a single compound purified compound from 
M1 F1 2 p4. 
1
H NMR Spectrum showed five protons in aromatic rings (Figure 5.74). 
The 
13
 C spectrum was too weak due to lack of material and did not show all signals 
(Appendix 3.52). The FTIR shown in (Figure 5.76) and showed alcohol group (3416 
cm 
-1
), aromatic group (2323 cm 
-1
) and alkene group (2161 cm 
-1
). The range of MS 
showed too many signal on positive and negative mode (Appendix 3.53 to 3.55) and 
the MS of the compound showed a peak at 285 which corresponds to the [M+H]
-
 ion 
in negative mode (Figure 5.77). 
 
 
Figure 5.73:
 1
H NMR Spectrum of M1 F1 2 P4 in CD3OD+TMS 
 
 
 
 176 
The sample was too impure so the spectra obtained were too complicated and was not 
possible to interpret. The sample was purified and only <1.8 mg was obtained 
therefore only 
1
H and COSY experiments were performed and as a result the structure 
was not confirmed. 
 
Purified compound from M1 F1 2 p4  
 
 
Figure 5.74: 
1
H NMR Spectrum of M1 F1 2 P4 in CD3OD+TMS 
 
 
 
Figure 5.75: 2D g-COSY NMR Spectrum of M1 F1 2 P4 in CD3OD acquired with 
smaller sweep width (SW) manually due a sample limited amount 
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Figure 5.76: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of M1 F1 2 p4 
 
 
Figure 5.77: The negative ion spectrum from LC MS-TOF of M1 F1 2 p4  
 
Summary of spectral data of compound M1 F1 2 p4 
1 
H-NMR (400 MHz, CD3OD): δ H 8.12 s, 7.9 (d), 7.26 (d of d), 7.24 (d of d), 7.03 
(d of d) and 6.95 (d) 
13
C NMR (400 MHz, CD3OD): 
Due limited amount of material 
13
C NMR was not obtained 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3367(br), 2980(ms), 2923(s), 2852(ss), 
2116(s), 1612(s), 1514(ms), 1449(sbr), 1385(sbr), 1238(br) and 1172(ss) 
MS: M/Z= 285 (M-H)
-
 
 
Six fractions (M1 F1 1 p3, M1 F1 3 p5, M1 F1 4 p6, M1 F2 2 p2, M1 F3 1 p2 and M1 
F3 2 p3) with very similar data to M1 F1 2 p4 are shown in the Appendix (3.56 to 
3.103) 
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M1 Fraction 3 3 p4 
 
The NMR results of M1 F3 3 p4 are shown in Figures 5.78 to 5.80, Appendix 3.104 to 
3.109. Data was not clear enough to define the confirmed structure but there was a 
clear signal on alkene proton (6.8 ppm) stronger than in the aromatic region (Figure 
5.78). The 
1
H NMR and 2D COSY spectra showed peak at 6.78ppm (2H), 7.63pp 
(2H) and 6.9ppm (1H), showing presence of possibly two benzene rings, 1,4-
disubstituted and penta substituted benzene ring respectively or an olefinic proton 
(Figure 5.78-7.80). Signal from 
13
 C, g-HMQC and HMBC showed the sample to be 
impure (Appendix 3.105, 3.107 and 3.109). The fraction was run on a better NMR 
instrument at Cambridge University to get higher resolution data but the results were 
the same as the Salford University results (Figure 5.80 and Appendix 3.105 to 3.109). 
The FTIR spectrum is shown in Figure 5.81 and showed the same groups as M1 F1 2 
p4. The range of MS showed to many signal on positive and negative mode 
(Appendix 3.110 to 3.112) and the MS of the compound showed a peak at 287 which 
corresponds to the [M+H]
-
 ion in negative mode (Figure 5.82). 
 
 
 
Figure 5.78: 
1
H NMR Spectrum of M1 F3 3 p4 in CD3OD+TMS 
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Figure 5.79: 2D g-COSY NMR Spectrum of M1 F3 3 p4 (expansion) in CD3OD  
 
 
 
Figure 5.80: H NMR Spectrum of M1 F3 3 p4 in CD3OD+TMS 
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Figure 5.81: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of M1 F3 3 p4 
  
 
Figure 5.82: The negative ion spectrum from LC MS-TOF of M1 F3 3 p4  
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Summary of spectral data of compound M1 F3 3 p4 
1 
H-NMR (400 MHz, CD3OD): δ H 7.63 (d of d), 6.90 (s), 6.78 (d of d)  
13
C NMR (400 MHz, CD3OD): δ 
13
C 174.61, 161.07, 135.60, 135.33, 133.05, 
132.99, 132.57, 132.39, 132.12, 131.46, 128.65, 127.52, 124.98, 122.52, 116.92, 
116.76 and 116.64   
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3367(br), 2980(ms), 2923(s), 2852(ss), 
2116(s), 1612(s), 1514(ss), 1449(sbr), 1385(sms) and 1238(br) 
MS: M/Z= 287 (M+H)
-
 
The FTIR, NMR and MS data are consistent with the structure shown in Figure 5.83 
(1′, 3′, 4′, 8 tetrahydroxyflavone). 
 
 
 
Figure 5.83: The chemical structure of compound M1 F3 3 p4 (C15H10O6, MW 
MZ=287 (M+H)-). 
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M1 Fraction 3 4 p5 
 
The NMR results of M1 F3 4 p5 are shown in Figures 5.84 to 5.89, Appendix 3.113 to 
3.117. The 
1
H NMR spectrum showed good signal in the aromatic region, five proton 
aromatic type and one proton alkene type (Figure 5.84).  The 2 D g-Cosy showed two 
aromatic rings, the 
1
H NMR spectrum and 2D COSY spectrum showed peak at 
7.11ppm (2H), 6.91ppm (2H) and 7.76ppm (1H), 7.14 ppm (1H), 6.82ppm (1H), 
7.98ppm (1H), showing the presence of two benzene rings, 1,4-disubstituted and 
1,2,4-trisubstituted respectively and an olefinic proton (Figure 5.84 and 5.85). The 
13
C 
NMR had fifteen signals, the signals at 172.6ppm, 170.3ppm corresponding to a 
carboxyl group and that at 160.4ppm, 159.7ppm with an enol group. The eleven 
remaining signals 139.5ppm, 135.8ppm, 132.4ppm, 131.8ppm, 128.3ppm, 127.8ppm, 
127ppm, 122.9ppm, 118.7ppm, 117.1ppm, 110.2 all fall into the aromatic region 
(Figure 5.86), the JMOD 
13
C NMR (Figure 5.89), 2 D g-HMQC (Figure 5.87) and 2 
D g- HMBC spectra (Figure 5.88) were determined to aid structure determination. 
The FTIR spectrum is shown in Figure 5.90 and showed the same groups asM1 F1 2 
p4. The range of MS showed to many signal on positive and negative mode 
(Appendix 3.118 to 3.120) and the MS of the compound showed a peak at 285 which 
corresponds to the [M+H]
-
 ion in negative mode (Figure 5.91) and the same MS result 
was obtained from LC MS at Salford University (Appendix 3.121). 
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Figure 5.84: H NMR Spectrum of M1 F3 4 p5 in CD3OD+TMS 
 
 
 
 
 
Figure 5.85: 2D g-COSY NMR Spectrum of M1 F3 4 p5 (expansion) in CD3OD  
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Figure 5.86: BB H1 Decoupled C13 Spectrum of M1 F3 4 p5 (expansion) in CD3OD  
 
Figure 5.87: 2D g-HMQC Spectrum of M1 F3 4 p6 (expansion) in CD3OD 
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Figure 5.88: 2D g-HMBC NMR Spectrum of M1 F3 4 p5 (expansion) in CD3OD 
 
 
 
 
Figure 5.89: JMOD C13 Spectrum of M1 F3 4 p5 in (expansion) CD3OD 
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  Figure 5.90: The FTIR spectrum (ATR) 4 cm 
-1
 (16 Scans) of M1 F3 4 p5 
 
 
Figure 5.91: The negative ion spectrum from LC MS-TOF of M1 F3 4 p5  
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Summary of spectral data of compound M1 F3 4 p5  
 
1 
H-NMR (400 MHz, CD3OD) ppm:  H 7.98(s), 7.76(d), 7.14(d of d), 7.11(d of d), 
6.91(d of d) and 6.82(d) 
13
C NMR (400 MHz, CD3OD): C 172.6, 170.3, 160.4, 159.7,139.5, 135.8, 132.4, 
131.8, 128.3, 127.8, 127, 122.9, 118.7, 117.1 and 110.2 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3290(br), 2980(sms), 2926(sms), 2116(s), 
1615(s), 1504(ms), 1447(ms), 1395(ms) and 1239(ms),  
MS: M/Z= 285 (M-H)
-
 
 
 
The IR, NMR and MS data are consistent with the structure shown in Figure 5.92 (2’, 
4’, 5, 8 tetrahydroxyisoflavone). 
 
 
 
 
Figure 5.92: The confirmed chemical structure of compound F3 4 p5 (C15H10O6, MW 
MZ=285 (M-H)). 
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Stack plots of 
1
H NMR spectra from F3 4 p5, M1 F3 1 p2 and M1 F1 4 p6 gave 
similar spectra as did M1 F3 1 p2, M1 F2 2 p3, M1 F1 2 p4 and M1 F1 3 p5 with 
different shifts on some of the peaks (Figure 5.93) suggesting that the compounds had 
similar structures.  
  
 
Figure 5.93: Comparison of 
1
H NMR spectra for M1 F3 4 p5 (A) M1 F3 2 3 (B), M1 
F3 1 p2 (C), M1 F2 2 p3 (D), M1 F1 4 p6 (E), M1 F1 2 p4 (F) and M1 F1 3 p5 (G). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A 
B 
C 
 
D 
E 
F 
G 
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M1 Fraction 3 5 p6 
 
The NMR results of M1 F3 5 p6 are shown in Figures 5.94 to 5.96 and Appendix 
3.122 to 3.29. 
All the data were the same as for M1 F3 3 p4 (Data was not clear enough to define the 
confirmed structure). 
The M1 F3 5 p6 was run on the better resolution NMR instrument at Cambridge 
University to get higher resolution data but the results were the same as the Salford 
University results (Figure 5.96 and Appendix 3.123 to 3.129). 
 
 
Figure 5.94: 
1
H NMR Spectrum of M1 F3 5 p6 in CD3OD+TMS 
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Figure 5.95: 2D g-COSY NMR Spectrum of M1 F3 5 p6 (expansion) in CD3OD 
 
 
 
Figure 5.96: H NMR Spectrum of M1 F3 5 p6 in CD3OD+TMS 
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Figure 5.97: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of M1 F3 5 p6 
 
 
Figure 5.98: The negative ion spectrum from LC MS-TOF of M1 F3 5 p6  
 
Summary of spectral data of compound M1 F3 5 p6 
1 
H-NMR (400 MHz, CD3OD): δ H 7.63 (d of d), 6.91 (s), 6.79 (d of d) 
13
C NMR (400 MHz, CD3OD): 
Due limited amount of material 
13
C NMR was not obtained. 
FTIR spectra (ATR) 4 cm 
-1
 (16 Scans): 3117(br), 3022(br), 2804(ms), 2112(ss), 
1747(sbr), 1605(s), 1510(s), 1440(sms), 1382(ms), 1174(s) 
MS: M/Z= 285 (M-H)
-
 
 
 192 
The IR, NMR and MS data are consistent with the structure shown in Figure 5.99 (2’, 
4’, 5’, 8 tetrahydroxyisoflavone). 
 
 
 
 
Figure 5.99: The proposed chemical structure of compound M1 F3 5 p6 (C15H10O6, 
MW MZ=285 (M-H)-). 
 
Stack plots of 
1
H NMR spectra from M1 F3 3 p4 and M1 F3 5 p6 showed very similar 
spectra with different shifts on some peaks (Figure 5.100).  
 
 
Figure 5.100: Comparison of 
1
H NMR spectra for M1 F3 3 p4 (A) and M1 F3 5 p6 
(B) 
 
 
 
 
A 
B 
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5.3 Discussion 
 
 
5.3.1 Purification of the Antibiotics Produced from Isolates Es1 and M1 11 
 
The results showed that it was possible to separate the components with antimicrobial 
activity despite the use of solid phase culture on agar. The extracts will have included 
cellular components and those present in the medium as well as the agents secreted by 
the cells which might have made their separations more difficult. However, in this 
study, RP-HPLC was used to fractionate the active components produced by cultures 
of two of the isolates Es1 and M111. HPLC was used in preference to TLC. TLC– 
bioautography combines TLC with both biological and chemical detection methods 
and has been widely used for the screening of organic extracts, mainly plant extracts, 
for antimicrobial activity e.g. see (Mehrabani et al., 2013, Horváth et al., 2010, 
Balouiri et al., 2016). In the present study, TLC was tried for fractionation of the 
crude extracts but the results showed a high loss of antimicrobial activity (results not 
shown) and therefore HPLC was used. It was necessary to optimize the analytical 
HPLC separation conditions, namely choice of the best eluting solvent, column 
specifications and adjusting the solvent flow rate. To get semi-pure fractions of the 
biologically active crude extracts, reversed-phase HPLC was used with the separating 
solvent system (H2O: MeOH, 30:70 v/v) which was found to give much better 
resolution and clearer peaks of the fractions. It has previously been recommended to 
not use mobile phases with less than 10 % organic solvent in water (Latif and Sarker, 
2012).  
HPLC is an extremely powerful and versatile technique. Any sample that can be 
dissolved in a liquid, HPLC has the ability to separate, identify, and quantitate the 
compounds that are present in this sample. RP-HPLC has been used extensively in the 
separation and identification of the bioactive compounds from extracts. One example 
was the fractionation of six bioactive compounds; terretrione D, methyl-
2([2(1Hindol3yl)ethyl]carbamoyl)acetate, tryptamine, indole-3-carbaldehyde, 3,6-
diisobutylpyrazin-2(1H)-one and terretrione C from Penicillium sp. CYE-87 (Shaala 
and Youssef, 2015), mahanine and mahanimbine alkaloids from Murraya koenigii 
(Pandit et al., 2011). 
Analytical and preparative chromatography has been used in many studies of the 
separation and identification bioactive compounds from natural products. In early 
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stages of isolation and purification of the active compounds, analytical HPLC is 
commonly used for method development (Gupta et al., 2012). To produce higher 
yields of collected fractions, preparative and semi-preparative HPLC are used. 
Nowadays use of preparative HPLC has become an essential tool in isolation of most 
classes of natural products (Latif and Sarker, 2012).   
In the RP-HPLC analysis the most common eluents used for natural products extracts 
are mixtures of aqueous and water-soluble organic solvent, methanol and acetonitrile 
are mostly used (Dolan, 1999). Use of a mobile phase of methanol-water mixture is 
the most commonly used RP- HPLC for the isolation of natural compounds. 
However, there is much published research that used mixture of water-acetonitrile in 
RP-HPLC natural products isolation. A survey of the period between 2008 and 2012 
by (Bucar et al., 2013) showed that methanol-water mixture was employed as a 
solvent system in about half of natural products isolation. Sticher (2008)
 
suggested 
that acetonitrile–water was better to use compared to other alcoholic solvents for RP-
HPLC, due to its lower viscosity, thus giving reduced back pressure. However, Gilar 
et al. (2014), pointed out that acetonitrile was more costly, especially the highly pure 
solvent. Moreover, viscosity properties do not affect the separation quality and as it 
does not affect either the HPLC system or the column, they suggested that the 
methanol should be used instead of acetonitrile as a cheaper alternative with the same 
separation quality.  Both Methanol–water and acetonitrile–water were used in the 
present study in a two stage purification process. 
Once the HPLC fractionation had been optimized, fractions were collected and bio-
assayed using the paper disc method and the S. aureus and E.coli to verify the 
antimicrobial activity of these fractions and the non-active fractions were not studied 
further. Such bioassay-guided isolation integrates the processes of separation of 
compounds in a mixture, using various analytical methods, with results obtained from 
biological testing. The first step of the process begins by testing a crude extract to 
confirm its biological activity presented in crude extract, followed by separation of 
the compounds in the extracts and in-vitro biological testing of purified compounds. 
In some fractions, further fractionation will be needed if the high purity level not 
obtained. Identification of chemical structures of the pure compounds is then 
performed (Jamil et al., 2012). 
By using bioassay-guided isolation during the last few decades, many compounds 
have been isolated from different extracts and many of these have been reported to 
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have significant biological activities, some of which are of interest from the point of 
view of potential drug development (Khurram et al., 2015, Ejele et al., 2014, Kang et 
al., 2013).  
 
Analytical column, HP Hewlett Packard Spherisorb ODS-2 5µm 250 mm x 4.6 I.D 
was used. One biologically active clear peak at retention time of 13.49 min gave the 
highest activity from the Es1 crude extract. It was observed that using these HPLC 
separation conditions, all fractions separated eluted before a retention time of approx. 
15 min. Since the retention time of the largest peak area from M1 11 extracts was 
13.58 min, this may indicate the possible similarity between the two components 
although obtained from two different fungal strains. 
It was reported that, using HPLC, similar antimicrobial secondary metabolites are 
commonly produced from different spp. related to Penicillium. This was attributed 
mainly to some sort of genetic resemblance between them and between their specific 
metabolic pathways through which they can be produced (Martín et al., 2010) 
Collectively, the results of HPLC analytical procedure for purification of the semi-
purified extracts from Es1 revealed that the best separating solvent system was (H2O: 
MeOH, 30:70 v/v), the best column was ACE Excel 5 C-18 amide column and three 
peaks numbered 3, 5 and 6 appeared at 12.23 (3), 27.27 (12) and 46.39 (46) min 
showed biological activity after being assayed using paper disc diffusion.  
The mycelia and culture broth of the fungus Penicillium sp. CYE-87 were extracted 
with organic solvents in a study by Shaala and Youssef (2015). The combined crude 
extracts were subjected to partition by using RP- HPLC and the purification was 
performed by injecting crude extract into a C18 reversed-phase semi-preparative 
HPLC column. 
For comparative purposes, the ethyl acetate extracts of the Es1 cultivated on AIA 
solid medium, AIB (broth) and mycelium (extracted by acetone) were subjected to 
two consecutive runs under same conditions, after which data of the three biological 
active fractions were recorded and compared. The results showed that, the three 
biological active fractions were present in all extracts with different concentrations. 
Using the area under the peaks as an indicator of concentration, fraction numbered 3, 
represented approx. 8.5%, 36% and 33.06% for solid, broth and mycelia as extraction 
sources. As regards fraction 5, its active components represented the highest 
percentage (17%) when being obtained by extraction with ethyl acetate from solid 
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AIA medium, while it was about 8.2% and 0.48% from AIB medium and its mycelia 
using acetone extracts, respectively. On the other hand, fraction 6 had the highest 
concentration as extracted from solid AIA medium (53.12%), while it reached about 
16% and 22% from Es1 cultivated on AIB medium and extraction of mycelium with 
acetone, respectively. This is similar to a study by (Svahn et al., 2015) who reported 
that the three major extracts they prepared from Penicillium nalgiovense Laxa, the 
filtrate of the liquid culture, the mycelial growth in the liquid culture, and the cultures 
growing on solid medium, the result showed antimicrobial activity was present in all 
three extracts with different concentrations. 
Preliminary results showed that active fractions from Es1 had four components and 
from M1 11 had ten components (see Table 5.5 and 5.7)   
This part of work was a useful way to give more definite features about the number of 
biologically active components, degree of similarities and adjustment of the HPLC 
separation and purification conditions. 
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Figure 5.101: Model extraction procedure for cultivation, extraction, and 
isolation of metabolites with antimicrobial activity from Penicillium nalgiovense 
Laxa  
Fractions without antimicrobial activity are marked with thinner arrows under the 
HPLC boxes, and those with antimicrobial activity are marked with an asterisk (*) 
modified from (Svahn et al., 2015). 
 
A generalized scheme modified from (Svahn et al., 2015) (Figure 5.101) was 
proposed to describe the stepwise procedure used to obtain pure fractions from 
organic extracts of biologically active components. These pure fractions were planned 
to be subjected to chemical structure elucidations using the approved modern 
techniques like proton and 
13
C NMR and 2D g-COSY….etc. Some known 
compounds, have been isolated from Penicillium sp. CYE-87. The structures of the 
isolated compounds were established by spectral analysis, including 1D (
1
H, 
13
C) and 
2D (COSY, multiplicity edited-HSQC and HMBC) NMR and HRESIMS, as well as 
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comparison of their NMR data with those in the literature. (Shaala and Youssef, 
2015). In the present study similar stepwise procedures were followed. 
5.3.2 Structure elucidation of the antibiotic(s) produced by isolates Es1 and M1 
11 
Spectrometry of the purified antibacterial compounds from the isolates Es1 and M1 
11 was performed to characterize their chemical structures.  
All fractions obtained were analyzed using 
1
H
 
NMR, 2D g-COSY, the infrared 
spectroscopy (IR) and MS for molecular weight determination. The elementary 
analysis for all samples was unfortunately not possible due to the lack of enough pure 
material of fractions. However, sufficient material was available for fractions Es1 5 
Es1 6, M1 F3 3 p4, M1 F3 4 p5 and M1 F3 5 p6 these were therefore subjected to 
BBH1 decoupled 
13
C analysis which indicated the total number of carbons included in 
the skeleton of compounds addition to JMOD 
13
C, 2D g-HMQC and 2D g-HMBC 
analysis.  
All the analytical data obtained using the above mentioned techniques indicated that 
the compounds Es1 F3/1 and Es1 F5 had similar structures with an extra oxygen in 
compound Es1 F3/1. Compounds Es1 F3/3 and Es1 F6 had very similar structure. On 
the other hand, compound M1 F3 3 p4 and M1 F3 5 p6 had very similar structures. 
The structures of the characterized compounds are summarized in Figures 5.102-
5.103, for ease of comparison. 
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Figure 5.102: Summary of the chemical structures of fractions F3/1, F5, F3/3, F6, 
isolated from Es1 compared to skeleton structures of the flavonol 
 
 
 
The skeleton structures of flavonol 
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Figure 5.103: Summary of the chemical structures of fractions F3 3 p4, F3 5 p6 and 
F3 4 p5 isolated from M1 11 compared to skeleton structures of the flavone 
 
 
 
 
The skeleton structures of flavone 
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Determination of the structures of seven of the fractions (Es1 fractions F3/1, F3/3, F5 
and F6 and M1 11 fractions F3 3 p4, F3 4 p5 and F3 5 p6) showed that the active 
compounds were flavonoids and isoflavonoid. Three of the compounds were 
flavonoids and four were isoflavonoid. The fractions from Es1 were flavonols Es1 
F3/1 (2′, 4′, 6′, 3, 6, 8- hexahydroxyflavone), Es1 F3/3 (1, 3′, 6, 7, 
tetrahydroxyisoflavone), Es1 F5 (2, 2’, 4′, 6, 8, pentahydroxyisoflavone) and Es1 F6 
(3, 4’, 7, 8 tetrahydroxyflavone), whereas those from M1 11 were flavones M1 F3 3 
p4 (1′, 3′, 4′, 8 tetrahydroxyflavone), M1 F3 4 p5 (2’, 4’, 5, 8 tetrahydroxyisoflavone) 
and M1 F3 5 p6 (2’, 4’, 5’, 8 tetrahydroxyisoflavone). Unfortunately it was not 
possible to obtain sufficient amounts of the other fractions to allow full chemical 
structures to be determined. However, some of the properties of those fractions were 
similar to those that were fully characterized and may have represented a family of 
related compounds. Flavonoids are frequently isolated from plant sources (Cushnie 
and Lamb, 2011). Flavonoids are ubiquitous in photosynthesising cells and are 
commonly found in fruit, vegetables, nuts, seeds, stems, flowers, tea, wine, propolis 
and honey (Cushnie and Lamb, 2005) but, with the exception of endophytic fungi 
(Bhardwaj et al., 2015a, Qiu et al., 2010) as far as the author is aware this is the first 
report of the production of such compounds from fungi from other sources. 
Gossypetin (3,5,7,8,3,' 4'-hexahydroxyflavone) isolated from the flowers of Hibiscus 
sabdariffa, it has possesses excellent antimicrobial activity against E. coli, S. aureus, 
B. subtilis, B. pumpilus and P. aeruginosa (Mounnissamy et al., 2002) The structure 
of gossypetin similar to the flavonol that been isolated from Es1 (Es1 F3/1 (2′, 4′, 6′, 
3, 6, 8- hexahydroxyflavone)) and the different is the position of the hydroxyl group. 
Fisetin (3,3′,4′,7-tetrahydroxyflavone), can be found in various fruits and vegetables, 
such as strawberry, apple, persimmon, grape, onion, and cucumber, numerous 
researches have demonstrated the effects of fisetin against several diseases. It is 
reported to have neurotrophic, anticarcinogenic, anti-inflammatory, and other health 
beneficial effects (Khan et al., 2013), the structure of fisetin similar to the flavonol 
that been isolated from Es1 (Es1 F6 (3, 4’, 7, 8 tetrahydroxyflavone)) and the 
different is the position of the hydroxyl group.  
Luteolin (3',4',5,7 tetrahydroxyflavone) is a common flavone that found in many types 
of plants including fruits, vegetables. Having multiple biological effects such as anti-
inflammation, anti-allergy and anticancer (Lin et al., 2008), the structure of luteolin 
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similar to the flavone that been isolated from M1 11 (M1 F3 3 p4 (1′, 3′, 4′, 8 
tetrahydroxyflavone) and the different is the position of the hydroxyl group. 
Genistein  (4',5,7‐ trihydroxyisoflavone) is an isoflavone which is the predominant 
isoflavone in legumes, such as soybeans, Numerous epidemiological studies have 
shown an inverse association between isoflavone consumption and the risk of breast 
cancer in Asians, indicating that dietary intervention may reduce the risk of breast 
cancer (Choi et al., 2013), (Peterson et al., 1991) report that genistein is a potent 
inhibitor of the growth of the human breast carcinoma cell lines (MDA-468 and 
MCF-7 and MCF-7-D-40) with IC50 values from 6.5 to 12.0 μg/ml, genistein has 
similar structures with isoflavones been isolated from M1 11 (M1 F3 4 p5 (2’, 4’, 5, 8 
tetrahydroxyisoflavone) and M1 F3 5 p6 (2’, 4’, 5’, 8 tetrahydroxyisoflavone)) that 
they have an extra oxygen and different position of hydroxyl group. 
The recent combining of natural product chemistry and metabolomic approaches in 
drug discovery can certainly contribute to the development of new leads from marine 
derived fungi. (Nicoletti and Trincone, 2016). The results obtained in the present 
study show that terrestrial aquatic and land invertebrates are also potential sources of 
novel compounds. 
 
The limitations of this part of the study were that many of the bioactive fractions were 
not  characterized or structures determined due to the lack of the sufficient material 
and further studies would require larger amounts of purified fractions.   
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Chapter 6 
 
Antimicrobial and anticancer activity 
 
6.1 Introduction  
 
6.1.1 Antimicrobial activity 
 
Minimum Inhibitory Concentrations (MICs) 
Minimum inhibitory concentrations (MICs) are considered the ‘gold standard’ for 
determining the susceptibility of organisms to antibiotic or antimicrobial agent and 
defined as the lowest concentration of a antimicrobial agent that prevents visible 
growth of a microorganism after 24 h incubation (for some organisms such as 
anaerobes this incubation time is extended as the organisms need more time to grow; 
Andrews, 2001). Microorganisms can be tested for their ability to produce visible 
growth on a series of agar plates (agar dilution), in tubes with broth (broth dilution), 
or in microplate wells of broth (broth microdilution) containing dilutions of an 
antimicrobial agent De Graaf, (2013). MICs are determined by dilution methods that 
used in relative testing of new antimicrobials agent, in diagnostic laboratories mainly 
to confirm unusual resistance, to confirm the susceptibility of organisms and to test 
those organisms when disc diffusion methods may be unreliable, for example when 
determining the susceptibility of coagulase- negative staphylococci to teicoplanin 
(Andrews, 2001).  
 
6.1.2 Anticancer activity 
 
Cancer is a broad term for diseases that are characterised by the uncontrolled 
proliferation of cells resulting from the disorder or dysfunction of regulatory signaling 
pathways that are naturally under tight control. Cancer can spread quickly and attack 
other tissues and organs and different cancers are recognized to have unique types or 
markers (McCauley et al., 2013). In countries all over the world cancer is a major 
public health hazard (Kinghorn et al., 2016). According to estimates from the 
International Agency for Research on Cancer (IARC), there were 14.1 million new 
cancer cases and 8.2 million cancer-related deaths in 2012 worldwide, which is 
predicted to increase to 23.9 million new cancer cases and 14.6 million cancer-
related deaths by 2035 (Are et al., 2017). 
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Over 50 years natural products have played a major beneficial role in cancer 
chemotherapy. In Western countries over an approximately 70-year period of 
introduced anticancer drugs therapy out of a total of 175 small-molecule about 49% 
were obtained from natural products either obtained from organisms directly or other 
natural products (Kinghorn et al., 2016). For example, natural products of terrestrial 
microbial origin are used in cancer chemotherapy, include several anthracyclines 
(such as daunorubicin, doxorubicin, epirubicin, idarubicin, and valrubicin), 
bleomycin, actinomycin D and mitomycin C (Cragg et al., 2011). In turn, members of 
four classes of plant- derived anticancer agents are used clinically as antitumor agents, 
namely, the bisindole (vinca) alkaloids, the camptothecins, the epipodophyllotoxins, 
and the taxanes (Kinghorn et al., 2009. 
An important aspect of the drug development for anticancer process is testing the 
natural product compounds for anticancer activity and cytotoxicity using human 
cancer cell cultures. To assess for preliminary anticancer activity, the MTT 3- (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in vitro assays are considered 
to be the most economic, reliable and convenient methods. This is based on their ease 
of use, accuracy and rapid indication of toxicity, as well as their sensitivity and 
specificity (McCauley et al., 2013). 
The assay is based on the capability of mitochondrial dehydrogenase enzymes in 
living cells to change the yellow water-soluble substrate 3-(4,5- dimethylthiazol-2-
y1)-2,5-diphenyl tetrazolium bromide (MTT) into a dark blue formazan product that 
is insoluble in water. Viable cells are able to metabolise the yellow MTT under 
tetrazolium ring cleavage to a water-insoluble purple-blue product which precipitates 
in the cellular cytosol and can be dissolved after cell lysis. However, cells that are 
dead following a toxic damage, cannot transform MTT. (Senthilraja et al., 2015) 
The part of this study was to investigate the anticancer effects of compounds isolated 
from the Es1, M1 11 and La1a. In the present study, three human cell lines (two 
human breast cancer cell lines MDA-MB 468, MCF 7 and a control cell line of 
immortalized human keratinocytes, HACAT) were used for in vitro evaluation of 
anticancer activity.  
 
The aims of this part of the study were to determine the MIC of the crude and purified 
antibiotic on bacteria and to determine their activity on cell culture. 
 
 205 
6.2 Results 
 
6.2.1 Antimicrobial activity 
 
MIC’s for E.coli and S. aureus (these organisms were selected as representatives of 
Gram negative and Gram positive bacteria as the amounts of antibiotic available were 
limited and further testing was not possible) were determined for crude and purified 
extracts by the broth micro-dilution method (Andrews, 2001) and the results are 
shown in Tables 6.1-6.3. The crude extracts had higher activity against S. aureus than 
E. coli. MIC values on E. coli were 2 (M1 11) and 4  (La1a) times higher than the 
effective dose of Es1 crude extract which had the highest antimicrobial activity with 
an MIC value of 0.39 µg/ml against S. aureus (Table 6.1).  
The MIC’s of fractions of Es1 (F3/1, F3/3, F5 and F6) were determined (Table 6.2). 
Fraction F3/1 had the highest value on both test organisms (6.25 µg/ml each). 
Fraction 6 had the best antimicrobial activity with MIC of 0.78 µg/ml on E. coli and 
0.39 µg/ml on S. aureus) similar to the crude extracts. Fractions F5, F3/3 and F3/1 
had lower activities which were 2, 4 and 8 x the MIC of F6 (Table 6.2).  
The only fractions of M1 11 with activity similar to the crude preparation was F3 4 p5 
(3.13 µg/ml E. coli and 1.65 µg/ml on S. aureus: Table 6.3). All other fractions (F1 1 
p3, F1 2 p4, F1 3 p5, F1 4 p6, F3 1 p2, F3 2 p3 and F3 3 p4) had lower antibacterial 
activities with MIC values between 6.25 and 50 µg/ml. 
 
Table 6.1: The Minimal Inhibitory Concentrations (μg mL-1) of the crude extracts of 
the isolates ES1, M1 11and La1. 
 
Extract E. coli S. aureus 
Es1 0.78 0.39 
M1 11 1.56 0.78 
La 1 a 3.13 1.56 
 
Determined by the microdilution plate method using AIB medium (Andrews, 2001)  
 
Table 6.2: The Minimal Inhibitory Concentrations (μg mL-1) of the Es1 fractions 
Determined by the microdilution plate method using AIB medium (Andrews, 2001)   
Es1 Fractions  Test organisms 
  E. coli S. aureus 
F3/1 6.25 6.25 
F3/3 3.13 1.56 
F5 1.56 0.78 
F6 0.78 0.39 
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Table 6.3: The Minimal Inhibitory Concentrations (μg mL-1) of the M1 11 fractions 
 
M1 11 Fractions E. coli S. aureus 
F1/1 p3 50 25 
F1/2 p4 12.5 6.25 
F1/3 p5 12.5 12.5 
F1/4 p6 25 12.5 
F3/1 p2 25 12.5 
F3/2 p3 25 12.5 
F3/3 p4 12.5 6.25 
F3/4 p5 3.13 1.56 
F3/5 p6 12.5 6.25 
    
 
Determined by the microdilution plate method using AIB medium (Andrews, 2001)  
  
 
  
 
6.2.2 Anticancer activity 
 
MDA-MB 468, MCF7 and HACAT cell lines were used to test the compounds for 
anticancer activity and cytotoxicity (again amounts of antibiotic were limited and 
three strains of cell line, two cancer cell lines and one normal cell line were therefore 
used). MTT viability assays were conducted as described in section 2.18.2, then 
Ascent software - Thermo Labsystem Multiskan Ascent plate reader was used to 
measure absorbance at 540 nm and calculate the inhibitory concentration (IC50). 
Figures 6.1- 6.5 show the growth inhibition curves and the IC50 values are 
summarised in Tables 6.4 and 6.5. The results showed that the crude extracts of Es1, 
M1 11 and La1a were found to have MDA-MB 468 IC50 values ranging from 13-21 
µg/ml. IC50 values were >100 µg/ml with the MCF7 and HACAT cell lines (data not 
shown).   In contrast, the purified fractions F6 and F3/3 were found to have HACAT 
IC50 values of 9 and 6  µg/ml respectively, lower than the crude extracts (Table 6.5).  
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Figure 6.1: Representative IC50 curve showing % growth inhibition effect of Es1 
extracts treatment on the MDA-MB 468 cell line.  
 
 
 
 
Figure 6.2: Representative IC50 curve showing % growth inhibition effect of M1 11 
extracts treatment on the MDA-MB 468 cell line.  
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Figure 6.3: Representative IC50 curve showing % growth inhibition effect of La1a 
extracts treatment on the MDA-MB 468 cell line.  
 
 
Figure 6.4: Representative IC50 curve showing % growth inhibition effect of F3/3 
compound treatment on the HACAT cell line.  
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Figure 6.5: Representative IC50 curve showing % growth inhibition effect of F3/3 
compound treatment on the HACAT cell line.  
 
 
 
Table 6.4: MDA-MB 468 IC50 values and standard error when treated with extracts 
of Es1, M1 11 and La1a   
 
MDA-MB 468 
Extracts IC50 (µg/ml) Standard Error  
Es1 21 5 
M1 11 13 4 
La1a1 17 15 
 
 
Table: 6.5: HACAT IC50 values and standard error values when treated with fractions 
F6 and F3/3  
 
HACAT 
Compound IC50 (µg/ml) Standard Error  
F3/3 9 5 
F6 6 8 
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6.3 Discussion 
 
 
6.3.1 Antimicrobial activity 
 
The results showed that crude extracts from all three strains showed higher activity 
against S. aureus than E. coli. MIC values for M1-11 and La1a crude extracts on E. 
coli were 2 to 4 times higher than that for Es1 extract. The Es1 crude extract was had 
the lowest MIC values on both E. coli and S. aureus at 0.78 and 0.39 µg/ml. This is 
similar to the reported MIC for Chrysoeriol (flavone) extracted from Capsicum 
frutescens (whole fruits, peel and seeds) against E. coli and S. aureus at 0.06 and 0.25 
µg/ml respectively (Nascimento et al., 2014), and is also similar to antibiotics used 
clinically against S. aureus e.g. gentamicin (0.125-0.25 µg/ml; (Sørensen and 
Sørensen, 1993); 0.5-1 µg/ml (Tam et al., 2006)) 
All four fractions of Es1 were active with F3/1< F3/3<F5 <F6 and F 6 had 
antimicrobial activity similar to the crude preparation. These results are in line with 
results for the published MIC for flavonoids. (Table 6.6) 
 
Table 6.6: MIC of some natural flavonoids  
Flavonoid MIC (μg/mL) 
Gram-positive Gram-negative 
Panduratin A 0.06–2.0 N/T 
Isobavachalcone 0.3–0.6 0.3 to >39.1 
Bartericin A 0.6–2.4 0.3–39.1 
Scandenone 0.5–8 2–32 
Kaempferol 3-O-α-l-(2″,4″-di-E-p-
coumaroyl)-rhamnoside 
0.5 to >16 >16 
Sepicanin A 1.2 N/T 
Isolupalbigenin 1.6–3.1 N/T 
Flavone 7.8–31.3 1.95–31.3 
3′-O-methyldiplacol 2–4 >32 
Licochalcone A 2–8 N/T 
Chrysoeriol 0.25 0.06 
Modified from (Cushnie and Lamb, 2011, Nascimento et al., 2014) 
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Fractions of M1 11 were comparatively weaker with MIC values between 6.25 and 50 
µg/ml except for F3 4 p5 with MIC of 3.13 µg/ml E. coli and 1.65 µg/ml on S. aureus 
The results showed that the resulting fractions were less active individually than the 
crude extract of M1 11 possibly indicating some synergistic effects between the 
fractions.  
 
6.3.2 Anticancer activity 
Flavonoids are a class of plant secondary metabolites possessing a broad spectrum of 
pharmacological activity including anticancer activities. Flavonoids have diversity of 
structural patterns this diversity has resulted in flavonoids being recognized as a rich 
source of compounds with potential anticancer properties (Ravishankar et al., 2013) 
In this study whole extracts of Es1, M1 11 and La1a were found to have anticancer 
activity against MDA-MB 468 cell line and showed IC50 values in the low microgram 
per millimeter (from 13 to 21 μg/ml) but IC50 values were >100 µg/ml with the MCF7 
and HACAT cell lines. This indicates that they might be useful anti-infective agents 
as they may show low cytotoxicity and the potential for use as an anticancer therapy 
is clearly worth investigating further. (Peterson et al., 1991) examined the effect of 
isoflavones (genistein, biochanin A and daidzein) on the growth of the human breast 
carcinoma cell lines, MDA-468, and MCF-7 and MCF-7-D-40 and reported that 
Genistein was a potent inhibitor of the growth of the human breast carcinoma cell 
lines (MDA-468 and MCF-7 and MCF-7-D-40) with IC50 values from 6.5 to 12.0 
μg/ml, whereas biochanin A and daidzein are weaker growth inhibitors (IC50values 
from 20 to 34 μg/ml). 
The purified fractions except Es1 F3/3 and Es1 F6 were found to have IC50 
values>100 µg/ml, High IC50 and low MIC may indicate fractions suitable for testing 
for treatment of human infections. The fractions Es1 F6 and Es1 F3/3 were found to 
have HACAT IC50 values of 9 and 6  µg/ml respectively and may be too cytotoxic for 
use as treatment for bacterial infections. Further testing was not possible due to 
limited amounts of materials and a much larger scale preparation would be necessary 
to provide enough material. 
The limitation of this part of the study were that only a few organisms and cell lines 
were tested due to the limited amount of the antibiotics (just two bacteria and three 
cell lines were tested), if much larger amount antibiotics were available more test 
organisms and cell lines could be tested.  
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Chapter 7 
 
General discussion and conclusions  
 
The objectives of this study were to investigate terrestrial and aquatic invertebrates 
for the presence of antibiotic producing microorganisms and to isolate the organisms, 
screen them for activity against Gram-positive and Gram-negative bacteria. The 
results showed that this was a promising source for antibiotic producing organisms 
and it was possible to isolate antibiotic producing strains from invertebrates from both 
sources. Whether the microorganisms that were present in the invertebrates had 
originated in the environment e.g. washed in from surrounding soils and ingested or 
were present on food ingested by the aquatic and terrestrial invertebrates or whether 
they were associated with the invertebrates is not clear.  Much of the previous work 
on terrestrial invertebrates has been on social insects e.g. ants (Mueller et al., 2008), 
termites (Rohland and Meyers, 2015) wasps (Kaltenpoth et al., 2005) and millipedes, 
all of which have been shown to harbour antibiotic producers (Liu et al., 2016). The 
present study included different kinds of invertebrates. Forty-seven antibiotic 
producers were isolated from terrestrial and aquatic invertebrates. On the primary 
screening program the results indicated that three strains isolated from Helix aspersa 
(Es1), Lumbriculus variegata (La1a) and Baetis larvae (M1 11) were selected for 
further study as they had broad spectrum antibacterial activity. When the isolates were 
subjected to PCR and sequencing of 16S and 18S rDNA for identification, this 
showed that the majority were in fact fungi; mainly Penicillium spp. and only 5 were 
Streptomyces spp. Although the media used were designed to isolate streptomycetes, 
just 11% of the isolated antibiotic producing microorganisms were Streptomyces spp. 
No antifungal agents were added to the media and, in fact, 89% of the isolated 
antibiotic producing microorganisms were fungi (the morphology of the fungi and 
streptomycetes colonies on the AIA were similar and were identified by molecular 
methods). On the secondary screening program the three isolates Es1, M1 11 and 
La1a which had best activity on the primary screening showed strong activity against 
Gram-positive and Gram-negative bacteria including MRSA and were therefore 
chosen for further study. Unfortunately it was not possible in the time available to test 
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all isolates especially isolates with narrow spectrum activity against Gram-negative 
bacteria only which may be useful therapeutically.  
For further identification of the organisms to species level, the isolates (Es1, M1 11 
and La1a) were sent to NICMB Limited Company, to sequence ITS region to 
distinguish between species because it has recently been accepted as the official 
sequence for identification of fungi (Schoch et al., 2012). The results confirmed that 
the isolate M1 11 was P. chrysogenum; Es1 and La1a were closely related and were 
probably also strains of P. chrysogenum. 
Isolate P. chrysogenum Es1 was chosen for secondary screening which included 
comparative cultivation in different types of growth media seeking optimal antibiotic 
production. Although the media used were designed for bacteria, the antibiotic 
activity was high and therefore media used for fungi were not used. Unfortunately, 
there were no lab facilities to scale up this process using liquid media and therefore, 
the work was re-planned to grow it on solid AI agar medium. This was rather time- 
and effort-consuming, however, antimicrobial material has previously been 
successfully isolated from solid medium (Svahn et al., 2015, Pandey et al., 2000). The 
process was suitable for scale-up. Following fractionation of the crude extracts, four 
pure fractions were obtained from Es1 crude extract (F3/1, F3/3, 5 and 6) and ten pure 
fractions from M1 11 (F1 1 p3, F1 2 p4 F1 3 p5, F1 4 p6, F2 2 p2, F3 1 p2, F3 2 p3, 
F3 3 p4, F3 4 p5 and F3 5 p6), all pure fractions analyzed using 
1
H
 
NMR, 2D g-
COSY, the infrared spectroscopy (IR) and MS for molecular weight determination.  
 
The elementary analysis for all samples was unfortunately not possible due to the lack 
of enough pure material of nine fractions. Meanwhile, the relative abundance of F5 
(10 mg) and F6 (24 mg) from Es1 isolate and F3 3 p4 (3 mg), F3 4 p5 (8 mg) and F3 
5 p6 (4 mg) from M1 11 isolate, enabled further chemical analyses, BBH1 decoupled 
13
C analysis which indicated the total number of carbons included in the skeleton of 
compounds addition to 2D g-HMQC and 2D g-HMBC techniques. Finally, these two 
fractions were analyzed by JMOD C13 analysis. 
The structure elucidation of the antibiotics obtained from the isolated organisms are 
conclusive and revealed that the compounds obtained from Es1 and M1 11 were 
flavonoids, three flavones and four isoflavones. As far as the author is aware the 
structures are unique and have not previously been isolated. These types of 
compounds are frequently isolated from plant sources (Cushnie and Lamb, 2011, 
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Cushnie and Lamb, 2005) but, with the exception of endophytic fungi (Bhardwaj et 
al., 2015a, Qiu et al., 2010), as far as the author is aware this is one of the first reports 
of the production of such compounds from fungi from other sources. It is possible that 
they represent endophytic fungi obtained from the food eaten by the invertebrates 
which includes plant material. Lumbriculus feed on decaying leaves and wood and 
ingest microorganisms, Helix sp. feed on plant materials and Baetis larvae feed on 
detritus and algae. 
Unfortunately it was not possible to obtain structures for all pure fractions due to the 
lack of enough material. However, some of the properties of those fractions were 
similar to those that were fully characterized and may have represented a family of 
related compounds.  
Examination of the genome for PKS genes would confirm the biosynthetic 
capabilities of the fungi. Juvvadi et al., (2005) discovered chalcone synthase (CHS) 
genes belonging to the type III PKS in Aspergillus oryzae. CHS genes are known to 
play a vital role in the biosynthesis of flavonoids in plants. CHSs in plants known to 
catalyze the first committed step in the phenylpropanoid pathway leading to the 
biosynthesis of flavonoids, isoflavonoids and anthocyanins by the condensation of 4-
hydroxycinnamoyl-CoA and three malonyl-CoA molecules to the chalcone derivative, 
naringenin chalcone (Figure 7.1: Ferrer et al., 1999). 
Until recent years it was believed that type III PKSs (PKSs are classified into three 
groups: types I, II, and III) existed exclusively in plants and bacteria, but recently 
several fungal genome sequencing studies revealed the presence of type III PKSs in 
filamentous fungi such as Aspergillus oryzae, Saccharomyces cerevisiae, 
Schizosaccharomyces pombe, and Neurospora crassa (Yu et al., 2012). 
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Figure 7.1: Flavonoids biosynthesis pathway modified from Juvvadi et al. (2005) 
 
 PAL: Phenylalanine ammonia-lyase; C4H: cinnamate-4-hydroxylase; 4CL: 4-
coumaroyl: CoA-ligase; CHS: chalcone synthase; CHI: chalcone isomerase; CHR: 
chalcone reductase. 
 
Preliminary examination for anticancer activity showed that crude extracts of Es1, M1 
11 and La1a may have some activity. This indicates that the potential for use as an 
anticancer therapy is clearly worth investigating further. The purified fractions except 
F3/3 and F6 were found to have IC50 values>100 µg/ml, High IC50 and low MIC may 
indicate fractions suitable for testing for treatment of human infections because they 
may have low toxicity.  
Overall, this investigation suggests that terrestrial and aquatic invertebrates are a rich 
source of antibiotic producing microorganisms. The antimicrobial activity of the pure 
compounds showed that they had high activity against Gram positive and Gram 
negative bacteria with low MIC values, which may represent a potential for 
pharmaceutical and/or agricultural applications. It is hoped that these components 
when isolated into pure constituents can serve as leads for the development of novel 
and potent antibiotics. 
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Further work  
The availability of some instrumentation would have improved the work of this study, 
for example if preparative HPLC were available for purification of the bioactive 
compounds, this would save much time for collecting the bioactive fractions. Also 
fermentation facilities to cultivate cultures of relatively large volumes of 10 L+ / run, 
would facilitate production of the crude extract and make the fractionation easier as 
there would probably be fewer contaminants when using cell free filtered medium 
than extraction from solid culture.   
The results of the antibacterial evaluation of the 47 isolates suggested that future work 
should include investigating the active compounds from the rest of the organisms in 
this study by using different extracting solvents with different polarities to retrieve as 
many active compounds as possible. This study has proved that the pure compounds 
obtained from Es1 and M1 11 have high antibacterial activity but the mechanism of 
action was not investigated due the limitation of the study time. Further studies would 
include determining the mode of action (MOA) of the compounds.  
The macromolecular synthesis assays (MMS) one of the most popular methods in 
MOA determination. MMS assays uses radioactively labeled precursors to determine 
whether a compound specifically inhibits protein, RNA, DNA, lipid, or peptidoglycan 
synthesis (Nonejuie, 2014, Nonejuie et al., 2013) by introduction of a radiolabeled 
precursor of a particular macromolecule into bacterial culture treated with 
antibacterial compound. This precursor is allowed to incorporate into its 
corresponding macromolecule for ten minutes of incubation, after which 
macromolecules are precipitated by the addition of trichloracetic acid and isolated by 
filtration, liquid scintillant add to filters, radiolabeled incorporation measure using a 
Chameleon multi label plate scintillation counter (Gerits et al., 2016), inhibition of the 
macromolecular process by the antibacterial compound is indicated by diminished 
levels of radioactivity (Low radioactive count). For example, it is possible to monitor 
inhibition of DNA, RNA, or protein synthesis by the addition of either [methyl-
3
H]thymidine, [5,6-
3
H] uridine or L-[G-
3
H]glutamine respectively to the bacterial 
cultures and determining whether there was any inhibition of incorporation into 
macromolecules as described by  Gerits et al.  (2016). 
Effects on membrane permeability can be determined by using SYTOX green stain as 
described by (Yaraksa et al., 2014, Gerits et al., 2016), this stain only enters the 
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cytoplasm if the membrane is compromised. Upon uptake, SYTOX green binds to 
nucleic acids, which in turn results in increased fluorescence (Roth et al., 1997).  
Previous studies on other flavonoids has shown the mode of action of selected 
flavonoids. The activity of quercetin, for example, has been at least partially attributed 
to inhibition of DNA gyrase, sophoraflavone G and (-)-epigallocatechin gallate inhibit 
cytoplasmic membrane function, and licochalcones A and C inhibit energy 
metabolism (Cushnie and Lamb, 2005). 
Further investigations are also needed for confirmation of the identification of 
Penicillium species by sequencing other genes e.g. β-tubulin (BenA) gene because 
there are clearly problems identifying Penicillium species by sequencing ITS alone.  
Further studies will also be needed to confirm whether the microorganisms were 
present in the invertebrates having been obtained from the environment or whether 
they were these as part of a symbiotic or other association. As far as the author is 
aware there is no evidence for symbiotic associations of invertebrates with 
Penicillium sp. but they are present as endosymbionts in plants. Further work could 
involve testing more examples of the invertebrates to see whether the microorganisms 
were always isolated which might indicate a symbiotic association. 
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Chapter 9 
 
Appendices 
 
Section 1: sequence alignments 
 
Appendix 1.1: Sequence alignments for La2 isolate with the three closest 
identification strains  
 
Uncultured Penicillium CHiv76 18S 
 
Uncultured fungus clone Aerocomp_EO40 
 
Penicillium commune strain IBT 15141 
 
Appendix 1.2: Sequence alignments for La4 isolate with the three closest 
identification strains  
 
Penicillium tardum strain KCTC16051 
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Penicillium chrysogenum strain 215 
 
Penicillium expansum 
 
Appendix 1.3: Sequence alignments for La5 isolate with the three closest 
identification strains  
 
Eupenicillium crustaceum 
 
Penicillium chrysogenum strain 215 
 
Penicillium chrysogenum strain KCTC6052 
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Appendix 1.4: Sequence alignments for M1 2 isolate with the three closest 
identification strains  
 
Penicillium tardum strain KCTC16051
 
Penicillium brevicompactum strain ATCC 16024 
 
 
Eupenicillium crustaceum 
 
Appendix 1.5: Sequence alignments for M1 3 isolate with the three closest 
identification strains  
 
Penicillium fimorum strain DTO 159-F1 
 
Penicillium fimorum strain CBS 140576 
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Penicillium sp DR1 
 
Appendix 1.6: Sequence alignments for M1 4 isolate with the three closest 
identification strains 
 
Penicillium sp. 2 BRO-2013 
 
Uncultured fungus clone T3_II_1a_04 
 
Penicillium sp HT-M15-LS 
 
Appendix 1.7: Sequence alignments for M1 8 isolate with the three closest 
identification strains 
 
Penicillium roqueforti  ATCC 10110 
 
Penicillium camemberti strain ATCC 10387 
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Penicillium dipodomyicola strain ACBF 002-3 
 
Appendix 1.8: Sequence alignments for M1 10 isolate with the three closest 
identification strains 
 
Penicillium tardum strain KCTC16051 
 
Penicillium chrysogenum KCTC6052 
 
Penicillium expansum 
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Appendix 1.9: Sequence alignments for M1 11 isolate with the three closest 
identification strains 
 
Penicillium chrysogenum strain 215 
 
Eupenicillium crustaceum 
 
 
Penicillium brevicompactum strain ATCC 16024 
 
Appendix 1.10: Sequence alignments for M1 13 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum ATCC 16024 
 
Penicillium chrysogenum strain KCTC6052 
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Eupenicillium crustaceum 
 
Appendix 1.11: Sequence alignments for M1 14 isolate with the three closest 
identification strains 
 
Penicillium expansum
 
Penicillium chrysogenum strain 215 
 
Penicillium tardum KCTC16051 
 
Appendix 1.12: Sequence alignments for M1 15 isolate with the three closest 
identification strains 
 
Penicillium solitum strain 20-01 
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Penicillium sp clone NJ-F4 18S 
 
Penicillium dipodomyicola strain ACBF 002-3 
 
Appendix 1.13: Sequence alignments for M1 16 isolate with the three closest 
identification strains 
 
Penicillium roqueforti strain ATCC 10110 
 
Penicillium sp BF79 
 
Penicillium sp BF18 
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Appendix 1.14: Sequence alignments for M1 18 isolate with the three closest 
identification strains 
 
Penicillium sclerotigenum strain NRRL 22813 
 
PenicilliumvulpinumstrainNRRL1002 
 
Penicillium vulpinum strain NRRL 2031 
 
Appendix 1.15: Sequence alignments for M1 20 isolate with the three closest 
identification strains 
 
Penicillium clavigerum NRRL 1003 
 
Penicillium griseofulvum NRRL 3523 
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Penicillium expansum strain NRRL 35259 
 
Appendix 1.16: Sequence alignments for M1 22 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum ATCC 16024 
 
Penicillium chrysogenum strain KCTC6052 
 
Penicillium expansum 
 
Appendix 1.17: Sequence alignments for Es1 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum strain ATCC 16024 
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Penicillium chrysogenum strain KCTC6052 
 
Eupenicillium crustaceum 
 
Appendix 1.18: Sequence alignments for Es2 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum strain ATCC 16024 
Penicillium chrysogenum strain 41H1 
 
Uncultured fungus clone CMH605 
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Appendix 1.19: Sequence alignments for Es9 isolate with the three closest 
identification strains 
 
Penicillium chrysogenum strain 215 
 
Penicillium expansum
 
Penicillium chrysogenum strain KCTC6052 
 
Appendix 1.20: Sequence alignments for Ant w1 isolate with the three closest 
identification strains 
 
Verticillium fungicola solate ARSEF 2065
 
Simplicillium lamellicola isolate UAMH 2055 
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Phytocordyceps ninchukispora strain CCRC 31900 
 
Appendix 1.21: Sequence alignments for Ant w2 isolate with the three closest 
identification strains 
 
Lecanicillium sp strain CCF 5201 
 
Lecanicillium sp CCF 5233 
 
Fungal sp. SLZ14 
 
Appendix 1.22: Sequence alignments for Ant w3 isolate with the three closest 
identification strains 
 
Simplicillium lamellicola isolate UAMH 2055 
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Cordyceps sp ATCC 36337
 
Fungal sp SLZ46 
 
Appendix 1.23: Sequence alignments for Ant b4 isolate with the three closest 
identification strains 
 
Uncultured marine ascomycete clone PRTBE7359 
 
Uncultured marine ascomycete clone PRTBE7237 
 
 
Exophiala oligosperma strain CBS 725.88 
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Appendix 1.24: Sequence alignments for M35 1 isolate with the three closest 
identification strains 
 
Penicillium roqueforti strain ATCC 10110 
 
Penicillium dipodomyicola strain ACBF 002-3 
 
Penicillium sp BF79 
 
Appendix 1.25: Sequence alignments for M35 4 isolate with the three closest 
identification strains 
 
Penicillium chrysogenum strain 215 
 
Penicillium expansum 
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Penicillium tardum KCTC16051 
 
Appendix 1.26: Sequence alignments for M35 5 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum strain ATCC 16024 
 
Penicillium chrysogenum KCTC6052 
 
Eupenicillium crustaceum 
 
Appendix 1.27: Sequence alignments for M35 9 isolate with the three closest 
identification strains 
 
Penicillium glandicola NRRL 985 
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Penicillium vulpinum strain NRRL 1002 
 
Penicillium glandicola strain NRRL 2036 
 
Appendix 1.28: Sequence alignments for M35 11 isolate with the three closest 
identification strains 
 
Penicillium sp HT-M15-L 
 
Uncultured fungus clone CMH605 
 
Uncultured fungus clone CMH224 
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Appendix 1.29: Sequence alignments for Pp3 isolate with the three closest 
identification strains 
 
Penicillium commune strain MA09-AL 
Penicillium coccotrypicola strain BRIP 59608 
Penicillium glandicola strain NRRL 985  
 
 
Appendix 1.30: Sequence alignments for S5 isolate with the three closest 
identification strains 
 
Uncultured Penicillium clone USN5 
 
Penicillium sp strain Y12 EG-2010 
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Penicillium glabrum strain KCTC16099 
 
Appendix 1.31: Sequence alignments for S6 isolate with the three closest 
identification strains 
 
Fungal sp Isolate nussu_195 
 
Fungal sp SLZ62 
 
Hypocrea sp SP-4 
 
Appendix 1.32: Sequence alignments for Sa1 isolate with the three closest 
identification strains 
 
Penicillium expansum 
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Penicillium chrysogenum strain 215 
 
Eupenicillium crustaceum 
 
Appendix 1.33: Sequence alignments for Sa2 isolate with the three closest 
identification strains 
 
Trichocomaceae sp. LM196 
 
Uncultured ascomycete 
 
Penicillium griseofulvum 
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Appendix 1.34: Sequence alignments for W1 isolate with the three closest 
identification strains 
 
Penicillium freii (IBT 3464) 
 
Penicillium dipodomyicola strain B64 
 
Penicillium gladioli strain NRRL 939 
 
Appendix 1.35: Sequence alignments for W2 isolate with the three closest 
identification strains 
 
Penicillium paneum strain NRRL 25162 
 
 
Penicillium solitum strain 20-01 
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Penicillium echinulatum isolate 00044 
 
Appendix 1.36: Sequence alignments for W3 isolate with the three closest 
identification strains 
 
Penicillium coccotrypicola strain BRIP 59608 
 
Penicillium tardum strain KCTC16051 
 
 
Penicillium griseofulvum 
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Appendix 1.37: Sequence alignments for W6 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum strain ATCC 16024 
 
Penicillium chrysogenum strain KCTC6052 
 
Eupenicillium crustaceum 
 
Appendix 1.38: Sequence alignments for W7 isolate with the three closest 
identification strains 
 
Penicillium vulpinum NRRL 1002 
 
Penicillium paneum NRRL 25162 
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Penicillium gladioli strain NRRL 939 
 
Appendix 1.39: Sequence alignments for W9 isolate with the three closest 
identification strains 
 
Penicillium sp clone NJ-F4 18S 
 
Uncultured fungus clone CMH067 
 
Uncultured fungus clone CMH605 
 
Appendix 1.40: Sequence alignments for W12 isolate with the three closest 
identification strains 
 
Penicillium expansum 
 274 
 
Penicillium chrysogenum strain 215 
 
Eupenicillium crustaceum 
 
Appendix 1.41: Sequence alignments for W13 isolate with the three closest 
identification strains 
 
Penicillium brevicompactum strain ATCC 16024 
 
Penicillium chrysogenum strain KCTC6052 
 
Eupenicillium crustaceum 
 
 
 
 
 275 
Appendix 1.42: Sequence alignments for Es1 isolate with Penicillium sp. (ITS) 
 
  
Appendix 1.43: Sequence alignments for M 1 11 isolate with Penicillium 
chrysogenum (ITS) 
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Appendix 1.44: Sequence alignments for La1a isolate with Penicillium sp. (ITS) 
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Appendix 1.45: Sequence alignments 0f Es1, M1 11 and La1a (ITS) 
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Appendix 1.46: Sequence alignments for Wata 2 isolate with the three closest 
identification strains 
 
Streptomyces sp SIA-Cu-E1 
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Streptomyces halstedii strain NRRL B-1238 
 
Streptomyces cyaneus strain ISP 5108 
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Appendix 1.47: Sequence alignments for Es5 isolate with the three closest 
identification strains 
 
Streptomyces sp GS01 
 
Streptomyces fimicarius strain G8A-2 
 
Streptomyces fimicarius strain G8A-17 
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Appendix 1.48: Sequence alignments for Pp1 isolate with the three closest 
identification strains 
 
Streptomyces sp GY2
 
Streptomyces sp C3001 
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Streptomyces sp. strain ARR4 
 
Appendix 1.49: Sequence alignments for Pp 2 isolate with the three closest 
identification strains 
 
Streptomyces sp. strain 194  
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Streptomyces violaceus strain RTAE11 
 
 
 
Streptomyces sp. strain CAE3 
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Section 2:  HPLC chromatograms 
 
Appendix 2.1: Fractionation of Es1 extracts by HPLC on Spherisorb using an 
isocratic mobile phase of 0.1% TFA in water: methanol 30:70 (v/v) 
 
 
Appendix 2.2: Fractions obtained by injecting 250 µl Es1 extracts on to a semi-
Preparative ACE Excel 5 C-18 amide column, flow rate 5 ml/min, the solvent systems 
was Gradient mobile phase water: methanol 30:70 (v/v). 
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Section 3: NMR, MS and FTIR data 
 
Appendix 3.1: 
1
H NMR Spectrum of F6 in D6DMSO+TMS 
 
 
Appendix 3.2: 
1
H NMR Spectrum of F6 in CD3OD+TMS, the peaks observed in the 
above spectrum is due to degraded of the main component 
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Appendix 3.3: 
1
H NMR Spectrum of F6 in D6DMSO+TMS after CD3OD dried 
sample 
 
 
 
Appendix 3.4: 2D g-COSY NMR Spectrum of F6 in D6DMSO+TMS 
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Appendix 3.5: 2D g-COSY NMR Spectrum of F6 (expansion) in CD3OD, the peaks 
observed in the above spectrum is due to degraded of the main component 
 
 
 
Appendix 3.6: 2D g-HMQC NMR Spectrum of F6 in D6DMSO+TMS 
 
 
 
 
 
ppm
6.86.97.07.17.27.37.47.57.67.77.8 ppm
6.8
6.9
7.0
7.1
7.2
7.3
7.4
7.5
7.6
7.7
7.8
NAME              GHFr6
EXPNO                11
PROCNO                1
Date_          20160524
Time              10.18
INSTRUM           spect
PROBHD   5 mm BBO BB-1H
PULPROG        cosygpqf
TD                 2048
SOLVENT            MeOD
NS                    8
DS                    8
SWH            3289.474 Hz
FIDRES         1.606188 Hz
AQ            0.3113460 sec
RG                228.1
DW              152.000 usec
DE                 6.50 usec
TE                296.2 K
D0           0.00000300 sec
D1           1.36728799 sec
D13          0.00000400 sec
D16          0.00010000 sec
IN0          0.00030400 sec
======== CHANNEL f1 ========
NUC1                 1H
P0                11.60 usec
P1                11.60 usec
PL1                2.00 dB
SFO1        400.1318974 MHz
====== GRADIENT CHANNEL =====
GPNAM1         SINE.100
GPZ1              10.00 %
P16             1000.00 usec
ND0                   1
TD                  128
SFO1           400.1319 MHz
FIDRES        25.699013 Hz
SW                8.221 ppm
FnMODE               QF
SI                 1024
SF          400.1300000 MHz
WDW                SINE
SSB                   0
LB                 0.00 Hz
GB                    0
PC                 1.40
SI                 1024
MC2                  QF
SF          400.1300000 MHz
WDW                SINE
SSB                   0
LB                 0.00 Hz
GB                    0
2D g-COSY NMR Spectrum of fraction 6 in D4MeOH
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Appendix 3.7: 2D g-HMBC NMR Spectrum of F6 in D6DMSO+TMS 
 
 
Appendix 3.8: BB H1 Decoupled C13 NMR Spectrum of F6 in D6DMSO+TMS 
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Appendix 3.9: BB H1 Decoupled C13 NMR Spectrum of F6 in CD3OD, after the 
peaks observed in the proton spectrum of F6 due to degraded of the main component 
 
 
Appendix 3.10: BB H1 Decoupled C13 NMR Spectrum of F6 (expansion) in 
CD3OD, after the peaks observed in the proton spectrum of F6 due to degraded of the 
main component 
 
 
 290 
Appendix 3.11: BB H1 Decoupled C13 NMR Spectrum of F6 in D6DMSO after 
CD3OD dried sample 
 
 
Appendix 3.12: BB H1 Decoupled C13 NMR Spectrum of F6 (expansion) in 
D6DMSO after CD3OD dried sample 
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Appendix 3.13: JMOD C13 Spectrum of F6 in D6DMSO+TMS 
 
 
 
Appendix 3.14: The negative ion chromatogram from LC MS-TOF of F6 
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Appendix 3.15: The positive ion chromatogram from LC MS-TOF of F6 
 
 
Appendix 3.16: The positive ion spectrum from LC MS-TOF of F6 
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Appendix 3.17: The negative ion spectrum from LC MS (Salford University) of F6 
 
 
 
Appendix 3.18: 2D g-COSY NMR Spectrum of F3/1in CD3OD 
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Appendix 3.19: The negative ion chromatogram from LC MS-TOF of F3/1 
 
 
Appendix 3.20: The positive ion chromatogram from LC MS-TOF of F3/1  
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Appendix 3.21: The positive ion spectrum from LC MS-TOF of F3/1 
 
 
Appendix 3.22: 2D g-COSY NMR Spectrum of F3/3 in CD3OD 
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Appendix 3.23: BB 1H Decoupled 13C NMR Spectrum of F3/3 in D6DMSO, the 
signal observed was weak as limited amount of material was available. 
 
 
 
Appendix 3.24: JMOD 13C NMR Spectrum of F3/3 in CD3OD the signal observed 
was weak as limited amount of material was available 
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Appendix 3.25: The negative ion chromatogram from LC MS-TOF of F3/3  
 
 
Appendix 3.26: The positive ion chromatogram from LC MS-TOF of F3/3 
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Appendix 3.27: The positive ion spectrum from LC MS-TOF of F3/3 
 
 
Appendix 3.28: 
1
H NMR Spectrum of F5 in CD3OD+TMS, the minor peaks 
observed in the above spectrum is due to degraded of the main component 
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Appendix 3.29: 
1
H NMR Spectrum of F5 in D6DMSO+TMS in D6DMSO after 
CD3OD dried sample 
 
 
Appendix 3.30: 2D g-COSY NMR Spectrum of F5 (expanded) in CD3OD, the minor 
peaks observed in the above spectrum are probably due to degraded of the main 
component 
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Appendix 3.31: 2D g-COSY NMR Spectrum of F5 in D6DMSO after CD3OD dried 
sample 
 
 
Appendix 3.32: 2D g-COSY NMR Spectrum of F5 (expansion) in D6DMSO after 
CD3OD dried sample 
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Appendix 3.33: 2D g-HMQC Spectrum of F5 in CD3OD, the minor peaks observed 
in the above spectrum is due to degraded of the main component 
 
 
Appendix 3.34: 2D g-HMQC Spectrum of F5 in D6DMSO after CD3OD dried 
sample 
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Appendix 3.35: 2D g-HMQC Spectrum of F5 (expansion) in D6DMSO after CD3OD 
dried sample 
 
 
Appendix 3.36: 2D g-HMBC Spectrum of F5 in D6DMSO after CD3OD dried 
sample 
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Appendix 3.37: BB H1 Decoupled C13 NMR Spectrum of F5 in CD3OD 
 
 
Appendix 3.38: BB H1 Decoupled C13 NMR Spectrum of F5 in CD3OD, after the 
minor peaks observed in the proton spectrum of F5due to degraded of the main 
component 
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Appendix 3.39: BB H1 Decoupled C13 NMR Spectrum of F5 (expanded) in CD3OD, 
after the minor peaks observed in the proton spectrum of F5 due to degraded of the 
main component  
 
 
 
Appendix 3.40: BB H1 Decoupled C13 NMR Spectrum of F5 in D6DMSO after 
CD3OD dried sample 
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Appendix 3.41: BB H1 Decoupled C13 NMR Spectrum of F5 (expansion) in 
D6DMSO after CD3OD dried sample 
 
 
 
Appendix 3.42: JMOD C13 Spectrum of F5 in CD3OD, after the minor peaks 
observed in the proton spectrum of F5 due to degraded of the main component 
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Appendix 3.43: JMOD C13 Spectrum of F5 (expansion) in CD3OD, after the minor 
peaks observed in the proton spectrum of F5 due to degraded of the main component 
 
 
Appendix 3.44: JMOD C13 Spectrum of F5 in D6DMSO after CD3OD dried sample 
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Appendix 3.45: JMOD C13 Spectrum of F5 (expansion) in D6DMSO after CD3OD 
dried sample 
 
 
Appendix 3.46: The negative ion chromatogram from LC MS-TOF of F5 
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Appendix 3.47: The positive ion chromatogram from LC MS-TOF of F5 
 
 
Appendix 3.48: The positive ion spectrum from LC MS-TOF of F5 
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Appendix 3.49: The negative ion spectrum from LC MS (Salford University) of F5 
 
 
Appendix 3.50: 2D g-COSY NMR Spectrum of F1 2 P4 in CD3OD 
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Appendix 3.51: 2D g-COSY NMR Spectrum of F1 2 P4 (expansion) in CD3OD 
 
 
Appendix 3.52: BB H1 Decoupled C13 NMR Spectrum of F1 2 p4 in CD3OD, the 
signal observed is weak as limited amount of material was available 
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Appendix 3.53: The negative ion chromatogram from LC MS-TOF of F1 2 p4 
 
 
Appendix 3.54: The positive ion chromatogram from LC MS-TOF of F1 2 p4  
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Appendix 3.55: The positive ion spectrum from LC MS-TOF of F1 2 p4  
 
 
 
Appendix 3.56: 
1
H NMR Spectrum of F1 1 P3 in CD3OD+TMS  
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Appendix 3.57: 2D g-COSY NMR Spectrum of F1 1 P3 in CD3OD
  
 
 
 
Appendix 3.58: 2D g-COSY NMR Spectrum of F1 1 P3 (expansion) in CD3OD 
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Appendix 3.59: 
1
H NMR Spectrum of F1 1 P3 in CD3OD +TMS  
 
 
Appendix 3.60: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F1 1 p3 
 
 
Appendix 3.61: The negative ion chromatogram from LC MS-TOF of F1 1 p3  
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Appendix 3.62: The negative ion spectrum from LC MS-TOF of F1 1 p3  
 
 
 
Appendix 3.63: The positive ion chromatogram from LC MS-TOF of F1 1 p3  
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Appendix 3.64: The negative ion spectrum from LC MS-TOF of F1 1 p3  
 
 
Appendix 3.65: H NMR Spectrum F1 3 p5in CD3OD+TMS 
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Appendix 3.66: 2D g-COSY NMR Spectrum F1 3 p5 in CD3OD 
 
 
 
 
Appendix 3.67: 2D g-COSY NMR Spectrum F1 3p5 (expansion) in CD3OD 
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Appendix 3.68: 
1
H NMR Spectrum of F1 3 p5 in CD3OD+TMS (Purified compound 
from F1 3 p5) 
 
 
Appendix 3.69: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F1 3 p5  
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Appendix 3.70: The negative ion chromatogram from LC MS-TOF of F1 3 p5 
 
 
Appendix 3.71: The negative ion spectrum from LC MS-TOF of F1 3 p5  
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Appendix 3.72: The positive ion chromatogram from LC MS-TOF of F1 3 p5 
 
 
 
Appendix 3.73: The positive ion spectrum from LC MS-TOF of F1 3 p5  
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Appendix 3.74: H NMR Spectrum of F1 4 p6 in CD3OD+TMS 
 
 
 
Appendix 3.75: 2D g-COSY NMR Spectrum of F1 4 p6 in CD3OD 
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Appendix 3.76: 2D g-COSY NMR Spectrum of F1 4 p6 (expansion) in CD3OD 
 
 
 
 
 
Appendix 3.77: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F1 4 p6 
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Appendix 3.78: The negative ion chromatogram from LC MS-TOF of F1 4 p6  
 
 
Appendix 3.79: The negative ion spectrum from LC MS-TOF of F1 4 p6  
 
 
 
 
 
 
 324 
Appendix 3.80: The positive ion chromatogram from LC MS-TOF of F1 4 p6  
 
 
Appendix 3.81: The positive ion spectrum from LC MS-TOF of F1 4 p6  
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Appendix 3.82: 
1
H NMR Spectrum of F2 2 p3 in CD3OD+TMS 
 
 
Appendix 3.83: H NMR Spectrum of F2 2 p3 in CD3OD+TMS (Purified compound 
from F2 2 p3) 
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Appendix 3.84: 2D g-COSY NMR Spectrum F2 2 p3 in CD3OD acquired with 
smaller sweep width (SW) manually due a sample limited amount 
 
 
Appendix 3.85: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F2 2 p3  
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Appendix 3.86: The negative ion chromatogram from LC MS-TOF of F2 p3 
 
 
Appendix 3.87: The negative ion chromatogram from LC MS-TOF of F2 p3 
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Appendix 3.88: 
1
H NMR Spectrum F3 1 p2 in CD3OD+TMS 
 
 
Appendix 3.89: 
1
H NMR Spectrum of F3 1 p2 in CD3OD+TMS (Purified compound 
from F3 1 p2) 
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Appendix 3.90: 2D g-COSY NMR Spectrum F3 1 p2 in CD3OD acquired with 
smaller sweep width (SW) manually du a sample limited amount 
 
 
 
Appendix 3.91: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F3 1 p2 
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Appendix 3.92: The negative ion chromatogram from LC MS-TOF of F3 1 p2  
 
 
Appendix 3.93: The negative ion spectrum from LC MS-TOF of F3 1 p2  
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Appendix 3.94: The positive ion chromatogram from LC MS-TOF of F3 1 p2  
 
 
 
Appendix 3.95: The positive ion spectrum from LC MS-TOF of F3 1 p2 
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Appendix 3.96: 
1
H NMR Spectrum of F3 2 p3 in CD3OD+TMS 
 
 
Appendix 3.97: 
1
H NMR Spectrum of F3 2 p3 in CD3OD+TMS (Purified compound 
from F3 2 p3) 
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Appendix 3.98: 2D g-COSY NMR Spectrum of F3 2 p3in CD3OD acquired with 
smaller sweep width (SW) manually due a sample limited amount 
 
 
 
 
Appendix 3.99: The FTIR spectra (ATR) 4 cm 
-1
 (16 Scans) of F3 2 p3 
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Appendix 3.100: The negative ion chromatogram from LC MS-TOF of F3 2 p3 
 
 
 
Appendix 3.101: The negative ion spectrum from LC MS-TOF of F3 2 p3  
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Appendix 3.102: The positive ion chromatogram from LC MS-TOF of F3 2 p3  
 
 
 
Appendix 3.103: The positive ion spectrum from LC MS-TOF of F3 2 p3  
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Appendix 3.104: 2D g-COSY NMR Spectrum of F3 3 p4 in CD3OD 
 
 
 
Appendix 3.105: BB H1 Decoupled C13 Spectrum of F3 3 p4 in CD3OD 
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Appendix 3.106: 2 D g-HSQC NMR Spectrum of F3 3 p4 in CD3OD 
 
 
Appendix 3.107: 2 D g-HSQC NMR Spectrum of F3 3 p4 (expansion) in CD3OD 
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Appendix 3.108: 2 D g-HMBC NMR Spectrum of F3 3 p4 in CD3OD 
 
 
Appendix 3.109: 2 D g-HMBC NMR Spectrum of F3 3 p4 (expansion) in CD3OD 
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Appendix 3.110: The negative ion chromatogram from LC MS-TOF of F3 3 p4  
 
 
 
Appendix 3.111: The positive ion chromatogram from LC MS-TOF of F3 3 p4  
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Appendix 3.112: The positive ion spectrum from LC MS-TOF of F3 3 p4  
 
 
Appendix 3.113: 2D g-COSY NMR Spectrum of F3 4 p5 in CD3OD 
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Appendix 3.114: BB H1 Decoupled C13 Spectrum of F3 4 p5 in CD3OD  
 
 
 
Appendix 3.115: 2D g-COSY NMR Spectrum of F3 4 p5 in CD3OD 
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Appendix 3.116: 2D g-HMBC NMR Spectrum of F3 4 p5 in CD3OD 
 
 
 
Appendix 3.117: JMOD C13 Spectrum of F3 4 p5 in CD3OD 
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Appendix 3.118: The negative ion chromatogram from LC MS-TOF of F3 4 p5  
 
 
Appendix 3.119: The positive ion chromatogram from LC MS-TOF of F3 4 p5  
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Appendix 3.120: The positive ion spectrum from LC MS-TOF of F3 4 p5  
 
 
Appendix 3.121: The negative ion spectrum from LC MS (Salford University) of F3 4 
p5 
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Appendix 3.122: 2D g-COSY NMR Spectrum of F3 5 p6 in CD3OD 
 
 
 
Appendix 3.123: 
1
H NMR Spectrum of F3 5 p6 (expansion) in CD3OD+TMS 
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Appendix 3.124: BB H1 Decoupled C13 Spectrum of F3 5 p6 in CD3OD 
 
 
 
Appendix 3.125: BB H1 Decoupled C13 Spectrum of F3 5 p6 (expansion) in CD3OD  
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Appendix 3.126: 2 D g-HMBC NMR Spectrum of F3 5 p6 in CD3OD 
 
 
Appendix 3.127: 2 D g-HMBC NMR Spectrum of F3 5 p6 (expansion) in CD3OD 
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Appendix 3.128: 2 D g-HSQC NMR Spectrum of F3 5 p6 in CD3OD 
 
 
 
 
Appendix 3.129: 2 D g-HSQC NMR Spectrum of F3 5 p6 (expansion) in CD3OD 
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Appendix 3.130: The negative ion chromatogram from LC MS-TOF of F3 5 p6  
 
 
 
Appendix 3.131: The positive ion chromatogram from LC MS-TOF of F3 5 p6  
 
 
 
 
 350 
Appendix 3.132: The positive ion spectrum from LC MS-TOF of F3 5 p6 
 
 
 
 
